|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Order Number | 0713308726 |
| Audit Mode | On-Site |
| Type of Audit | |  |  |  | | --- | --- | --- | | ☐ Stage 1 | ☐ Stage 2 | ☐ Stage 1 + Stage 2 | | ☒ Re-Certification | ☐ 1st Surveillance | ☐ 2nd Surveillance | |
| Audit criteria | ☒ (DIN) EN ISO 13485:2021  ☒ EN ISO 13485:2016+A11:2021  ☐ ISO 13485:2016  ☒ ISO 9001:2015  ☒ Defined processes and documentation of the auditee’s  Quality Management System  ☒ Taiwan GMP  ☐ Other:  ☒ European Directives including the additional requirements of MDR Article 120 (3) after May 26th 2021 and IVDR Article 110 (3) after May 26th 2022:   ☒ Council Directives 93/42/EEC (MDD) – annex II (w/o 4)   ☐ Council Directives 93/42/EEC (MDD) – annex V  ☒ European Regulations:   ☒ Medical Device Regulation (EU) 2017/745 – annex IX Chapters I and III  ☒ MDSAP with additional country-specific requirements: ☒ Australia (TGA)   ☒ Brazil (ANVISA)   ☒ Canada (HC)   ☒ Japan (MHLW/PMDA)   ☒ United States (FDA) |
| Audit period (on site) | 2023-09-18 - 2023-09-22 |
| Auditee (s) / Location(s) | 1) Drägerwerk AG & Co. KGaA, Moislinger Allee 53-55, 23542 Lübeck, GERMANY (10578) 2) Drägerwerk AG & Co. KGaA, Revalstrasse 1, 23560 Lübeck, GERMANY (90464) |
| Audit Responsible | Ulf Hagedorn |
| Lead Auditor / Auditor | Martin Szepannek / George Pavlov, Melanie Gaßen, Gabriele Mousset (under routine-monitoring ISO 9001 by M. Szepannek), Honorata Donnermaier |
| Expert / Trainee | Somesh Rasal (deputy Expert for Jan Küffner) - Cybersecurity |
| Auditor/ Expert Covering Code | George Pavlov (MDT 2002, MDT 2010, MDT 2011, MDT 2012, EAC 14, EAC 19, EAC 33, MDA 0203, MDA 0307, MDA 0315, MD 1101.1, MD 1301, MD 1302, MD 1402\_1, MDS 1005\_2, MDS 1009, MDS 7006\_2) Gabriele Mousset (EAC 19, MDT 2010, MDT 2011, MDT 2012, MDA 0307, MDA 0315, MDA 0312\_1, MD 1101.1, MD 1102, MD 1111, MD 1301)  Honorata Donnermair (MDT 2001, MDT 2003, MDN 1201)  Martin Szepannek (EAC 19, MDT 2010, MDT 2011, MDA 0203, MDA 0303.1, MD 1301, MDA 0307, MDA 0315, MDA 0316, MD 1302)  Melanie Gaßen (MDT 2002, MDN 1201, MDN 1214, MD 0101.1) |
| Auditor Reg. No. (Mainland China only) | n/a |
| Translator /  Observer and their organization | n/a |
| Audit Language | German / English |
| Client / Company and Company  Number | 10578  Drägerwerk GmbH & Co KGaA |
| Client Management Representative | Stefanie Hirsch (Head of Quality & Regulatory Affairs) |
| TÜV SÜD Contact | Maximilian Sanno, MHS-AP5 |
| Proposed next  regular Audit - Date / Type of audit | September 16, 2024 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 1 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

Index

1 INFORMATION ABOUT THE COMPANY, SCOPE, AUDITED FACILITIES, GENERAL 3

2 DATA CONCERNING AUDIT 3

2.1 Audit scope, objectives, and criteria 3

2.2 Audit location and time 3

2.3 Audit Team 3

2.4 Audit preparation 4

2.5 Audit Trails 5

2.5.1Management and Quality Management System 5

2.5.2Device Marketing Authorization and Facility Registration, Customer Related Processes 14

2.5.3Measurement, Analysis, and Improvement, CAPA and Internal Audit 17

2.5.4Device Adverse Events and Advisory Notices Reporting, PMS and Vigilance 27

2.5.5Design and Development 30

2.5.6Design and Development (non-medical Software ISO9001 only) 48

2.5.7Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23) 50

2.5.8Production and Service Controls - #10578 (Anlauffabrik / Startup Factory) 58

2.5.9 62

2.5.10Production and Service Controls - #90464 (Revalstraße / Ambia) 63

2.5.11Production and Service Controls - #90464 (Revalstraße / Central Supply Hoses) 67

2.5.12Production and Service Controls - #10578 (Moislinger Allee / Service Center) 71

2.5.13Production and Service Controls - #90464 (Revalstraße / BabyLeo) 77

2.5.14Production and Service Controls - #90464 (Revalstraße / HM Filter) 84

2.5.15Purchasing 91

2.5.16Cyber Security 97

2.5.17STB assessment of cleaning instruction (Atlan) 98

2.5.18Technical Documentation Assessment 101

2.6 Areas not audited although within the original Audit scope 102

2.7 Obstacles encountered, reliability of the Audit 102

2.8 Verification of effective implementation of corrective action(s) from the previous Audit 102

2.9 Conclusion for Action Items derived from various sources (e.g. source TÜV SÜD CBW) 103

3 EVENTS, CHANGES, FOLLOW-UP, ACTION ITEMS 104

3.1 FSCA/FSN, Recalls, Product Removals, Replacements, other Vigilance Information 104

3.2 Substantial / Significant Changes Since the Last Audit 104

3.3 Audit Program Status 104

4 CONCLUSION, FINAL SUMMARY AND RECOMMENDATION TO THE NOTIFIED BODY /

CERTIFICATION BODY 105

4.1 Multi-Site / Facility Audit 105

4.2 Audit Team recommendation 105

5 DISCLAIMER STATEMENT 107

6 ATTACHMENTS 107

7 VERSION HISTORY 107

ID: 31505 Doc No: MED\_T\_09.50 Revision: 12 – released Effective: 28 May 2021 Page 2 of 107

|  |  |  |
| --- | --- | --- |
| **1** | **Audit Report**  Report No: 0713308726  Version 1 |  |
| **Information about the company, scope, audited facilities, general** |

The application’s appendix A/B/C for the applicable certificate contains comprehensive information about the company, including current certification scope, processes, relevant facilities, critical suppliers, contact person(s), products, management system etc. The application’s appendix A/B/C is released together with this audit report.

2 Data concerning Audit

2.1 Audit scope, objectives, and criteria

The audit plan contains detailed information about the audit. The specific audit scope as documented in the audit plan defines locations / organizational units, activities, and processes with reference to standard clauses covered during this audit as well as to related audit duration (see section 2.2).

The objective of this audit is to verify the conformity and effectiveness of the manufacturer’s quality management system (or parts of it) with applicable requirements (statutory, regulatory, and contractual requirements, etc.) as specified on page 1, to ensure reasonable expectation it can achieve its specified objectives.

Representative areas of the client/company organization were audited on a sample basis to achieve an overview of the Quality Management System’s effectiveness. A management system certification Audit (initial, surveillance or recertification Audit) is not a legal compliance Audit (see ISO/IEC 17021-1:2015, 9.2.1.2 b).

2.2 Audit location and time

The following site(s)/ facility(ies) were visited during this Audit:

|  |  |  |  |
| --- | --- | --- | --- |
| # | Client  Number | Site/ Facility | Audit duration (on-site man- days) |

|  |  |  |  |
| --- | --- | --- | --- |
| 1 | 10578 | Drägerwerk AG & Co. KGaA,  Moislinger Allee 53-55, 23542 Lübeck | 12,6 |

|  |  |  |  |
| --- | --- | --- | --- |
| 2 | 90464 | Drägerwerk AG & Co. KGaA, Revalstrasse 1, 23560 Lübeck | 7,0 |

See latest version of audit plan for Audit Duration.

2.3 Audit Team

See page 1 for Audit Team composition as well as included Experts (if applicable). The audit team is authorized for the audit criteria mentioned on page 1 of this report.

Until May 25th 2021 TÜV SÜD Product Service GmbH was the Notified Body for conformity assessment according to the directives 93/42/EEC (MDD) and 90/385/EEC (AIMDD) listed on NANDO.

On the respective Date of Application of the regulations and according to MDR Art. 120(3) (May 26th 2021) TÜV SÜD Product Service GmbH is responsible for the appropriate surveillance of all applicable requirements relating to the devices it has certified under MDD.

TÜV SÜD America Inc. is the Auditing Organization for Medical Device Single Audit Program (MDSAP).

TÜV SÜD Japan is the Registered Certification Body under Japanese Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics (PMD Act).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 3 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| **2.4** | **Audit preparation** |

Prior to the Audit the following documentation was reviewed and used as an input for Audit planning.

|  |  |
| --- | --- |
| ☒  ☒  ☒  ☒  ☒ | Updated applicable application(s)’ appendix A/B/Cincluding site/facility data, codes and certificate data relevant for the Audit project (see attachment for current version)  Audit program and calculated audit duration taking into consideration reported changes in the organization, quality management system or products (see section 3.2)  Quality management system documentation information  Any certified client’s statements with respect to its operations for review of proper promotional use of certifications (certificates and certification marks). This includes checking e.g., promotional material and website content and any referenced links and attachments. Use of certification mark and references in documents, product labelling and websites must not be misleading.  Post market surveillance data collected from the manufacturer or in public accessible data bases (see section 3.1) |

• Information from the vigilance reporting system • Recalls performed • Field safety corrective action(s) • Field safety notices

|  |  |
| --- | --- |
| ☒ | Post market surveillance data collected for product code / specific characteristics from applicable test program (PPP, PPP MDR, PPP IVDR) (see section 3.1)  Audit report from the previous audits (regular, unannounced and special) including findings and customer responses (if applicable, see section 2.8)  Evaluation results of changes to quality management system or device-range covered by the certificate(s) including change notification approval(s) (if applicable, see section 3.2)  Relevant information filed against the client at any TÜV SÜD certification body involved (if applicable, see section 2.9)  Results of technical documentation assessments to be followed up during the next audit (if applicable, see section 2.9)  Audit release information issued by the certification body(ies) (if applicable, see section 2.9)  The CBW facility report(s) has / have been checked for any "action items" derived from various sources including internal MHS-CRT information about vigilance cases from the manufacturer or competent authorities (if applicable). Applicable "action items" (if any) are addressed in section 2.9 of this report.  Re-Certification Audit: Audit results from the last three years were considered for Audit planning of this Audit |
| ☒  ☒  ☒  ☐ ☒  ☒  ☒ |

|  |  |
| --- | --- |
| 3-Year History | Reports  Number(s) |
| Recertification (2020) | 0713193628 |
| Surveillance 1 (2021) | 0713225401 |
| Surveillance 2 (2022) | 0713270541 |
| UAA  (2022) | 0713277581 |
| Notes | --- |

|  |  |  |  |
| --- | --- | --- | --- |
| Major NC | Minor NC | MDSAP Grades | Comments / Systemtics |
| 0 | 4 | 3,4,3,3 | none |
| 1 | 4 | 3,1,3,3,3 | none |
| 0 | 5 | 1,3,3,3,3 | none |
| 0 | 0 | -- | none |
| --- | --- | --- | --- |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 4 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| **2.5** | **Audit Trails** |

Description of activities covered during the Audit, key element summary for each audited subsystem.

|  |  |
| --- | --- |
| 2.5.1 | Management and Quality Management System |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
| Audit trail  records of | Martin Szepannek / George Pavlov / Gabriele Mousset / Honorata Donnermair |
| Area(s) visited (location, e.g., site visited) | Location # 10578 (all Tasks)  Location # 90464 (Task 9/11)  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Management: QMS Planning, Implementation, Changes and Quality Manual (MDSAP Chapter 1, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.1, 4.1.2, 4.1.3, 4.2.2, 4.1.4, 5.4.2 + (DIN)(EN) ISO 9001 - 4.3, 4.4, 6.1, 6.3, 7.5.1, 8.4 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(4) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.1, 5.6 + MDSAP - Japan - MHLW MO169: 5-1, 5-2, 5-3, 5-4, 7, 14; [Old3: 5, 7, 14] + MDSAP - USA - 21 CFR 820.20 + MDR - Article 10.8 ¶1, 10.9 ¶1 S2, 10.9 ¶3 (a, e); Annex IX 2.1⑦, 2.2 ¶2 (c1, c3); Annex XI 6.4 + MDD - Annex II (3.1,3.2)" "Management: Management Representative (MDSAP Chapter 1, Task 2, Site: 10578);  (DIN)(EN) ISO 13485 - 5.5.2 + (DIN)(EN) ISO 9001 - 5,3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(ii) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.5 + MDSAP - Japan - MHLW MO169: 16 + MDSAP - USA - 21 CFR 820.20(b) + MDR - Article 15 + MDD - Annex II (3.2)"  "Management: Quality Policy and Quality Objectives (MDSAP Chapter 1, Task 3, Site: 10578);  (DIN)(EN) ISO 13485 - 5.3, 5.4.1 + (DIN)(EN) ISO 9001 - 5.2, 6.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(a) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1 + MDSAP - Japan - MHLW MO169: 12, 13 + MDSAP - USA - 21CFR 820.20(a) + MDR - Annex IX 2.2.¶2 (a); Annex XI 6.2 ¶2 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Management: Organizational Structure, Responsibility, Authority, Resources (MDSAP Chapter 1, Task 4, Site: 10578);  (DIN)(EN) ISO 13485 - 5.1, 5.5.1, 5.5.2, 6.1, 6.2 + (DIN)(EN) ISO 9001 - 5.1, 5.3, 7.1.1, 7.1.2, 7.2, 7.3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.2, 2.2.3. 2.2.4, 2.3 + MDSAP - Japan - MHLW MO169: 10, 15, 16, 21, 22, 23 + MDSAP - USA - 21 CFR 820.20(b), 820.25 + MDR - Annex IX 2.1⑥⑦, 2.2 ¶2 (a, b1); Annex XI 4 & 6.2 ¶2; Article 10(16) + MDD - Annex II (3.1, 3.2), Annex V (3.1, 3.2), Annex VI (3.1)"  "Management: Extent Of Outsourcing (MDSAP Chapter 1, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.5, 4.2.1 + (DIN)(EN) ISO 9001 - 4.4, 8.4, 7.5.1 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.5 + MDSAP - Japan - MHLW MO169: 5-5, 6; [Old: 5, 6] + MDSAP - USA - 21 CFR 820.50 + MDR - Article 10.9 ¶3 (d); Annex IX 2.2 ¶2 (a, b3); Annex XI 6.2 ¶2, 12 ¶1; Article 10 (15) + MDD - Annex II (3.2 (b, d, e)), Annex V (3.2(b, c, d), Annex VI (3.2), [EK-MED 3.09B16]"  "Management: Personnel Competency and Training (MDSAP Chapter 1, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.2 + (DIN)(EN) ISO 9001 - 7.2, 7.3, 7.5.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.3, 2.2.4, 2.3 + MDSAP - Japan - MHLW MO169: 6, 22, 23 + MDSAP - USA - 21 CFR 820.20(b)(2), 820.25 + MDR - Annex IX 2.1 ¶1, 2.2 ¶2 (a), Article 15, [MPDG §83] + MDD - Annex II (3.1, 3.2), Annex V (3.1, 3.2), Annex VI (3.1)"  "Management: Risk Management Planning and Review (MDSAP Chapter 1, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.2 (b), 7.1 + (DIN)(EN) ISO 9001 - 4.4, 8.1, 8.4 + MDSAP - Australia - TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4 + MDSAP - Japan - MO169: 5-2.1.2, 26; [Old: 26] + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.9 ¶3 (e);Annex IX 2.2 ¶2 (c3); Annex I (2,3,4,5,8) & II (5) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Management: Document and Record Controls (MDSAP Chapter 1, Task 8, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.4, 4.2.1, 4.2.4, 4.2.5 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 7.5.2, 7.5.3, 8.4 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(4), 1.9; Reg 5.10 + MDSAP - Brazil - RDC ANVISA 16/2013: 3.1 + MDSAP - Japan - MO169: 5-4, 6, 8, 9, 67, 68; [Old: 5, 6, 8, 9] + MDSAP - USA - 21 CFR 820.40, 820.180 + MDR - Article 10.8 ¶1, 10.9 ¶1 S2; Annex IX 2.2 ¶2 (a, c); Annex XI 12 ¶1; Article 10, 11, 12, 22, 27, 29, 31, 51, 52, [MDCG 2019-16, 2021-19], [MPDG § 5)] + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.1, 3.2) [EK-MED 3.09 B20]"  "Management: Management Reviews (MDSAP Chapter 1, Task 9, Site: 10578);  (DIN)(EN) ISO 13485 - 5,6 + (DIN)(EN) ISO 9001 - 9,3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(iii)(f) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.6 + MDSAP - Japan - MO169: 18, 19, 20 + MDSAP - USA - 21 CFR820.20(c) + MDR - Article 10.8 ¶1 S2; Annex IX 2.2 ¶2 (c8) + MDD - Annex II (3.1), Annex V (3.1), Annex VI (3.1)"  "Management: Distribution of Devices with Appropriate Marketing Authorization (MDSAP Chapter 1, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 5.2, 7.2.1, 7.2.3 + (DIN)(EN) ISO 9001 - 4.4, 5.2.1, 7.5.1, 8.2.1, 8.2.2, 8.4 + MDR - Article 10.9 ¶3 (a); Annex IX 2.2 ¶2 (c1), Article 19, Annex IV, Annex IX ch III.6, Annex XI 2, 6 + MDD - Annex II (3.2)"  "Management: Top Management Commitment to Quality (MDSAP Chapter 1, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.1, 4.1.4, 5.1, 5.5.3 + (DIN)(EN) ISO 9001 - 4.4, 5.1.1, 7.4, 8.4 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.1, 2.2.1 + MDSAP - Japan - MO169: 5-1, 5-4, 10, 17; [Old: 5, 10, 17] + MDSAP - USA - 21 CFR 820.20(a), 820.5 + MDR - Article 10.9 ¶3 (c) + MDD - Annex II (2, 3.1)" |
| Brief description of processes or activities  evaluated to  demonstrate  what was  audited related  to the listed key QMS documents and records  reviewed below considering  inputs, outputs, and measures | General Info (GM)  >16.000 employees word wide  3,4 Mio EUR net sales  Lübeck HQ (DWAG) (Moislinger Allee) , Revalstr. (production and logistics)  Safety and Medical Business (Medical Business around 2/3 of annual revenue)  Organised in therapeuticel Busienss Units (BU Therapy, Patient Monitroing, Workplace Infrastraucture, Hospital Consumables and Accessories, Global Services)  Production Sites Worldwide  DWAG = Drägerwerk AG  2240 Employees in Medical Business  895 in R+D  630 n Production  1530 in Moislinger allee  710 in Revalstraße (Production)  Changes since last year:  BU Therapie:  EVITA some products in phase out  New product M11.3 (CO² sensor)  EVITA group Changes release 2.0 and prep 3.0  Qxylog 3000 Plus, SW change to v 1.10  Savina 300 new SW Version 5.02.01  Savina Color EoP June 2023  ATLAN family (A 300/A350), new SW features, v.2.0 (Cyber) and bugfixes, all MDSAP countries Perseus A500 CE mark MDR since 04/2023  Zeus IE, SW update 2.03, only Australian and Canada  Dräger One PM:  ICM (intregrated Care Manager), SW14.0.0  New product: lung protective ventilation analytics, non medical SW  SPV smart pilot view; v 3.03, currently TD review stage  Core new product, Infinity to STC and back, SW 1.0 + Converter Service, currently TD review stage |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 5 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | MPW (mobile patient watch), v2.0, functional enhancements, IIb  BU WPI:  Ambia ceiling supply, SW 2.2  Ponta, MDR since 2023, IIB  Valia New Arm System (supplier Ondal), IFU changes, handle material change, MDR CE Mark class I  BU HCA:  Delta P Flow Sensor (oxylog family), MDR Mai 2023  Self test lung, poduct enhancement, reprocessing optimized, November 2022 ; MDR class I  HumidStar 2 Plus Luer-Lock, different sizes available, August 2023 IIa MDR  Supplier location change Bood pressure cuffs, reusable and single change MD calss I, change January 2023 Vascumat Tube class I, new supplier and Dräger design change  Organization /IT/processes:  BU Therapie restructured.  BU Data business terminated (e.g. Dräger one to PM  Clinical and central regulary affairs one BU  Stepahn Kruse (BU Therapy) left the company.  Dr Rainer Wobe (BU clincal affaires) left.  Dr. Bettina Möbius new Head of central clincal and regulatory affairs IT Systems Change to S4 HANA  Processes: continuous update  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  **ISO 9001:**  There is a process in place to continual improvement (see Management review)  There is evidences for stringent customer focus / satisfaction (see section below, Device Marketing Authorization and Facility Registration / Customer Related Processes)  There is a process in place for Changes and risks (see CAPA, and D&D changes)  There is evidences for knowledge management (see Management review)  See also extra section for ISO 9001  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  Management Responsibility  M1 - Quality Management System Planning (MSz)  Confirmed that quality management system planning is performed to ensure that all required processes are identified, documented, implemented, monitored and maintained in order to conform to the applicable requirements and meet quality objectives.  Verified that changes to the quality management system are managed to maintain the conformity of the quality management system and of the devices produced.  Verified that a quality manual has been documented.  Dräger keeps an Integrated Management Systems that applies to all Dräger Companies and integrates processes with dirfferent underlying Stakeholder requirements, i.e. regulatory, quality, environmental, health and Safety, and financial requirements.  BIC (Business Information Center) is used as process management system. All process desriptions are included within that system (this exceeds regulatory required processes). Furthermore the process flow charts are displayed, responsibilities, inputs, outputs, templates etc.  Corporate QRA is responsible for approval of Global Standards and Draägerwerk Ag & Dräger safety AG. Local adopted standards are approved by Global process Owners in alignment with Corporate QRA, if local Quality Manager has specific local needs. Localisatio rules are implemented, usually they allow for translations, minor changes to process step descriptions, forms, tools, responsibilities, applications, references to internal and external documents. See DEALL PQ 3130.  Interested Parties are:  - Authoristies and Certifcation Bodies  - Busienss parteners  - Customers  - Dräger family  - Emolyees  - Financial Stakeholders  - Legislation  - Society  Their main requirements to the organisation are documented within Quality manual 4.1 Corporate Strategy.  M2 - Management representative, awareness (GM) 5.5.2  *Regulatory requirements*  MDR:  Article 15; Annex IX 2.1 & 2.2 (2a, b1); Annex XI 4 & 6.2(2); Article 10(16)  MDD: Annex II (3.1, 3.2), Annex V (3.2), Annex VI (3.2) (e.g. Declaration of conformity/ system etc)  Management Representative`s appointment and responsibilities are documented in organization charts and Job descriptions. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 6 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | Job description Stefanie Hirsch (medical devision/corporate Q&RA Leader) with tasks of management representative and PRRC were reviewed. Role description includes several details as e.g. RA and clinical and TD declaration of conformity. SH is also appointed as authorized representative for Dräger DMSI (USA- Monitoring Systems).  PRRC role is devided into several responsibilities (TD and DoC`s responsibility Stefanie Hirsch )  Frau Hilmer (PRRC PMS)  Frau Hering (PRRC clinical aspects) and others. All PRRC responsibilities are documented in Liste ausgewählter Beauftragter im IMS, which have been audited.  M3 - Quality policy, objectives (GM) 5.3, 5.4.1;5.1; 4.2.1(a)  Quality policy and objectives have been set at relevant functions and levels within the organization.  The quality objectives are measurable and consistent with the quality policy, the overview of objectives (QM initiatives) in MR as well as an example of follow up (RIM/ARAS) migration have been audited.  Quality objectives are deduced from the strategic quality aspects: e.g. renewal of product-portfolio/system-  infrastructure/system applications/ efficacy/organization mindset/external triggers  Quality objetives are followed up by action plans that define sub targets, responsible person(s), due dates and resources needed. Overview regarding project-status and needed actions will be given e.g. by monthly “Führungskreis Meetings”: QAA Steering Meeting medical/QAA Steering meeting corporate.Additionally, weekly QAA standup meeting will be performed for tracking of relevant QM topics and actions.  M4 - Org. structure, responsibilities (GM) 5.5.1; 6.1 ;5.1; 6.2 (Moisler- and Revalstr.)  The manufacturer’s organizational structure and related documents have been reviewed. Organizational structure have been presented during audit in introduction presentation with links to concrete org. Charts (related Q douments). Responsibilities and authorizations are described by functional descriptions.  Disciplinary and reporting lines are outlined in the organizational chart.  PRRC and medical representative is announced (see also M3). For all MDD medical products the product owners are responsible. MDR role PRRC is devided into subset responsibilities with different persons in charge (see M3). The critical roles in respect to the QMS are listed and dedicated in document “Liste ausgewählter Beauftragter im IMS”  M5 - Extent of Outsourcing (HD)  According to the QMH the outsourced processes are monitored and managed according to internal procedures. A list of outsourced processes in maintained and was demonstrated during the audit. The outsourced process includes examples such as:  - Archiving of documents & records  - Design & Development  - Human Resources, training organization & record Administration  - Installation, repair & maintenance (to Drager Sales & Service entities)  - IT-Services  - Logistic services incl. final inspection & test  - Sterilization  - Supply of finished medical devices  List of approved suppliers was demonstrated.  Spot check made based on sampling – The supplier of 2K seals (contact with breathing gas) supplier Trellabo Sealing CS 11649 and supplier AB Ulax CS 145240 ( supplier of medical device Humidstar 2+LL) - were found in the list.  The suppliers based on the classification and criticality underlay different monitoring measurements such as annual delivery and quality evaluation (DQPE), audits etc. The QSV, audit reports and DQPE for both sampled suppliers were reviewed during the audit.  Additional country-specific requirements:  Australia: The Drager Australia Pty is identified as AU Sponsor.  The Distribution Agreement with Draeger Australia PTY was demonstrated.  Canada  CANADIAN Regulatory role is fulfilled by the Regulatory Affairs Central in Lubeck, The Canadian distributor is not performing the role.  The Canadian Distribution Agreement is available and demonstrated as email.  M6 - Competencies for personnel (GM) 6.2  The team manager determines the required trainings for each employee (role specifics), together with the qualifications which are communicated to HR and evaluated once a year. Basic requirements are predefined for types of roles and entities (e.g. leader, or D&D)  The team leaders are responsible to communicate the requirements for new employees. There are general trainings that all employees should perform (e.g.: data security, work safety, among others). The responsibility of the  performance of the trainings is taken by the corresponding management.  Once the requirements have been identified, there will be training measures set. Depending on characteristics of needed qualifications trainings will be identified covering required competences.  The trainings performed are documented in training records. Templates are used ( e.g. Teilnehmerliste).Trainings could be online or onsite trainings.  Effectiveness checks of trainings can be defined individually for all trainings and e.g. doumented on “Teilnehemerliste” or other suplemental documents if needed.  Generrally, the effectiveness checks will be performed during each training. The team leader determines whether additional effectiveness checks of the trainings should be done, based on the responsibilities of the employee (the latest Q-check).  A yearly effectiveness check will be performed by team leaders for every enployee and documented on Q-Check template. Additionnally, an individual apraisal will be performed for each employee which can be denied by employee but is mandatory to provide by teamleader. Generally the apraisals will not be documented (requirement defined by “Beriebsrat”). In case of needed actions these will be doumented in action-plans for the respective employee. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 7 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | Overview of trainings per role or employee can be seen in “Trainingsportal” (TCM)  Q-Check document: is the document to control which kind of trainings have been performed individually and shows the status of those trainings. All the trainings which are defined in the Q-Check are mandatory.  The Q-Check can be released only when all trainings are completed or planned.  The general documentation of the trainings is the participants list, there are also other records e.g.: prove of competence, self-study and the corresponding documentation, external certificates will be also accepted as training records.  The Q-Check incl. update of documentation is performed once a year. In case the required trainings are not fulfilled or in case of lack of competency, it is responsibility of the corresponding managers to implement measures. The training records are stored paperbased and Q Checks additionnally on a the central system TCM.  Onbording training is the same as described above. The defined trainings (basic and individual once) should be done during the first 3 months (latest after one year). The temleader is responsible to check whether all mandatory trainings have been performed before giving any quality relevant tasks to the employee.  Brazil :  Confirm that the manufacturer ensures that any consultant who gives advice regarding design, purchasing, manufacturing, packaging, labeling, storage, installation, or servicing of medical devices has proper qualification to performsuch tasks. Those consultants shall be contracted as a formal service supplier, according to purchasing controls defined by the manufacturer [RDC ANVISA 16/2013: 2.3.3].  External consultants will be addressed in Purchasing session Mr Pavlov.  The training process will be also followed for external employees (especially regarding definition of needed trainings and Q-Check`s). For sub-contractors, the qualifications should be put in respective contracts.  There is an online training - platform in place (TCM) used for internal and external personnel, which can be configured to show the requirements of the roles, the qualifications are defined within packages (e.g. leader; rsik managemnet etc.). The training status is identified in colour code (red and green).  The tool allows the users to select the trainings and perform them, either online or onsite.  The Medical Consultants should have several trainings related to their responsibilities; the respective managers determine which qualifications are needed according to the products and roles they are assessing.  A council determines the required qualifications for the different roles. This includes participants from the legal, HR, Data security, compliance, operations, quality, academy departments.  A Trainer is a person, which is qualified to perform training measures, he/she will be selected by the training organization and Dräger.  Trainings will be performed by experienced employees.  M7 - Risk Management Planning and Review (HD)  The organization has established risk management throughout the quality management system, the link to the other processes such as clinical evaluation, change management, R&D, PMS is evident. The main description of the risk management process is defined in Risk Policy and acceptance criteria. The process defines 12 steps (plan RM process, plan change specific RM, identify hazards, support CE process, evaluate identified risks, review RM process etc)  The acceptance criteria (insignificant, considerable and substantial) are available in Attachment A06 to the risk policy. In section 3 overall residual risk is considered. Overall risk management is reviewed on a regular base. The detailed risk management process related to design is performed during design and development process.  The link to management review is established. Overview of risk management is a part of the annual management review (Product Risk Management incl. product usability). In the most recent management review the following KPIs are defined: occurrence rate of harm, PSUR/ PMSR performed and required Risk Reducing Measures, status – withing acceptance thresholds 33/0.  The risk management system is fully effective. However, the tight resource situation in one area (BU Therapy) needs to be reviewed.  The annual risk reports for flow sensor (MP 20092 and MP 20093) were presented.  Post-production Information Risk Review Report includes yearly review of following topics: product and product version, review of EVRI reports, review of clinical data, review of cybersecurity, specific risk assessment, gap analysis.  **MDR 2017/745 - Article 10\_2**  (Risk management system established, documented, implemented and maintained - section 3 of annex I) Manufacturers has established, implemented, documented, and maintained a risk management system. The risk management process is carried out as continuous activity throughout the entire lifecycle of the device. The updating frequency and triggers are defined.  M8 - Documents and Records Control (MSz)  Verified that procedures have been defined, documented, and implemented for the control of documents and records of both internal and external origin required by the quality management system.  Confirmed that the medical device organization retains records and at least one obsolete copy of controlled documents for a period of time at least equivalent to the lifetime of the device, but not less than two years from the date of product release.  Handling of documents and records is described in DEALL PQ3130.  Controlled documents are created within BIC.  Documentation Matrix defines types of records to be created within a process, and retention periods (minimum retention period required is 15 years, for product related records it is 30 years.  Process Owners are reponsibles for keeping conrtrolled documents up to date; this is alt least carried out by a regular review (recommended all 5 years, at least all 10 years).  BIC contains also a change log for changes on a global and local level. Herein, changes are described.  Australia (TGA): |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 8 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | Confirmed that Quality Management System documentation and records in relation to a device described in TG(MD)R Sch3 P1 1.9 are retained by the Manufacturer for at least 5 years (actually 30 years, 11 Years reflected in wirtten Agreements between Australian Sponsor and Drägerwerk).  Brazil (ANVISA):  Verify that change records include a description of the change, identification of the affected documents, the signature of the approving individual(s), the approval date, and when the change becomes effective [RDC ANVISA 16/2013: 3.1.5]. DEALL PQ3130 : Control of Documents and Records/ Lenkung von Dokumenten und Aufzeichnungen/ Records DEALL PQ3130‐en\_de‐04.00 , Rev. 04.00  Confirm that the manufacturer maintains a master list of the approved and effective documents [RDC ANVISA 16/2013: 3.1.5]. Corporate Procedure List  Verify that electronic records and documents have backups [RDC ANVISA 16/2013: 3.1.6]. if electronic records are defined, a Backup and Archive Plan is created individually case specific; Backup & Archive Plan for BIC QPS 484: Daily backups are performed; recovery point is 24 hrs. recovery Time is 4 hours. Backup storage is handled by the provider amazon web services in accordance with 27001.  Japan (MHLW)  Confirm that Quality Management System documentation and records in relation to a device are retained by the Registered Manufacturing Site for the following periods (5 years for training records and documentation) [MHLW Ministerial Ordinance No.169: 8.4, 9.3, 67, 68]:  30 Years is defined anyway for product related documentation.  United States (FDA)  Verify that electronic records and documents have backups [21 CFR 820.180]. Part of Software Validation  **MDR:**  Inaddition, Drägerwerk AG & Co. KGaA assumes the role of authorized representative according to MDR or MDD/MPG for Dräger manufacturers outside Europe, e.g. for Draeger Medical Systems, Inc. (USA) or Draeger India Pvt. Ltd. (India). Drägerwerk AG & Co. KGaA assumes the roles of "importer" and "distributor" for various products, acts as a "system or procedure pack producer" in accordance with the MDR, and in some constellations also acts as an original equipment manufacturer (OEM) for other medical technology manufacturers.  PQ2110 A01 Template for Table of Contents of Technical Documentation  M9 Management Review (all auditors) 5.6; 5.1  The overall approach to MR process was explained in the presentation.  The risk-based approach with Traffic light indication (red /amber /green) is in use to indicate topics which contain MR will be done and approved with relevant members of management-board.  Period one year (LMR March 2023 data from March 2022 to March 2023)  Management procedure is documented in DEMF CS1100, no relevant changes since previous external audit.  Management reviews are conducted at planned intervals (annually)  The audited management review addresses all topics required by the standards and requirmenets of all regulatory aspects.  Main chapters of MR: Management Summary/ Quality and Objectives/ Establishing inputs/Management evaluation Main aspects of MR: Product in focus/Handling in focus/Process in focus/ System in focus.  The management review report is signed by Stefanie Hirsch and Mr. Schrofner (responsible management members). KPI´s (covering main processes) are defined and represented with trends in the MR: e.g. CAPA-> 80% CAPA handlig in time (2022 65%/ not reached, justification given actions defiend CAPA process focus topic)  e.g. audits; auditplans and fulfilment; supplier audits 2022 58 planned 48 fulfilled.  Responsible employees for the preparation of management review input and required attendees are defined. Quality policies and quality objectives are installed and reviewed during the management review.  MR includes a review of the suitability and effectiveness of the quality policy, quality objectives and quality managemenrt system.  The latest MR record from March 2023 were demonstrated – Top Management and Executive management team - CEO was present at the company.  Verifed that management review procedures have been documented, management reviews are being conducted at annual intervals and that they include a review of the suitability and effectiveness of the quality policy, quality objectives, and quality management system to assure that the quality management system meets all applicable regulatory requirements.  Structured into Management Summary, Quality Obkectives, established Review Input, Evaluation  A traffic light principle for management Summary demonstrates status of Topics for the Clusters “Product in Focus”,  “Handling in Focus, Process in Focus + System in Focus”; Top targets and expectations last year;  Only red topic was CAPA handling in Cluster “Handling in Focus”; Taget Values are >80%, Current values are 65%, 48% System, 68% within 30 days, 41% CAPA Plan define dwithin 67 days.  From 7 Follow-up action items of prior year, 6 could be closed within 2023 Management Review; 1 remained open  (“Handling of CAPAs”);  In regards to Quality Policy and Objectives, Key issues in 2022 was “Number and Business Impact of Field Actions: Several KPIs behind target”.  The Q&RA responsble persons of the different Business Units and Regions report in a dotted line to Head of Q&RA in Moislinger Allee, which therefore is able to provide global input into Management Review.  Since 2022, a new global web based training is available in 15 languages and the qualification has been included in  the “Global Basic Profile” (for all employees).  Focus 2023 for separate Business Units is approved within Management Review.  The following elements were assessed specifically as examples of Management review content: -Management Summary/focus topics/process KPI  -Follow up actions: one action item continuation (CAPA handling), 6 closed |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 9 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | -Quality policy (defined in the QMH- not changed in 2022/2023, covers integrated MS) and objectives , incuding quarterly Quality reports, focus issues: FSCA some actions behind target regarding planned timelines- action item management reactions and further dates with focus on this topic.  -Human Ressources and changes of responisbilities ere represented in current MR e.g. changes in Q&RA&clinical responsibilities, overview regional sales and services.  -Focus for BU´s e.g. BU Therapy launches ATLAN family  -2023 Quality&RA initiatives (objectives): e.g. support for product portfolio (Dräger One), organizational topics. The  genaral topics will be followed in detail during further meetings: example 1 “channel one complaint project” (global improvement project), improvement of efficacy of complaint process; example II “Labeling @Dräger: centralization of labeling topics and used tools  -MR Inputs: product performance/Product compliance/risk Management/Usability/Handling of complaints and CAPA´s/FSCA/Design changes/Internal external audits/QMS changes/performance Service, distribution and production  For all of these Input topics it exists a One Pager to show the status of all of the topics: find the samples under records  2023 Initiatives are documented top-down, and broken down into projects (slide 22 in Mgmt review PPT), both for Medical, Corporate and Safety. Example: Labelling @Dräger. For this project, a separate organisational structure under the Global Q&RA has been establish.  Establisehd Management review Inputs are:  - Product performance pro BU  - Product Compliance incl. new/updated regulatory requirements - Product Risk management incl. Usability  - Product Feedback  - Handling Complaints incl. reporting to regulatory authorities - Handling CAPAs focus System and Focus Product CAPAs - Handling design Changes focus Q&RA  - Handling Field actions  - Performance Sourcing  - Performance Production  - Performance Distribution  - Performance Service  - External + Interbal audits  - Changes Affecting QMS  - Environmental, health and performance.  Management Review has been signed as to be Adequate and suitable quality policy & objectives, adequate and suitable QMS, Risks and Opportunities considered, Q-Targets for next year are approved, Actons and decisions are committed.  Based especially on Action Item 4 (Product Risk Management) and 5 (Oxygen 90+), the Top mangement poved commitment by the decision to note down an action item into the acton Item List, although it was not suggested by the Management review team.  Action Item list contains a status a status indicator for the progress and completion of actions. This review is done at least bi-annuallly and aligned with the quarterly Q-Reports for management.  M10 - Distribution of Devices with Appropriate Marketing Authorization (GP)  The organization has defined and implemented controls to ensure that only devices that have received the appropriate marketing authorization are distributed or otherwise offered for commercial distribution into the applicable markets. The devices are listed the Global Matrix data sheet, which insures only the registered devices are correctly distributed in the respective region.  To add the device to the global Country Matrix, the regional organizations shall submit the Global Matrix request the table of applicable requirements for each jurisdiction is documented to ensure the regulatory requirements are maintained.  The physical distribution is controlled by ERP system. The Market Clearance Form is field by the Market Clearance manager and forwarded to the SAP administrator, to setup the permitted distributing regions.  The process for maintenance of the devices in SAP (Market Clearance) was demonstrated - documented as DCGL PQ12180 -en -037-01 Rev 1 Country Matrix  Foe registration expels for specific devices – REF to DMA+FR-1  M11 - Management Commitment (all auditors GM version) 5.1; 5.5.3  Based on the sampled evidence, it was observed that Top Management has demonstrated the commitment to the QMS, this particularly achieved by the provision of resources, establishment of respective processes, analysis of data and active participation in the Management review.  E.g. needed lacks have been identified (CAPA process), topics of IRS are adressed and evaluated. Relevant roles and responsbilities are defined. Strategic quality issues are defined and followed. |
| Reviewed  documents and records  (identification  and revision) | Documents (all, also M1, M8, M11):  DEMF CS1100 : Management Review DEMF‐CS1100‐en‐00.00 , Rev. 00.00  DEALL HR3400 : Employee Qualification Process DEALL HR3400‐en\_de‐05.00 , Rev. 05.00, last changes: implementation of some digitalization aspects; administrative changes, effectiveness checks change of head, approval of trainings adjusted, documentation of effectiveness checks integrated in trainings measure, adjustment Anlage . A01/A01/A011/A012 , global process: product and user trainings are integrated in this process.  New personnel should be trained during the first 3 months not longer than 1 year. Some trainings (“Arbeitssicherheit” should be done on the first day).  ODWAG/DCGL CS1000-de-07.00 Quality Manual Rev 08, 01.05.2023 including policy integrated MS Template Teilnehmerliste:  DEALL HR3400 Anlage A01-en\_de-0.5.00, including trainer, date, trainee, availability, effectiveness (in case of effectiveness check during training)  Template Q-Check: |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 10 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | DEALL HR 3400\_A13-en\_de-01.00, name of employee, ID, role, description of qualifications, signature of employee and team leader  Template individueller Einarbeitungs Plan:  DEALL HR 3400\_ xls (related information 15)  DWAG IN4203 : Product Verification DWAG IN4203‐en‐02.00 , Rev. 02.00  DEMF CS1100 : Management Review DEMF‐CS1100‐en‐00.00 , Rev. 00.00  DWAG CS1000 : Dräger Integriertes Managementsystem ‐ Handbuch der Drägerwerk AG & Co. KGaA DWAG  CS1000‐de‐08.00 , Rev. 08.00  DEALL PQ3130 : Control of Documents and Records/ Lenkung von Dokumenten und Aufzeichnungen/ Records DEALL PQ3130‐en\_de‐04.00 , Rev. 04.00  PQ2110 A01 Template for Table of Contents  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐03.00 , Rev. 04.00  Management-review summary 2023- 23 March 2023  Action Items List (from Management review) 2022  Records (all, also M1, M8, M11):  DCGL PQ12180 -en -037-01 Rev 1 Country Matrix  Organisational Chart Medical Division 2023-07-01  Core Procedures DWAG 20230914.pdf  Audit Trail (Electronic Documentation of approval) for DCGL PQ3130-en-04 from 2022-11-25  Audit Trail for approval of local adopted global standard: eMail communication to DCGL SE1200 “Installation & Commissioning” between Dräger Safety Equipment China and Global process owner of Drägerwerk, dated 2023-06-28  DEALL PQ3130\_A02 Documentation Matrix  PQ3130\_2023-06-29\_Documented\_Procedures\_older\_than\_10\_years  Distributor agreement Dräger australia PTY Ltd. 10.08.2018  STED\_Table\_of\_Contents\_T500.pdf / MDR106-011, compiled 2023-08-16  Technical Documentation is kept in ClearCase Configuration Management Tool and can be manually exported to e.g. file server structure or design dossier requirements. Respective structural needs are decsribed within PQ2110 Regulatory approval to Market  M2 (GM)  Tätigkeitsbeschreibung Stefanie Hirsch, 01.09.2023, signed by Toni Schrofner and Stefanie Hirsch, QRA Medical and Corporate, Purpose of function e.g. representation and awareness QM, strategic plans, integrated MS, audit programs, continuous improvement, management representative for QMS regulations: Compliance Committee and Risk committee.  Liste ausgewählter Beauftragter im IMS, Stefanie Hirsch MR, 11.09.2023, rev 09  PRRC´s:   Konformität der Produkte: (Kevin Dornau (BU Therapy) Marcus Vorwerk (BU WPI), Timo Harms (BU HCA) Jakob Kleissl (BU Patient Monitoring)  TD: Kevin Dornau (BU Therapy) Marcus Vorwerk (BU WPI), Timo Harms (BU HCA) Jakob Kleissl (BU Patient Monitoring), Bettina Möbius (Central Regulatory affairs), Stefanie Hirsch ( QRA)  PMS Inverkehrbringung/Vigilance : Sonja Hilmer  Anhang XV Kapitel 2 (Prüfprodukte): Dr Sonja Hering  M3 (GM)  High level description of policy in Intranet  DCP 0005-en-040-02 Intranet including link to Quality Broschüre: aspects Quality /Environment/Employees/Society, 2019  ODWAG/DCGL CS1000-de-07.00 Quality Manual Rev 08, 01.05.2023 including policy integrated MS  Presentation Dräger Recertification Audit 2023, objectives/initiatives:  1. Finalization of MDR program-> last steps realization (until 2024  2. QMS readiness Dräger One-> new portfolio with focus on SW connected devices.  3. Regulatory management; Rapid (SAP module) migration to ARAS  4. Advance regulatory knowledge/awareness  5. CAPA process improvement  6. External triggers: UDI/UKCA and others  7. Restructuration of complaint-process (Channel One)  Objectives will be reviewed on a monthly base in management Team:  One Pager RIM (3) strategy meeting on 07.09.2023 , evaluation of project status, weekly QRA standup meeting, responsible Marcus Richter, first step regulatory information management (integration from WWRD and RAPID into one platform): start 02/2021 planned finalization 07.2024, fulfillment status total project 60%, fulfilment this year 45%, top 3 topics 2023: fulfillment SW packages/user tests/ migration preparation, output e.g. low deadline performance IT provider action: RIM Guidance Board, last meeting 05.09,2023, e.g. some tasks will be handed over , project risk management, low resources Mediatec, responsible persons for specific resource risks  M4 (GM)  Organizational Chart Dräger, 01.07.2023 B Therapy/ BU Patient Monitoring/BU WPI/ BU HCA/BU Global Services Organizational Chart Dräger, 01.09.2023 Q&A  Liste ausgewählter Beauftragter im IMS, Stefanie Hirsch MR, 11.09.2023, rev 09  M5 (HD)  DWAG CS1000-de08.00\_english translation |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 11 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | LIST OF OUTSOURCED PROCESS 2023-08-25 revision 7  DEMF SP 2110 Supplier Phase in and Quality Approval Rev 03.00  DEMF SP6250: Identification and Control of Prioritized Suppliers DEMF SP6250‐en‐03.00, Rev. 03.00 QSV Trellabo Sealing dd 11.08.2017.  DQPE Trellabo 20.03.2023  Audit report Trellabo PR 26356  Audit report AB Ulax 24.03.2021  DQPE AB Ulax 29.03.2023  QSV AB Ulax dd 20.11.2017  DEMF SC 513 A07 de-02.00 FAI Results MP05840 (AB Ulax) – release for series delivery.  Draeger Australia Distribution agreement 10/08/2018  Memorandum of Understanding Between Drager Australia Pty and Drager Germany Co KG 03/08/2018 The Distribution Agreement inclusive Amendment 1 dd02.08.2019  M6 (GM)  Example trainings overview Bätz Johanna (01374868):  Overview Trainingsportal (D&D) Qualifikationsprofile Dr. Bätz (System engineer): Rollenzuweisung : Mitarbeiter DWAG (e.g. „Arbeitssicherheit”/Electronical signature)/System Egineer(e.g. 606001-1 and subset of relevant processes/GLOB\_ Mitarbeiter (e.g. data protection. Anti corruption , fishing)  Q-Check 01374868, signed 17. and 18,04 2023, all trainings performed.  Overview Trainingsportal (production) Qualifikationsprofile: Bernowitz Michael (1003945) Teamleiter (Sawina) Rollenzuweisung: GLOB\_ Führungskraft (e.g. Anti Coruuption, Tax awareness), DE Führungskraft DWAG (Arbeitsssicherheit, Führung Grundlagen Leadership) ,DE Leitung Teamleiter MT (e.g. ESD , Ergonomie Basis, yearly EMV)  Q-Check 1003945, signed by employee and Teamleader, 09.05.2023. all trainings performed, no additional comments.  Q Check Janson (Produktionsplanerin/Teamleiterin (1002146) 2022, 22.02.2022  DEALL HR 3400\_ xls (related information 15) (1002146),actionist, Development as Leader, additional trainings shopfloor leading, communication, working time, 22.02.2022.  Onboarding sample:  Overview last new employee in D&D Dr. Robert Ott (0176537) (Risk Manager ventilation), onboarding 01.11.2022 First Q Check , 05.01.2023 (1002146), signed by team leader and employee.  Current status (1002146) TCM trainings role risk manager DWAG, open trainings funktionale Sicherheit and Cyber Security, can be finished until November 2023.  DEALL HR 3400\_ xls (related information 15), individueller Einarbeitungsplan (1002146), incl e.g. external training 14971, done 26.10.2022  Example external resources (Brazil)  Q check Dr. Spengler (verification Intensive care Evita V600/V800), (1372386), all defined trainings done, e.g. the Dräger process DWAG IN4203 product verification DWAG  External consultant contract „Arbeitnehmerüberlassungsvertrag (between Dräger and qtec services)1372386 (Dr. Spengler), current version , 01.07.2023, chapter 4.1definition of role (test engineer), qualification profile-> transmitted into TCM.  M7 (HD)  DWAG IN 42 10 A06- 03-00 16-04-2023 Risk Policy and acceptance criteria  Risk Management Plan Carina/ Oxylo BC 2021-01-03  RAT (11265056) Risk Assessment Table Carina/ Oxylo BC - 2022-07-13 revision 0 ID 11221574 PRMR Carina/ Oxylo BC Version 01 2023-07-14  ID 11228196 RM Process review report carina \_ and Oxylog Braething 29.11.2022, revision 00 Management Review 2022-03-30  M8 (MSz)  See above  M9, M11 (all)  DEMF CS1100: Management Review DEMF‐CS1100‐en‐00.00 , Rev. 00.00  Management-review summary 2023- 23 March 2023  Action Items List (from Management review) 2022  Presentation Dräger Recertification Audit 2023  Quality Policy – documented as part of the Quality manual  DWAG site plan Moislinger Allee, current version overview  DWAG site site plan Revalstr., current version overview, audit mainly in W23/Haus 10/MLZ  Organizational Chart Dräger, 01.07.2023 B Therapy/ BU Patient Monitoring/BU WPI/ BU HCA/BU Global Services Organizational Chart Dräger, 01.09.2023 Q&A  Manual DWAG CS1000, rev 8 effective since 01.05.2023  Management Review 2022 – DWAG 2022-03-22, signed by Stefanie Hirsch and Mr. Schrofner  One pager MR input 2023:  Example One Pager CAPA: problem timely performance of CAPA´s, evaluation in red area, actions defined: management support/priorities-> currently KPI on track  Example WPI: failure rate in target/ Complaint reliability rate only timelines not in target  Example One Pager Therapy: problem intime execution complaints |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 12 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Management - Quality Management System** |
|  | Example One pager HCA: 3 field actions highlighted; Field failure rate slightly above target, complaint timelines not in target.  Example One Pager Product feedback, general in target (I all feedback will be evaluated not limited to complaints) Example One Pager Risk management: action Item resources  Example One pager Product compliance  Example One Pager complaints, yellow: slightly negative trend regarding backlog and timely closing; Quality project: process redesign (channel one)  Example Handling of field action: 40 new opened, total 48- actions defined because of big backlog  Example One Pager Handling of Design changes: view on long-term processing changes  Example One Pager performance Sourcing: e.g. supplier audits, Supplier PPM slightly above target (e.g. supplier for accessories)  Example One Pager Performance of distribution: all topics on track  Example One Pager Performance of Service: all topics on track  Example One Pager internal and external audit: all topics on track  Example One Pager changes affecting QMS: all topics on track, e.g. all changes in regulatory will be evaluated.  Action List MR 2022 – Action Item List – Update 2023-09-18.xls  M10 (GP)  DCGL PQ12180 -en -037-01 Rev 1 Country Matrix |
| Names and titles of persons  interviewed | (all other tasks)  Stefanie Hirsch (Head of Quality & Regulatory Affairs)  Ulf Hagedorn (Head of Integrated Management Systems Audit Management)  Kevin Dornau (Director Quality & Regulatory Affairs Business Unit Therapy)  Timo Harms (remote) (Director Quality & Regulatory Affairs BU HCA)  Marcus Vorwerk (Director Quality, Regulatory Affairs and Purchasing Business Unit Workplace Infrastructure) Jakob Kleissl (President Program Draeger ONE & BU Patient Monitoring)  Bettina Möbius (Head of Central Regulatory & Clinical Affairs)  Sonia Mess (Head of Integrated Management System)  Sonja Hillmer (Head of Post Market Surveillance)  Marcus Schüler (Head of Q&RA Central)  Jana Wienke (scribe) (Quality System Manager Auditing)  M2, M3, M4 (GM)  Stefanie Hirsch (Head of Quality & Regulatory Affairs)  Marcus Schüler (Head of Q&RA Central)  Jana Wienke (scribe) (Quality System Manager Auditing)  M 6 (GM)  Barabara Drews (HR Manager Quality Center of Expertise Labour & Employment Human Resources) Reinhard Zimmermann (Head of Learning Eco System, Quality & Processes Global Academy) Christian Elsenbach (Teamleiter R&D, System Engineering & Risk.Management, BU Therapie) Dirk Geisteier (Head of Production Line Respiratory Care/ Warming Therapy)  Jana Wienke (scribe) (Quality System Manager Auditing) |
| Products,  components, or projects  reviewed | Not applicable |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for this subsystem | This process is effectively implemented and conforms to requirements. Management uses appropriate data to monitor and evaluate the QMS. The organizational structure and the QMS ensure the competence and qualification of personnel. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 13 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.2 | Device Marketing Authorization and Facility Registration, Customer Related Processes |

|  |  |
| --- | --- |
| Subsystem | **Device Marketing Authorization and Facility Registration, Customer Related Processes** |
| Audit trail  records of | G. Pavlov |
| Area(s) visited (location, e.g., site visited) | Location # 10578  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Device Marketing Authorization and Facility Registration: Submission for Device Marketing Authorization and Facility Registration (MDSAP Chapter 2, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 5.2, 7.2.1, 7.2.3 + (DIN)(EN) ISO 9001 - 4.4, 5.1.2, 7.5.1, 8.2.1, 8.2.2, 8.4 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - As required by MDSAP AU P0002 + MDSAP - Canada - As required by MDSAP AU P0002 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - As required by MDSAP AU P0002 + MDR - Article 32, 52, Article 10.1, 10.9 ¶3 (b, j), 10.14, 10.15; Annex IX 2.2 ¶2 (c2), 2.4, 3.2; Annex XI 6.4, 7 ¶1, [MDCG 2019-9], [MPDG § 4(2)] + MDD - Article 11"  "Device Marketing Authorization and Facility Registration: Evidence of Marketing Clearance or Approval (MDSAP Chapter 2, Task 2, Site: 10578); (DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 5.2, 7.2.1, 7.2.3 + (DIN)(EN) ISO 9001 - 4.4, 5.1.2, 7.5.1, 8.2.1, 8.2.2, 8.4 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - As required by MDSAP AU P0002 + MDSAP - Canada - As required by MDSAP AU P0002 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - As required by MDSAP AU P0002 + MDR - Article 19 & 20, Annex IV, Annex IX ch III.6, Annex XI 2, 6 + MDD - Article 11"  "Device Marketing Authorization and Facility Registration: Notification of Changes to Marketed Devices or to the QMS (MDSAP Chapter 2, Task 3, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 5.2, 7.2.1, 7.2.3, 7.3.9 + (DIN)(EN) ISO 9001 - 4.4, 5.1.2, 7.5.1, 8.2.1, 8.2.2, 8.3.6, 8.4, 8.5.6 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - As required by MDSAP AU P0002 + MDSAP - Canada - As required by MDSAP AU P0002 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - As required by MDSAP AU P0002 + MDR - Article 10.9 ¶1 s2, 10.9 ¶3 (a); Annex IX 2.2 ¶2 (c1, c8) + MDD - Annex II (3.2) " |
| Brief description of processes or activities  evaluated to  demonstrate  what was  audited related  to the listed key QMS documents and records  reviewed below considering  inputs, outputs, and measures | #1 - Submission for Device Marketing Authorization and Facility Registration  Verified that the medical device organization has complied with regulatory requirements to register and/or license device facilities and submit device listing information in the appropriate jurisdictions where the medical device organization markets or distributes their devices  The regulatory requirements for new products are prepared in the form of four documents:  - Medical Device Classification  - Regulatory approval plan  - List of applicable standards  - List of regulatory deliverables  The requirements are registered in Medical device File.  After registration in specific countries , the market clearance is initiated: The Process for release to the marked in defined on SOP IN8071.  The results documented as special form DCGL IN8071 A02 – MC form is saved as part of DHF, the product release is performed in SAP.  The Changes to the country requirements are controlled as part of Change description. The review is performed by the regulatory teams in the respective countries.  The assessment if the change is significant –is documented in PTI (Pre-tailoring Investigation) document. If the change is significant, the regulatory review is repeated.  The product changes are assessed in PTY (Product change description) document.  Decisions to be done in RA Process:  - MD QMS  - Certification Scope Check  - Review of TD (DHF) by Project Manager,  - Quality Assurance Manager and RA Manager.  - PRRC approves DOC.  Country specific requirements:  The list of regulatory device regiments I documented as designed input The following certificate have been reviewed:  CAN and US is managed directly; other regions are covered by Subsidiaries ore Sales Channel Partners, Acting as the regulatory correspondents.  The regulatory suppliers in MDSAP countries were demonstrated:  Example: New Product Introduction M11.3 CO2 sensor –  M11.3\_RAP Regulatory approval plan CO2 mainstream sensor M11.3  Market Clearance CO2 mainstream sensor M11.3 USA – 20232-70-20  Marc Clearance EU (including assessment of the language requirements) 2023-05-31  SAP release to the registered countries : Part No 6873570 generated  The examples for the country release: from SAP was generated on the day the audit:  It was demonstrated the M11.3 CO2 sensor – it was observed the device is correctly released for all MDSAP countries and EU, but not for Brazil and Canada – this is in line with demonstrated license registration.  Canada:  Draegerwerk AG&Co Company ID 103279 , The regulatory corresponded registered Mr. Mebius from Draeger Germany,  Annual medical Device License renewal demonstrated Oct 28, 2022  Canada renewal conformation by the letter from health Canada: 2022-11-09  Registration for the established device  Oxylog 3000 Plus System – Canada License 85214 verified in MDAL data base during the audit |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 14 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Device Marketing Authorization and Facility Registration, Customer Related Processes** |
|  | New device: New Product Introduction M11.3 CO2 Sensor s check the sensor is not yet repaired and not released The samples for the new was selected New Product Introduction M11.3 CO2 Sensor  US:  Establishment registration verified - verified from FDA data base - demonstrated:  DRAEGERWERK AG & CO.KGAA GERMANY 3001104093, 2023 – Revalstrasse; production  DRAEGERWERK AG & CO.KGAA GERMANY 9611500 , 2023 – Mudslinger alee - specification developer;  510(k)  New Product Introduction M11.3 CO2 Sensor  The 510K registration verified – 510 No K221118 from 05 April 2023 (decision date)  Verification of market clearance for existing product  Oxylog 3000 plus - USA Class II, no longer supplied - 510K – No K103625 - from 06 Oct 2010 The product is longer available, however, active license was demonstrated from FDA webs site  Brazil,  The representative in Brazil is Draeger Industria e Comercio Ltd, Centre Impresarial tambore 06460-100 Sao Paolo , Brazil  The Agreement with the Brazilian regulatory representative was demonstrated:  Distributor agreement Drager Brazilia – 52/08/2018  1827778/ 21-1 Brazilian Good Manufacturing Practice (GMP) certificate 02.05.2024  02\_DOU Importer establishment has ANVISA Draeger Industria e Comercio Ltd CNPJ :02.535.707/0001-28 – ISSN 1677—7042 Supplement 108  Device registration  M11.3 CO2 Sensor – not yet completed in the moment of the audit, in preparation ANVISA Device certificate Oxylog 3000 plus - Brazil III BRA20/01250 10/08/2020  Australia  The registered Sponsor is Dräger Australis PTY , Noting Hill. Vic 3168 Australia The Distributor agreement – contains the responsibility of the Australian sponsor Distributor Agreement Drager Australia PTY 10.08.2018.  New Product Introduction M11.3 CO2 Sensor –  ARTG license: M11.3 CO2 Sensor 414435 registered from 24/07/023 Medical device Class IIa  Oxylog 3000 plus License ARTG 169507 registered from 01/03.2010 demonstrated from Australia regulatory authority web site during the audit  Japan  The MAH for Japan is Draeger Japan LTD  The Distributor Agreement Dräger Japan 27 may 2019  The Facility registration was demonstrated: 13B1X00173 from 2-13-17  The manufacturing facilities are registered with respective registration numbers: Dräger GMBH – Moislinger Alee BG21300929  Drager GmbH – Revalstrasse BG21300930  Device registration for JAPAN  Registration Certificate japan Oxylog 3000 plus Class III 22300BZX00184000  #2 - Evidence of Marketing Clearance or Approval  It could be confirmed that the medical device organization has received appropriate marketing clearance or approval in the regulatory jurisdictions where the medical device organization markets their devices.  Ref to task DMA+FR-1 for specific examples of device market clearance for MDSAP jurisdictions  #3 - Notification of Changes to Marketed Devices or to the QMS  Verified during the audit that the medical device organization has identified changes to marketed devices or the quality management system which require notification to regulatory authorities.  Country specific requirements: Australia / Brazil / Canada / Japan / US  Following notification of changes in each jurisdiction were demonstrated:  The change of the device Savina 300 (Select, Classic, NIV) New Software Version 5.02.01 The change is documented under Package Number PKG-2022-001602  PKG-2022-001602 Software Version 5.02.01 Bugfix Feb 23, 2023  Japan  The regulatory assessment japan - necessary action internal assessment => immediate product release Regulatory approval planning Savina SW 02.02.01 Ver 02 31/03/2023  USA – approval necessary – letter to File demonstrated as per 510K requirements: USA Letter to file Change Software Savina SW 02.02.01 Ver 02 31.03.2023 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 15 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Device Marketing Authorization and Facility Registration, Customer Related Processes** |
|  | Australia  Assessment performed – no regulatory submission needed 2023-03-01  Canada  the change will be covered Annual renewal of Market registration  Brazil  according to internal Tool WWRD - no regulatory approval necessary  Australia  The Internal documentation - no submission  **MDR 2017/745 - Article 31**  Process for registration of manufacturers, authorized representatives and importers (as soon as electronic system to create the single registration number is available)  The reqgualtruy requremnts are documented in the technical File Tale of contenst  The devices are registered in DMIDS Dutch Information and Databank system  BFARM data base: rev=cord was demonstrated for CO2 Detector  000053337 BFARM registration CO2 Sensor 2023-01-23  The facility registration in EUDAMED was demonstrated for 3 roles: DE-MF-000005329 Legal Manufacturer  DE-IM-000008374 Importer  DE-AR-000005330 – Legal representative,  **EU: assessment of impact of significance of change:**  Regulatory Change assessment Europe Savina 300 2023-03-01 |
| Reviewed  documents and records  (identification  and revision) | DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐03.00 , Rev. 03.00 IN8071 EN02 market Clearance |
| Names and titles of persons  interviewed | Bettina Möbius, Head of Central Regulatory & Clinical Affairs Kenvin Schlünß, Country Expert Regulatory Affairs  Carolin Bombeck,Country Expert Regulatory Affairs  Volker Ständer, Head of Process & Project Management Office Ruven Brenzek (scribe) Regulatory Affairs Support |
| Products,  components, or projects  reviewed | Savina SW 02.02.01  M11.3 CO2 Sensor  Oxylog 3000 plus |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for this subsystem | This process is effectively implemented and conforms with requirements |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 16 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.3 | Measurement, Analysis, and Improvement, CAPA and Internal Audit |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
| Audit trail  records of | Martin Szepannek / Gabriele Mousset / Honorata Donnermair |
| Area(s) visited (location, e.g., site visited) | Location # 10578  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Measurement, Analysis and Improvement: Procedures for Measurement, Analysis, and Improvement of QMS Effectiveness and Product Conformity (MDSAP Chapter 3, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 8.1, 8.2.1, 8.2.6, 8.5 + (DIN)(EN) ISO 9001 - 7.5.1, 8.5.5, 8.6, 9.1.1, 9.1.2, 10 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii), (f) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.3.1, 7.1, 7.2 + MDSAP - Japan - MO169: 6, 54, 55-1, 58, 59, 62, 63, 64; [Old: 6, 54, 55, 58, 59, 62, 63, 64] + MDSAP - USA - 21 CFR 820.100(a) + MDR - Article 10.9 ¶3 ( m); Annex IX 2.2 ¶2 (b2, e); Annex XI 13 + MDD - Annex II (3.2)" "Measurement, Analysis and Improvement: Sources of Quality Data (MDSAP Chapter 3, Task 2, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.4, 8.1, 8.2.1, 8.2.6, 8.4 + (DIN)(EN) ISO 9001 - 8.5.5, 8.6, 9.1.1, 9.1.2, 9.1.3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii), (f) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.1, 9.1 + MDSAP - Japan - MO169: 43, 54, 55-1, 58, 59, 61; [Old: 43, 54, 55, 58, 59, 61] + MDSAP - USA - 21 CFR 820.100(a) + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 (b); Article 88 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Investigation of Nonconformity (MDSAP Chapter 3, Task 3, Site: 10578);  (DIN)(EN) ISO 13485 - 8.5.2 + (DIN)(EN) ISO 9001 - 10.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii),(f), TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 6.5.1, 7.1.1.2 + MDSAP - Japan - MO169: 63 + MDSAP - USA - 21 CFR 820.100 (a)(2) + MDR - Article 10.9 ¶3 (l) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Investigation of Potential Nonconformity (MDSAP Chapter 3, Task 4, Site: 10578);  (DIN)(EN) ISO 13485 - 8.5.3 + (DIN)(EN) ISO 9001 - 0.3.3, 6.1, 10.1, 10.3 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii),(f),TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 7.1.1.1 + MDSAP - Japan - MO169: 64 + MDSAP - USA - 21 CFR 820.100(a)(2) + MDR - Article 10.9 ¶3 (l) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Correction, Corrective Action, and Preventive Action (MDSAP Chapter 3, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 8.2.1, 8.2.5, 8.3.1, 8.5.2, 8.5.3 + (DIN)(EN) ISO 9001 - 0.3.3, 6.1, 8.5.5, 9.1.1, 9.1.2, 10.1, 10.2, 10.3 + MDSAP - Australia - TG(MD)R Sch1 P1 2, TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii), (f) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 6.5, 7.1.1.3, 7.1.1.4, 7.1.1.5 + MDSAP - Japan - MO169: 55-1, 57, 60-1, 63, 64; [Old: 55, 57, 60, 63, 64] + MDSAP - USA - 21 CFR 820.100(a)(3), 820.100 (a)(4),820.100(a)(6), 820.100(b) + MDR - Article 10.9 ¶3 (l) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Assessment of Design Change Resulting from Corrective or Preventive Action (MDSAP Chapter 3, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.3.9 + (DIN)(EN) ISO 9001 - 8.1, 8.3.6, 8.5.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.10 + MDSAP - Japan - MO169: 26, 36-1; [Old: 26, 36] + MDSAP - USA - 21 CFR 820.30(i), 820.30(g) + MDR - Article 10.9 ¶1 s2, 10.9 ¶3 (a); Annex IX 2.2 ¶2 (c1, c8) + MDD - Annex II(3.2)"  "Measurement, Analysis and Improvement: Assessment of Process Change Resulting from Corrective or Preventive Action (MDSAP Chapter 3, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.2, 4.1.4, 4.1.6, 4.2.1, 7.1, 7.5.2, 7.5.6, 7.5.7 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 8.1, 8.4, 8.5.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2; Sch3 P1 1.5(4); TG(MD)R Sch3 P1 1.5(2) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.6, 7.1.1.4 + MDSAP - Canada - CMDR 1, 34 + MDSAP - Japan - MO169: 5-2, 5-4, 5-6, 6, 26, 29, 41, 45, 46; [Old: 5, 6, 26, 41, 45, 46] + MDSAP - USA - 21 CFR 820.100(a)(4), 820.100(a)(5), 820.70(b), 820.75(c) + MDR - Annex IX 2.2 ¶2 (d); Annex XI 6.2 ¶2, 12 + MDD - No specific requirements"  "Measurement, Analysis and Improvement: Identification and Control of Nonconforming Product (MDSAP Chapter 3, Task 8, Site: 10578);  (DIN)(EN) ISO 13485 - 8.3.1, 8.3.2 + (DIN)(EN) ISO 9001 - 8.7, 10.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(iii) + MDSAP - Brazil - RDC ANVISA 16/2013: 6.5, 7.1.1.6 + MDSAP - Japan - MO169: 60-1, 60-2; [Old: 60] + MDSAP - USA - 21CFR 820.90(a) + MDR - Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2, 12 ¶1"  "Measurement, Analysis and Improvement: Action Regarding Nonconforming Product Detected After Delivery (MDSAP Chapter 3, Task 9, Site: 10578); (DIN)(EN) ISO 13485 - 8.3.3, 8.5.2 + (DIN)(EN) ISO 9001 - 8.7, 10.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2, TG(MD)R Sch3 P1 1.4(3)(a),(b), (5)(b)(iii), (f) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 7.1.1.8 + MDSAP - Japan - MO169: 60-3, 63; [Old: 60, 63] + MDSAP - USA - 21 CFR 820.100(a) + MDR - Article 10.9 ¶3 (k), 10.12; Article 87- 92 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Internal Audit (MDSAP Chapter 3, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 6.2, 8.2.4 + (DIN)(EN) ISO 9001 - 7.2, 7.3, 9.2 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(iii) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.3 + MDSAP - Japan - MO169: 22, 23, 56 + MDSAP - USA - 21 CFR 820.22, 820.100 + MDR - Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Information Supplied for Management Review (MDSAP Chapter 3, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 5.6.2 + (DIN)(EN) ISO 9001 - 9.3.1 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(b)(iii) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.6, 7.1.1.7 + MDSAP - Japan - MO169: 19 + MDSAP - USA - 21 CFR 820.100 (a)(7) + MDR - Article 10.9 ¶1 S2; Annex IX 2.2 ¶2 (c8)"  "Measurement, Analysis and Improvement: Evaluation of Information from Post-Production Phase, Including Complaints (MDSAP Chapter 3, Task 12, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 7.5.4 (a), 8.2.1, 8.2.2, 8.5.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.2.1, 8.5.5, 9.1.2, 10.1, 10.3 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(3), 1.4(5)(b)(iii) &1.4(5)(f) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.2 + MDSAP - Canada - CMDR 57-58 + MDSAP - Japan - MO169: 6, 29, 43, 55-1, 55-2, 62; [Old: 6, 29, 43, 55, 62] + MDSAP - USA - 21 CFR 820.198 + MDR - Article 10.9 ¶3 (i), 10.10; Annex IX 2.1 ⑧⑨, 2.2 ¶2 (b2); Annex XI 6.2 ¶2; Article 83 - 86 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Measurement, Analysis and Improvement: Communications with External Parties Involved on Complaints (MDSAP Chapter 3, Task 13, Site: 10578); (DIN)(EN) ISO 13485 - 4.1.5, 7.4.1, 8.3.1 + (DIN)(EN) ISO 9001 - 4.4, 8.4, 10.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.6 + MDSAP - Japan - MO169: 5-5, 37, 60-1; [Old: 5, 37, 60] + MDSAP - USA - 21 CFR 820.100(a)(6) + MDR - Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Article 10" "Measurement, Analysis and Improvement: Evaluation of Complaints for Adverse Event Reporting (MDSAP Chapter 3, Task 14, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 8.2.3 + (DIN)(EN) ISO 9001 - 4.4, 8.2.1, 8.4, 8.5.5 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(c) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.8, RDC ANVISA 67/2009 + MDSAP - Canada - CMDR 59-61.1 + MDSAP - Japan - MO169: 6, 29, 55-3; [Old; 6, 29, 62] + MDSAP - USA - 21 CFR 803 + MDR - Article 10.9 ¶3(k), 10.12, 10.13; Article 80, 87, 88, 89, 94 + MDD - Article 10"  "Measurement, Analysis and Improvement: Evaluation of Quality Problems for Advisory Notices (MDSAP Chapter 3, Task 15, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 8.3.3 + (DIN)(EN) ISO 9001 - 4.4, 8.2.1, 8.4, 8.7 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(3)(c) + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.8, RDC ANVISA 23/2012 + MDSAP - Canada - CMDR 63-65.1 + MDSAP - Japan - MO169: 6, 29, 60-3; [Old: 6, 29, 60] + MDSAP - USA - 21 CFR 806, 820.100(a) + MDR - Article 10.9 ¶3 (k), 10.12; Article 80, 87, 88, 89, 94 + MDD - Article 10"  "Measurement, Analysis and Improvement: Top Management Commitment to Measurement, Analysis, and Improvement Process (MDSAP Chapter 3, Task 16, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.3, 5.2, 8.1, 8.5.1 + (DIN)(EN) ISO 9001 - 4.4, 5.1.2, 8.4, 9.1.1, 10.1, 10.3 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1 + MDSAP - Japan - MO169: 5-3, 11, 54, 62; [Old: 5, 11, 54, 62] + MDR - Article 10.9 ¶3 (c) + MDD - Annex II (2, 3.1)" |
| Brief description of processes or activities  evaluated to  demonstrate  what was  audited related  to the listed key QMS documents and records  reviewed below considering  inputs, outputs, and measures | MAI 1 - Procedures for measurement, analysis and improvement (GM) 8.1;8.2.1; 8.2.6; 8.5 => Focus on System Affected roles: Requester/Responsible Person/ CAPA Reviewer/CAPA Owner  The process DEMF PQ3300 describes the evaluation of system CAPA´s  CAPA triggers are e.g. audits/feedback/issues/proposals/complaints/data-analysis.  Requester and Responsible person have to make an immediate decision whether direct measures would be necessary. The quality manager will be responsible for further investigation steps and for the CAPA decision. The issue can be followed as “documented action” or as full CAPA. The documentation from here will be in Track Wise. Main CAPA triggers: Major NC´s from audit/issue with effect on efficacy of system and increase of risk for health or environment or missing process descriptions or external requirements.  Each case will be evaluated regarding risk within the risk form: PQ3300 – A01 Risk evaluation template. Following aspects will be evaluated: Environment, Employees, Health of patients or users, integrated Managemensystem /certification, and product conformity. If there is any risk identified a description and evaluation of the situation have to  be documented. Based on this evaluation the decision for further processing “CAPA” or documented action “ will be done.  For each CAPA (not for “documented action”) a CAPA plan should be provided and the CAPA plan have to be checked and approved by CAPA reviewer. The CAPA reviewer will take the decision whether the planned actions are appropriate to the risk. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 17 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | For both -CAPA and “documented action”- root cause and risk analysis, actions, corrective actions and effectiveness checks have to be defined and implemented.  It is differentiated in CAPA procedures between quality problems and nonconforming product. Two different procedures are in place. The sources and impact of all issues will be analyzed and documented.  DEMF/DCS PQ2510 product CAPA  DEMF PQ3300 system CAPA  Furthermore, the handling of nonconforming product are defined in: DEMF SC6110 : Behandlung von Abweichungen in der Produktion DEMF SC6111 : Lenkung von fehlerhaftem Material  These procedures are linked to each other.  For each documented action (issue) and CAPA correction and corrective - (preventive) action) is defined.  USA:  Verify procedures ensure that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of problems [21 CFR 820.100(a)(6)].  Confirm procedures provide for the submission of relevant information on identified quality problems, as well as corrective and preventive actions, for management review [21 CFR 820.100(a)(7)].  The manufacturer ensures that information about quality problems or nonconforming products are properly disseminated to those directly involved in the maintenance of product quality and to prevent occurrence of such problems. This is assured via regular Quality Boards meetings in each BU or product family/PQB.  During the audit the auditor focused according to audit plan on system related samples.  The CAPA´s (Systems and product) are analyzed and results provided for MR: see One pager CAPA  Brazil:  Verify that the manufacturer has ensured that information about quality problems or nonconforming products are properly disseminated to those directly involved in the maintenance of product quality and to prevent occurrence of such problems [RDC ANVISA 16/2013: 7.1.1.6].  The manufacturer ensures that information about quality problems or nonconforming products are properly disseminated to those directly involved in the maintenance of product quality and to prevent occurrence of such problems. This is assured via regular Quality Boards meetings in each BU or product family/PQB.  During the audit the auditor focused on system related samples.  MAI 1 - Procedures for measurement, analysis and improvement (GM) => Focus on Product  The process to measure, analysis and improve the QMS is established and documented. The process describes the evaluation of the data from the product.  Investigations are conducted to identify the cause of the detected and potential nonconformities.  Input from various sources, which may represent a complaint is registered, and investigated. The investigation is conducted as part of NC, CAPA and supplier quality processes in line with requirements of respective SOPs.  The CAPA criteria are defined (risk negative impact on product safety, caused death or injury, cybersecurity unacceptable risk, not fulfilled regulatory requirements) when an action should be evaluated. In case no action is started this will be documented. CAPA can be also started without the intervention of the Quality Board, depending on the meeting of the criteria for CAPA.  When CAPA are set and implemented, these should be evaluated for effectiveness, including the root cause analysis. All will be documented in the product CAPA in TrackWise. The roles and responsibilities are defined. The timeline for processing is defined e.g.: 7 days for initial analysis, 60 days for implementation of CAPA plan. It is possible to include annexes in the documentation.  If the CAPA has a systematic cause, there is a link to the system CAPA process and the other way around.  The KPIs are defined for CAPA process and are monitored in monthly meeting. The last 12-month report was reviewed states the 78% of CAPAs are completed withing set up due target. 22 CAPA were completed in 2022. In time completion rate: risk assessment 89%, Investigation 41%, completion 65%The KPIs are splitted in BU and shows CAPA status: ongoing, completed, overdue or effectiveness check overdue.  (Brazil, US) Data will be analysed in Quality Boards, these will be managed by the product quality manager. This information includes statistical information or individual cases e.g.: complaints. The decision to start a CAPA will be taken in the Product quality board and documented. It is taken based on three criteria.  When CAPA actions are marked as completed and will be closed only when the effectiveness check is completed.  Additional country-specific requirements:  Brazil (ANVISA):  The manufacturer ensures that information about quality problems or nonconforming products are properly disseminated to those directly involved in the maintenance of product quality and to prevent occurrence of such problems. This is assured via Quality Boards meeting as describe above.  United States (FDA):  The Procedure ensures that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of problems – This performed via Quality board mechanism and statistical approach as discussed above |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 18 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | During the audit the auditor focused on product related samples.  MAI 2 - Sources of Quality data (GM) 8.4  Appropriate sources of quality data have been identified for input into the measurement, analysis and improvement process, including customer complaints, feedback, service records, returned product, internal and external audit findings, nonconformities from regulatory audits and inspections, and data from the monitoring of products, processes, nonconforming products, and suppliers.  This have been verified with the last MR where all these data have been verified.(One pager´s based on the above mentioned topics have been audited)  Data from these sources are accurate and analyzed according to a documented procedure -DEMF PQ8050 : Statistical Techniques - for the use of valid statistical methods (where appropriate) to identify existing and potential product and quality management system nonconformities that may require corrective or preventive action.  MAI 2 - Sources of Quality data (HD) 8.4  Input from various sources, which may represent a complaint is registered, and investigated. The investigation is conducted as part of NC, CAPA and supplier quality processes in line with requirements of respective SOPs. Further sources such as trends, production quality control data, service records, audit finding etc. are analysed and evaluated.  Complain trainings, warranty trending, FFR rates and Supplier PPM rate evaluations are performed in quarterly meetings.  MAI3 - Root cause analysis of detected NC´s (GM) 8.5.2  Investigations are conducted to identify the underlying cause(s) of detected nonconformities, where possible.  Several cases have been audited as samples to verify, that cause analysis have been cunducted:  #122371/#122373/#122374/#122377/#122378  Investigations are commensurate with the risk of the nonconformity. This is asured by conducting risk analysis for each issue “documented action” or “CAPA”, system and product related as described under MAI 1  Additional Sample risk analysis audited:#103501  Monitoring and measurement of processes (8.2.5), product (8.2.6)  MAI 3 – Investigation of Nonconformity (HD) 8.5.2  Investigation of Nonconformity & Investigation of Potential Nonconformity  The process is established. Investigations are conducted to identify the (underlying) cause of the detected nonconformities. Several established methods for root cause analysis are used, such as 5W or Fishbone. Investigations are proportional to the risk of the nonconformity (risk-based approach), criteria are defined e.g.: Go as far as possible if following applies:  -Death or injury  -Complain indicate new trend  -Client or authority request deep investigation  -Complain classified as AE  Potential non-conformities are also detected and analysed accordingly. The root cause is determined for all CAPA.  PR 124066 dd. 03.11.2022– Brazil. The foreign body in expiratory membrane of Babylog VN600 the device was not in use. Complain investigation report states that this is impurity of manufacturing process. It is in ex breathing membrane and cannot go to the patient. The risk is known. Action communication with supplier.  PR 1321136 dd. 21.06.2023 USA - FoA (Warranty) anaesthesia circuit flex 6. No patient involvement. Circuit cracking/tearing impacts the ventilation of patient (reduced breathing). Risk is known and evaluated no new / higher risk. An DCR (design change request) was started to evaluate if other material could ensure more mechanical force DCR 2023 – 004142.  PR 126323 dd. 06.12.2022 Canada- disposable birthing hose. The investigation was performed no new or unknown risk.  PR 126748 dd. 08 12.2022 Australia ECG Mono Leads 4.1m MP0531. The cable caused pressure injury by the patient. The new mono lead has higher dimeter as the old version. DCR 2023-001245 it was decided to update the risk management file including update of IFU (new IFU) as the risk was not identified. The IFU update with proper use of cables.  MAI 4 - Investigation of potential NC´s (GM) 8.5.3  Potential non-conformities regarding product and product processes are analyzed within FMEA`s.  Sample of FMEA´s have been audited: FMEA PIA-PIA2  Investigations are conducted to identify the (underlying) cause of the detected nonconformities. Several established methods for root cause analysis are used in general, such as 5W or Fishbone. Investigations are commensurate with the risk of the nonconformity.  Furthermore, during each MR an evaluation of internal audit results related to QMS processes will be done and documented to estimate whether any new or higher risk related to main QMS processes can be assumed derived from current internal audit performance. Evaluation of internal audit results of MR 2023 have been audited.  Corrective action (8.5.2), Preventive action (8.5.3) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 19 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | MAI 4 - Investigation of potential NC´s (HD) 8.5.3  The investigation of potential non-conformities is documented and performed in the same way as for non-conformities, as discussed in Task 3.  CAPA process is defined in SOP PQ2510 and contains criteria to raise a CAPA.  The inputs for the product quality boards are prepared by the report owner, based on the criteria defined in the process. There is an investigation plan in place.  This data includes information from failure rate in production, installation, complaints, failure of parts, among others. CAPAs are also triggered by non-conformities detected in other processes.  There is the possibility to close a CAPA without actions, the rationale has to be documented.  MAI 5 - Confirm corrections, corrective actions and preventive actions (GM) 8.5.2; 8.5.3  Corrections, corrective actions, and preventive actions for system CAPA are defined and implemented according to the documented procedure – DEMF PQ3300.  Inputs and outputs are defined. CAPA triggers, criteria and responsibilities are defined. See MAI 1  Systems CAPA triggers are e.g.: management review, processes, procedures, records of services, systematic problems, etc. The CAPAS are documented in Track Wise. Some events according to the CAPA criteria are  documented as “Documented Action” and not as CAPA. The investigation process for “documented action “ is not  that extensive as by the CAPA. It requires a “documented action response report” after investigation. Each “documented action” can be escalated to CAPA.  Each case will be evaluated regarding risk within the risk form: PQ3300 – A01 Risk evaluation template. Following aspects will be evaluated: Environment, Employees, Health of patients or users, integrated Managemensystem /certification, and product conformity. If there is any risk identified a description and evaluation of the situation have to be documented. Based on this evaluation the decision for further processing “CAPA” or documented action “ will be done.  For each CAPA (not for “documented action”) a CAPA plan should be provided and the CAPA plan have to be checked and approved by CAPA Reviewer. The CAPA reviewer will take the decision whether the planned actions are appropriate to the risk.  For both CAPA and documented action root cause and risk analysis, actions, corrective actions and effectiveness checks have to be defined and implemented.  It is differentiated in CAPA procedures between quality problems and nonconforming product. Two different procedures are in place. The sources and impact of all issues will be analyzed and documented.  MAI 5 - Confirm corrections, corrective actions and preventive actions (HD) 8.5.2; 8.5.3  Correction, Corrective Action, and Preventive Action  Corrections, corrective actions, and preventive actions for product CAPA are defined and implemented according to the documented procedure DCS PQ2510-013.  Inputs and outputs are defined. CAPA triggers, criteria and responsibilities are defined. The CAPA criteria are defined (risk negative impact on product safety, caused death or injury, cybersecurity unacceptable risk, not fulfilled regulatory requirements) when an action should be evaluated  The CAPAS are documented (Track Wise). Some events according to the CAPA criteria are documented as Documented Action and not as CAPA. The investigation process is not that extensive as by the CAPA. It requires a Documented Action Response Report after investigation. Each Documented Action can be escalated to CAPA. The timeline for processing is defined e.g.: 7 days for initial analysis, 60 days for implementation of CAPA plan. It is possible to include annexes in the documentation.  If the CAPA has a systematic cause, there is a link to the system CAPA process and the other way around.  The KPIs are defined for CAPA process and are monitored in monthly meeting. The last 12-month report was reviewed states the 78% of CAPAs are completed withing set up due target. The KPIs are splitted in BU and shows CAPA status: ongoing, completed, overdue or effectiveness check overdue.  For reviewed CAPA examples see records  MAI 6 - Assessment of Design Change resulting from Corrective or Preventive Action (HD) WWhen the CAPA is outcome in Design change – Change Control process is involved.  The routes for design changes are possible depends on the significant of changes are described in procedure. Relevant steps are documented. Wen DCR is accepted the – PKG (Package) will be created including the list of deliverables. Further steps are investigation, plan DC, implement DC, execute DC, transfer and DC closure.  PR 126748 dd. 08 12.2022 Australia ECG Mono Leads 4.1m MP0531. The cable caused pressure injury by the patient. The new mono lead has higher dimeter as the old version. DCR 2023-001245 it was decided to update the risk management file including update of IFU (new IFU) as the risk was not identified. The IFU update with proper use of cables.  DCR 2021-006406 PKG 2020-002624 EHF (DCR flow sensor). The flow sensor produced previously by supplier was transfer to the DWAG production line in Lübeck. As part of this change also the color of the housing was changed as well as slight changes in the housing shape.  MAI 7 - Process change -> revalidation (GM) 7.5.6; 8.5.2  When a corrective or preventive action results in a process change, the process change is assessed to determine if any new risks to the product are introduced. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 20 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | This is assured with approval process DEMF SC6500, which defines for creation, changes and approvals of process descriptions.  Risk evaluation :  Samples process change with DEMF SC6500: Anlage A02: DEMF SC6500: Anlage A02 ATLAN Arbeitsplatz SM2 SM1 DEMF SC6500: Anlage A02 Babyleo Arbeitsplatz SM2 SM1,  Canada:  Verify that the manufacturer has a process or procedure for identifying a “significant change” to a class III or IV device.  Verify that information about “significant changes” is submitted in a medical device license amendment application [CMDR 1, 34].  Requirements implementation Verified and described withis two audited samples:  DEMF SC6500: Anlage A02 zu Dokumentation von Produktionsprozessen, 02, point 4. „Bewertung der Änderungen“ including question „Aktuailsierung Process FMEA „ and „ Verification needed” and Validierung erforderlich” . Additional it is assured that if any change in STED of products is needed (change in PQ 2110), that the Design change process is applicable and respective reports will be done. Assessment of changes are triggered and the following SOP´s and instructions have to be followed for decision about significant change and related duties:  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐04.00 , Rev. 04.00  A08 DWAG PQ2110 Assessment of changes to medical devices, rev 04.00 – specifics of all MDSAP countries are inserted (Canada/Brazil/Japan/Australia/USA/Europe) and supported by change overview matrix with further country specifics of all MDSAP countries helping for the decision whether there is a significant change. If any significant change is evaluated a regulatory affairs manager will be informed for conduction of all further needed steps related to different MDSAP areas affected  Australia:  Confirm that the Manufacturer’s procedure for dealing with substantial changes to a critical process (e.g. sterilization, processing materials of animal origin, processing materials of microbial or recombinant origin, or processes that incorporate a medicinal substance in a medical device), requires the Manufacturer to notify the Auditing Organization of their plans before implementing a change to a critical process. The Auditing Organization is to assess the proposed change before implementation by the Manufacturer, to determine if the requirements of the relevant conformity assessment procedure will still be met after the change. [TG(MD)R Sch3 P1 1.5(2)].  If the Manufacturer is also a holder of a TGA Conformity Assessment Certificate, then the Manufacturer is also required to notify the TGA of these changes, prior to implementation.  Requirements implementation Verified and described within two audited samples:  DEMF SC6500: Anlage A02 zu Dokumentation von Produktionsprozessen, 02, point 4. „Bewertung der Änderungen“  including question „Aktuaisierung Process FMEA „ and „ Verification needed” and Validierung erforderlich” . Additional it is assured that if any change in STED of products is needed (change in PQ 2110), that the Design change process is applicable and respective reports will be done. Assessment of changes are triggered and the following SOP´s and instructions have to be followed for decision about significant change and related duties:  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐04.00 , Rev. 04.00  A08 DWAG PQ2110 Assessment of changes to medical devices, rev 04.00 – specifics of all MDSAP countries are inserted (Canada/Brazil/Japan/Australia/USA/Europe) and supported by change overview matrix with further country specifics of all MDSAP countries helping for the decision whether there is a significant change. If any significant change is evaluated a regulatory affairs manager will be informed for conduction of all further needed steps related to different MDSAP areas affected  Japan:  Confirm that when the Registered Manufacturing Site plans to make a significant change to a manufacturing processes (e.g. sterilization site change, manufacturing site change), the Registered Manufacturing Site notifies the Marketing Authorization Holder so as the Marketing Authorization Holder can take appropriate regulatory actions [MHLW MO169: 29].  Requirements implementation Verified and described within two audited samples:  DEMF SC6500: Anlage A02 zu Dokumentation von Produktionsprozessen, 02, point 4. „Bewertung der Änderungen“  including question „Aktuaisierung Process FMEA „ and „ Verification needed” and Validierung erforderlich” . Additional it is assured that if any change in STED of products is needed (change in PQ 2110), that the Design change process is applicable and respective reports will be done. Assessment of changes are triggered and the following SOP´s and instructions have to be followed for decision about significant change and related duties:  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐04.00 , Rev. 04.00  A08 DWAG PQ2110 Assessment of changes to medical devices, rev 04.00 – specifics of all MDSAP countries are inserted (Canada/Brazil/Japan/Australia/USA/Europe) and supported by change overview matrix with further country specifics of all MDSAP countries helping for the decision whether there is a significant change. If any significant change is evaluated a regulatory affairs manager will be informed for conduction of all further needed steps related to different MDSAP areas affected.  MAI 8 – Identification and Control of Nonconforming Product (HD)  Manufacturer has established the process to assure controls are in place to ensure that product which does not conform to product requirements is identified, isolated and investigation is performed.  The auditor has reviewed examples of communication and documentation and investigation of NC product – the examples are listed below in the key records.  MAI 9 - Action Regarding Nonconforming Product Detected After Delivery (HD) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 21 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | When a nonconforming product is detected after delivery or use the action is taken appropriate with the risk, or potential risks, of the nonconformity.  The risk of the detected non-conformity is evaluated for the devices already delivered. Also, potential risks are evaluated.  MAI 10 - Internal audit (HD)  Regular internal audits are conducted at planned intervals, all department/ processes have to be audited minimum once withing 3 years (some each 2 years, some annually). The frequencies are defined in Internal Audit Covering document. If a critical deviation is found during the regular audit, an unannounced surveillance audit is also carried out. The audit triggers are defined. An internal audit includes to follow the internal audit procedure, internal audit plan, Protocol / Checklist MD and global internal audit summary report. The action / MNC or NC issued during the internal audit must be followed up. The NC/ MNC can be documented as documented action or as CAPA and are processed in Trackwise. There are 24 internal audits listed in Audit program 2022, 17 were performed, 4 were  postponed due to the resource’s issues. The rationale for postponed audit is documented. The KPI for internal audit are defined e.g.: complete 100 % of audit report within 14 days. The target has been reached with 89%.  During the audit we check the last internal audit of PQ calibration process conducted in February 2023 and the Internal audit of BU Workplace Infrastructure. It could be shown that the customer adheres to his procedure and all required documents could be presented. The qualification of internal auditors is defined and documented, also the role of expert is considered. As an internal lead auditor, you have to have three years of experience as an auditor and depending on the standard / regulation you need at least three audits as an auditor. The manufacturer conducts annually auditor exchange/ training for authorized auditors.  MAI 11 - Information Supplied for Management Review (MSz)  It could be determined that if relevant information regarding nonconforming product, quality management system nonconformities, corrections, corrective actions, and preventive actions has been supplied to management for management review.  One-pager for management review includes and Handling complaints including Reporting to regulatory authorities.  Reported to management review:  - Numer of Complaints, number of reportable comlaints,  - Number of Compentent Board meetings  - Number of cases of death involving Dräger device  - Complaint reliabilty rate (general + individually by BU)  Trending for complaints vs prior years.  For Field actions:  Number of ongoing (56) and new (40) field action  Total Number of new field actions  Thereof FSCA (12)  Thereof FQ Improvement actions (28)  Number of ongoing field actons end of year (56)  Overdiue at the end of the year (28)  Overdue >3 months (22)  2023 was an all time high for field actions.  MAI 12 - Evaluation of Information from Post-Production Phase, Including Complaints (MSz)  Confirmed that the medical device organization has made effective arrangements for gaining experience from the post-production phase, including postmarket surveillance, handling complaints, and investigating the cause of  nonconformities related to advisory notices with provision for feedback into the Measurement, Analysis and Improvement process.  Verified that information from the analysis of production and post-production quality data was considered for amending the analysis of product risk, as appropriate.  Records of complaints for review that represent the highest risk to the user or have the largest impact on the ability of the device to meet its essential design outputs have been selected.  DCS PQ2010 describes Complaint handling (for all Dräger products, not only medical devices; however, process distinguihses between medical devices and non-medical devices).  Input to Complaint Handling can come from any complaining person (internal or external). Respective Forms are available (Attachment A01). Trackwise is used to electronically handle complaint information, fed either by members of the Sales and Service organsations, or supervisory unit (PMS department Lübeck). Responsible legal manufacturer (Lübeck, China, India, USA, Dräger Safety UK + China) of product will be informed by PMS Department -all legal manufacturers work with trackwise. Legal Manufacturer decides if complaint is accepted and if it is marked as adverse event.  MAI 13 - Communications with External Parties Involved on Complaints (MSz)  Where investigation determines that activities outside the medical device organization, contributed to a customer complaint, it could be verified that records show that relevant information was exchanged between the organizations involved.  DCS PQ2010 Step 6 “Acknowledgement; request for additional information and/or return of material.”  Australia (TGA):  DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00  Brazil (ANVISA):  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 22 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | Canada (HC):  Complaint and recall Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  DEMF PQ2520 : Field Action (FA) DEMF PQ2520‐en‐05.00 , Rev. 05.00  Japan (MHLW/PMDA)  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  United States (FDA):  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  MAI 14 - Evaluation of Complaints for Adverse Event Reporting (MSz)  Verified that the medical device organization has defined and documented procedures for the evaluation of complaints for adverse event reporting.  It could be confirmed that decisions to not report complaints were made according to established procedures and a documented rationale.  MAI 15 - Evaluation of Quality Problems for Advisory Notices (MSz)  Confirmed that decisions to not report complaints were made according to established procedures and a documented rationale.  Records for review of quality problems that were evaluated for potential issuance of advisory notices (include records where a decision was made not to issue an advisory notice as well as records of decision to issue advisory notices) and assess whether the organization has taken actions appropriately based on risk and documented the rationale have been selected.  MAI #16 Top Management Commitment to Measurement, Analysis, and Improvement Process (MSz)  Based on the assessment of the Measurement, Analysis and Improvement process overall, it could be determined that management provides the necessary commitment to detect and address product and quality management system nonconformities, and ensure the continued suitability and effectiveness of the quality management system. |
| Reviewed  documents and records  (identification  and revision) | MAI 1 (GM)  DCGL/DCS PQ2510-013-en-00 SOP Corrective and Preventive Actions (BIC no new toll modulation) DEMF/DCS PQ2510 : Corrective and Preventive Actions ‐en‐, Rev. 00.01 (BIC no new tool modulation ) DEMF PQ3300 System related Corrective and Preventive actions revision 4.00 20. 06 2022  CAPA trigger& criteria PQ3300 – A01 2022-06-20 revision 04.00  PQ3300 – A02 Risk evaluation template, RI 02.00  DEMF SC6110 : Behandlung von Abweichungen in der Produktion DEMF‐SC6110‐de‐00.00 , Rev. 00.00  DEMF SC6111 : Lenkung von fehlerhaftem Material DEMF‐SC6111‐de‐00.01 , Rev. 00.01  Management Review 2022 – DWAG 2022-03-22, signed by Stefanie Hirsch and Mr. Schrofner  One pager MR input 2023:   Example One Pager – Handling of CAPA´s:  Product CAPA 22 CAPA´s closed on 2022, risk in time completion 98%  System CAPA: CAPA plan closing within 30 days (68% reached) CAPA completed until target due date (only 48%)- > actions defined on CAPA plan  Action list status 18.09 2023 Handlings CAPA a) provision of timely CAPA handling last result positive trend of system CAPA handling, 15.09.2023  MAI 1 (HD)  DCS PQ2510-013-en-00.01 SOP Corrective and Preventive Actions. Rev. 00.01. 03.09.2020 DEMF PQ2510 A01 en 00.02 CAPA Criteria  CAPA decision template, revision 2  DWAG - CAPA Monthly Report 2023-08  PR ID 121799 Product CAPA report - BU HCA  PKG 2022-003059 dd 2022-12-12  MAI 2 (GM)  DEMF PQ8050 : Statistical Techniques ‐en\_de‐00.00 , Rev. 00.00 , including tool-boxes for concrete statistical methods. It s required that in every SOP it should be evaluated whether statistical method is needed and that the appropriate method should be chosen by proses autor and reviewer  Management Review 2022 – DWAG 2022-03-22, signed by Stefanie Hirsch and Mr. Schrofner  One pager MR input 2023:  Example One Pager Product feedback, general in target (I all feedback will be evaluated not limited to complaints) Example One Pager Risk management: action Item resources  Example One pager Product compliance  Example One Pager complaints, yellow: slightly negative trend regarding backlog and timely closing; Quality project: process redesign (channel one)  Example Handling of field action: 40 new opened, total 48- actions defined because of big backlog  Example One Pager Handling of Design changes: view on long-term processing changes  Example One Pager performance Sourcing: e.g. supplier audits, Supplier PPM slightly above target (e.g. supplier for accessories)  Example One Pager Performance of distribution: all topics on track  Example One Pager Performance of Service: all topics on track  Example One Pager internal and external audit: all topics on track  MAI 2 (HD) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 23 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | DCS PQ2510-013-en-00.01 SOP Corrective and Preventive Actions. Rev. 00.01. 03.09.2020 CAPA decision sheet 2023\_Q2 Humidification  MAI 3 (GM)  #122371/#122373/#122374/#122377/#122378-> all audited cases have root cause analysis  One case audited deeper with related 5 WHY analysis:  Audit 19.09.2023 #122373 (documented action)  Re-open Product CAPA PR96387 and update 3D5Why - complete Root Cause analysis and derive necessary (corrective) actions if applicable product “Babyleo” TN500 unacceptable pollution degree- root analysis reopened and updated under usage of 5 Why- root cause result: mistakenly not identified as “complex component”. 5 Why template updated,30.06.2023.  #103501 production and process controls, rework not documented on process. Risk evaluation, no risk for product/user/patient/employees/environment but a risk for IMS  PQ3300 – A02 Risk evaluation template to #103501 risk for IMS documented but accepted because only IMS and not product patient user or environment affected.  #117431 CAPA timelines, overdue. Risk evaluation, no risk for product/user/patient/employees/environment but a risk for IMS  PQ3300 – A02 Risk evaluation template to #117431 risk for IMS documented certification endangers  certicication\_actions are defined -> see action list under MAI 1  MAI 3/4 (HD)  DCS PQ 2010 de 013 -02.00 Complain Handling 2020-03-01.  DSC SC 5220 Handling of supplier nonconformance reports for field materials.  DWAG IN4230 design changes revision 5.0 dd. 30.06.2023 DCS PQ 2030 The letter to customer  DCS PQ 2010 A05 Investigation report on the complaint  DCS PQ 2010 A07 revision 13 List of criteria for examinations PR 124066 – Brazil   Email Fa. GPE dd 09.12.2022  PR 124066 dd. 03.11.2022  PR 1321136 dd. 21.06.2023  PR 126323 dd. 06.12.2022  PR 126748 dd. 08 12.2022  DCR 2023 – 004142  DCR 2023 000515  DCR 2023-001245  MAI 4 / MAI 5 (GM)  1/2DR -000069 Prozess-FMEA PIA-PIA2\_00, 18.10.2022 (0 revision because of usage of a new FMEA tool)- underlying sources of identified risks have been evaluated and documented  Management Review 2022 – DWAG 2022-03-22, signed by Stefanie Hirsch and Mr. Schrofner  Onepager MR input 2023:  Example One Pager: internal audit results: findings will be analysed acc. to relation to all relevant processes. Observed unsusual amount of findings in a process will be used as indicator to define some preventive action in the  related area. An evaluation will be done at each MR and an overall result documented on page “evaluation Internal Audits” -> data related to One pager- 2023 result no unexpected accumulation of mayors  Example One Pager – Handling of CAPA´s:  Product CAPA 22 CAPA´s closed on 2022, risk in time completion 98%  System CAPA: CAPA plan closing within 30 days (68% reached) CAPA completed until target due date (only 48%)- > actions defined on CAPA plan  Action list status 18.09 2023 Handlings CAPA a) provision of timely CAPA handling last result positive trend of system CAPA handling, 15.09.2023  #103501 production and process controls, rework not documented on process. Risk evaluation, no risk for product/user/patient/employees/environment but a risk for IMS  PQ3300 – A02 Risk evaluation template to #103501 risk for IMS documented but accepted because only IMS and not product patient user or environment affected.  #117431 CAPA timelines, overdue. Risk evaluation, no risk for product/user/patient/employees/environment but a risk for IMS  PQ3300 – A02 Risk evaluation template to #117431 risk for IMS documented certification endangers  certicication\_actions are defined -> see action list under MAI 1  MAI 5 (HD)  DCS PQ2510-013-en-00.01 SOP Corrective and Preventive Actions. Rev. 00.01. 03.09.2020 DEMF PQ2510 A01 en 00.02 CAPA Criteria  CAPA decision template, revision 2  DWAG - CAPA Monthly Report 2023-08  PR ID 121799 Product CAPA report - BU HCA  PKG 2022-003059  CAPA PR ID 118754 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 24 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | PKG 2022-002059  PR 127593- \_ Rerecords for effectiveness check  PR 127593\_ FQA Warranty evaluation 2023-09-06  DCR 20222-004758  MAI 6 (HD)  DWAG IN4230 design changes revision 5.0 dd. 30.06.2023  PR 1321136 dd. 21.06.2023  PR 126748 dd. 08 12.2022  DCR 2023 – 004142  DCR 2023-001245  Project EHF Verification Summary report 06.03.2023  SAP Stammdaten ZM90 version 11  DCR 2021-006406 PKG 2020-002624 EHF  Complain record BU HCA 01.09.2022-13.09.2023  SAP Case Management PSB/CFT330 PPM Accessories  MAI 7 (GM)  DEMF SC6500: Anlage A02 ATLAN Arbeitsplatz SM2 SM1, change of work step have been transferred from 2 to 1, Vorgang 0030, step enhanced and transferred to Vorgang 0040 (Typenschildanbringung component) , signed 23.08.2023 (two eyes principle-> no significant change, no validation needed, no change in process FMEA, no training needed,  DEMF SC6500: Anlage A02 Babyleo Arbeitsplatz SM2 SM1, change of work step have been transferred from Vorgang 0500 to Vorgang 0400, step enhanced and transferred to Vorgang 0040 no new steps , signed 03.02.2023 (two eyes principle-> no significant change, no validation needed, no change in process FMEA, no training needed. DEMF SC6500: Anlage A02 zu Dokumentation von Produktionsprozessen, 02, point 4. „Bewertung der Änderungen“  including question „Aktuailsierung Process FMEA „ and „ Verification needed” and Validierung erforderlich” .  Additionally, it is assured that if any change in STED of products is needed (change in PQ 2110), that the Design change process is applicable and respective reports will be done. Assessment of changes are triggered and the following SOP´s and instructions have to be followed for decision about significant change and related duties.  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐04.00 , Rev. 04.00  A08 DWAG PQ2110 Assessment of changes to medical devices, rev 04.00 – specifics of all MDSAP countries are inserted (Canada/Brazil/Japan/Australia/USA/Europe) and supported by change overview matrix with further country specifics of all MDSAP countries helping for the decision whether there is a significant change. If any significant change is evaluated a regulatory affairs manager will be informed for conduction of all further needed steps related to different MDSAP areas affected  DEMF SC6500 : Dokumentation von Produktionsprozessen DEMF SC6500‐de‐00 , Rev. 0  DEMF SC6500: Anlage A02 zu Dokumentation von Produktionsprozessen, 02, point 4. „Bewertung der Änderungen“  including question „Aktuaisierung Process FMEA „ and „ Verification needed” and Validierung erforderlich” . Additional it is assured that any change in STED of products is needed (change in PQ 2110), that the Design change process is applicable and respective reports will be done.  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐04.00 , Rev. 04.00 A08 DWAG PQ2110 Assessment of changes to medical devices, rev 04.00  MAI 8 (HD)  DCS PQ 2030 The letter to customer  Email Fa. GPE dd 09.12.2022  MAI 9 (HD)  CAPA PR 121799  Risk Management Hazard Analysis Nova & classical Star NIV Masks. 2023. 01.30  MAI 10 (HD)  DEMF PQ3210-013-en-06.00 Internal Audits 01-05-2023  DEMF PQ3210 \_ A99 Requirements for internal Auditors  Management Review 30.03.2023 including action list.  Annual Auditors Exchange &Training - Dräger Lübeck 2023-02-17 Internal Audit program 2022 revision 03, Feb 7, 2023.  Internal Audit program 2023 Rev 02 signed on July 24, 2023.  DWAG IMS – Audit 2023 QRA PQ Calibration ( #115859)  Audit Agenda DWAG IMS 2023 QRA PQ \_ PR 127001 rev01 20230220 Audit report PR#114859 signed 27-02-2023.  Internal Audit Covering 2023-2025 rev 00 signed Feb 7, 2023 List of internal auditors 2023-07-19 as per PQ 3210  Bildungslebenslauf Auditor Dr. LN 2023-09-06  Internal Audit Report PR# 115861 BU Workplace Infrastructure  MAI 11 - 16 (MSz)  One Pager für Management review, 2023-03-31, Page 39+40  All Records kept in Trackwise complaint system  DCS PQ2010 Step 7: “Reporting Requirements applicable?”  DCS PQ2010 Step 6 “Acknowledgement; request for additional information and/or return of material.” DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00  DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 25 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Measurement, Analysis, and Improvement - CAPA and Internal Audit** |
|  | DEMF PQ2520 : Field Action (FA) DEMF PQ2520‐en‐05.00 , Rev. 05.00  **MDR**:  There are processes in place for CAPA and Post-Production Phase, Including Complaints (see above) |
| Names and titles of persons  interviewed | Ulf Hagedorn-Head of IMS Audit Management  Ralf Kornmann -Product Manager Therapie  Wasner, Carsten -Cyber security Engineer  Other particpants including roles will be provided by Ulf Hagedorn Both Stephan - Quality System manager  Quality & Regulatory Affairs |
| Products,  components, or projects  reviewed | DEMF SC6500  DWAG PQ2110  #103501 production and process controls  #117431 CAPA timelines  2DR -000069 Prozess-FMEA  CAPA`s #122371/#122373/#122374/#122377/#122378  Management Review 2022 – DWAG 2022-03-22 |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for this subsystem | This process is effectively implemented and conforms with requirements |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 26 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.4 | Device Adverse Events and Advisory Notices Reporting, PMS and Vigilance |

|  |  |
| --- | --- |
| Subsystem | **Device Adverse Events and Advisory Notices Reporting**  **Post-Market Surveillance and Vigilance** |
| Audit trail  records of | Martin Szepannek |
| Area(s) visited (location, e.g., site visited) | Location # 1  For more details related to Audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Medical Device Adverse Events and Advisory Notices Reporting: Notification of Adverse Events (MDSAP Chapter 4, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 8.2.2, 8.2.3 + (DIN)(EN) ISO 9001 - 7.5.1, 8.2.1, 8.5.5, 9.1.2 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - As required by MDSAP AU P0002 + MDSAP - Canada - As required by MDSAP AU P0002 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - As required by MDSAP AU P0002 + MDR - Article 10.9 ¶3(k), 10.12, 10.13; Article 80, 87, 88, 89, 94 + MDD - Article 10" "Medical Device Adverse Events and Advisory Notices Reporting: Notification of Advisory Notices (MDSAP Chapter 4, Task 2, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.2.3, 8.2.3, 8.3.3 + (DIN)(EN) ISO 9001 - 7.5.1, 8.2.1, 8.5.5, 8.7 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - As required by MDSAP AU P0002 + MDSAP - Canada - As required by MDSAP AU P0002 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - As required by MDSAP AU P0002 + MDR - Article 10.9 ¶3 (k), 10.12, 10.13; Article 80, 87, 88, 89, 94 + MDD - Article 10" |
| Brief description of processes or activities  evaluated to  demonstrate  what was  audited related  to the listed key QMS documents and records  reviewed below considering  inputs, outputs, and measures | MDAER #1 Notification of Adverse Events (Msz)  Verified that the medical device organization has a process in place for identifying devicerelated events that may meet reporting criteria as defined by participating regulatory authorities.  Verified that the complaint process has a mechanism for reviewing each complaint to determine if a report to a regulatory authority is required.  Confirmed that the medical device organization’s processes meet the timeframes required by each regulatory authority where the product is marketed.  DCS PQ2010 A02\_Rev-03.00 Decision Tree for Medical device Reporting  This Tree is used to retrieve informaton on reporting timelines and countries to report. 30 countris + EU is listed.  17 MA, 2 Feldaktionen  Samples taken:  PR#121742 Doctors Hospital Augusta Infinity ACS Workstation CC (V500/C500) Stopped providing breaths and registered data failure Date of Registration in Trackwise 2022-09-08 - reportable  Complaint Closure Report 121742  Date of Event: 2022-08-17  Complaint accepted 2022-08-17  Root Cause: printed Circuit Board failure  Decision: 2022-09-19 - Reportable due to Death/Serious Injury possible, in case bretahing pressure drops to ambient, and therefore deterioation of heatlh can not be excluded.  Countries to report: USA, China, Malaysia  122106\_MDR.pdf  Trackwise Manufacturer Report 9611500-2022-00241  Final Report 9611500-2022-00241 Follow-Up #1  PR#131186 Bana University medical center Phoenix Perseus A500 “Vent fail” Trackwise entry 2023-06-14 - reportable Complaint Closure Report 131186  Date of Event: 2023-06-12  Complaint accepted: 2023-06-14  Case Reported 2023-06-28  Root Cause: coul not be tracked down to device failirure (external leakage)  Decision: 2023-06-28, reportable due to not excludeable device failure  Countries to report: USA; China, Malaysia  MDR\_Initial\_Report\_PR131186.pdf  Trackwise Manufacturer Report 9611500-2023-00236  Final Report 2023-08-08 9611500-2023-00236 Follow-Up #1  PR#121766 Maxima Medisch Centrum Babyleo TN500 “Matress Failure during use” Trackwise entry 2022-09-09 – non-reportable  Complaint Closure Report 121766  Date of Event: 2022-08-09  Complaint accepted  Root Cause: misplaced NTC sensors during Production of matress  Decision: 2023-05-04  PR#121670 Martini Ziekenhuis Babyleo TN500 „Overflow of Humidifier and onto mother`s leg” Entry 2022-09-07 – non reportable  Complaint Closure Report 121670  Date of Event 2021-06-24  Complaint accepted 2022-09-07  Root Cause: narrowed opening of a nozzle  Decision: non-reportable 2022-09-14  FSCA-Case:  PR#116051 Klinikum Ludwigsburg Polaris Multimedia “Ausleger mit Federarm und Monitor während laufender OP abgestürzt“ - reportable  Complaint Closure Report  Date of Event: 2022-02-22  Complaint accepted: 2022-03-15  Case Reported: 2022-03-01  Root Cause: faulty Dräger installation instructions and accordingly wrong installation |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 27 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Device Adverse Events and Advisory Notices Reporting**  **Post-Market Surveillance and Vigilance** |
|  | Decision: 2022-03-16  Countries to report: EU incl. CH, UK ( DE) , USA  MIR MDV Initial Report PR116051.pdf form 2022-03-15  Trackwise Manufacturer Report  FSCA Dräger Ref 123143  MIR Final Report PR116051 BfARm ref 06223/22 from 2022-11-08  Competent Board Meeting Minutes 2022-09-30 for Meeting 2022-08-22, including documented evidence for decision to do FSCA  eMail 2022-10-30 to Dräger QR responsible Personens of the countries  QRA Network Letter Display Holder 2022-10-30  Safety Notice EN.pdf from October 2022  Reply and Order card\_EN  Competent Board Process describes the procedure for carrying out Competent Board meetings; theses take place in cases to evaluate a poetantially serious product risk, and decide on necessary measures to mitigate the potentially serious product risk. Competent Board responsibility is delegated by Top Management to appointed management employees of interdiscipliniary areas. Competent Board meetings are decision meetings.  Australia (TGA):  DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00  Brazil (ANVISA):  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  Canada (HC):  Complaint and recall Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  DEMF PQ2520 : Field Action (FA) DEMF PQ2520‐en‐05.00 , Rev. 05.00  Japan (MHLW/PMDA)  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  United States (FDA):  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  MDAER #2 Notification of Advisory Notices (Msz)  Verified that advisory notices are reported to regulatory authorities when necessary and comply with the timeframes and recordkeeping requirements established by participating regulatory authorities.  CRT Action Item Dräger FSCA ICM PR126573, TPS ID VM63012:  “The investigation confirmed that when ICM is used in combination with a syringe pump connection, under certain under certain conditions, ICM may show entries in the daily curve that were not deliberately created by the user. These entries cannot be edited or deleted by the user. If these additional entries  unnoticed, this can lead to inaccurate documentation of prescriptions or previous treatment in the program.  program and thus potentially lead to incorrect treatment decisions.” Action Item: “Since the Cause of the behaviour has been identified, please review the rationale for not updating the affected systems, considering the principle of integrated safety”.  During audit, manufacturer provided updated information on that case and behavior. This behavior has been changed in the next regular release of the Software (V14) and in Bugfix Version (V 13.02, released 07/2023). Therefore the requested rationale is not needed anymore.  The Bugfix Version will be rolled out with a new Field action (see “Decision and Order”) Background Information (as communicated to BFARM 2023-08-08):  ICM is used by customers in 5 different Software Versions (V9-V13).  Bug fixing was available with V13.02 (available since 07/2023) and V14.  Installation of V12 + V13 are technically updateable to 13.02; however, this involves a high effort withing hospitals, since the IT infrastructure is involved; therefore, Dräger forecasts this update to take around 12 months time.  The problem described within FSCA can only happen in installations that use the option “Syringe Pumps Connection”; this connection is only be used by very few customers. Dräger will approach customers with these versions in order to either update to V13.02 or to deactivate the option causing the issue.  Records for this case:  Competent Board Decision 2023-01-13  Specific Risk Assessment RM CAPA PR123704-signed.pdf  TSB\_4\_ICM\_Decision and Order\_signed.pdf 2023-08-01  „13.02 ist verfügbar“ Release Notes ICM Patientenmanagement Software 13.02 6495.525\_de, versendet 2023-07-28  Kundeninformationsschreiben im Entwurf vorhanden (…), wird noch im September versendet.  eMail 2023-08-08 to Competent Authority Landesamt für soziale Dienste Schleswig-Holstein PR123101 Decision Closure Report 2023-09-19  Jira-Defect Entry Ticket ICM-13149  Jira-Defect Entry Ticket ICM-13254 – for V13.02 – 1306887 Test case 13254: Approved, Passed RQM Test case 114863  SW-release-No mt-1622 Prt-No. MK0517103 for V13.02  ICM Customer letter Fluid Management Deutsch update \_final.pdf (2023-09) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 28 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Device Adverse Events and Advisory Notices Reporting**  **Post-Market Surveillance and Vigilance** |
|  | Australia (TGA):  DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00  Brazil (ANVISA):  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  Canada (HC):  Complaint and recall Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00 DEMF PQ2520 : Field Action (FA) DEMF PQ2520‐en‐05.00 , Rev. 05.00  Japan (MHLW/PMDA)  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  United States (FDA):  Complaint Procedures: DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00  **MDR:**  Vigilance reporting and analysis  DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00  DWAG IN4250 : Clinical Evaluation DWAG IN4250‐en‐04.00 , Rev. 04.00  Trend Reporting is described in Attachment 04 of PQ2000 (general trendingand trend reporting in accordance with artice 88)  **MDR**  The importer undertakes to notify TÜV SÜD PS without delay of the non-compliance and of any corrective action taken where the device with identification number CE 0123 presents a serious risk or in the course of the post-market surveillance, a need for preventive or corrective action or both is identified |
| Reviewed  documents and records  (identification  and revision) | DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00  DEMF PQ2010 : Complaint Handling DEMF‐PQ2010‐en‐02.00 , Rev. 02.00 DCS PQ2030: Complaint Handling in Sales and Service, Rev. 06.00  DCS PQ 2020: Competent Board Rev. 01  DEMF PQ2020 Competent Board\_A01-en-02.00 Rev. 02:00  DEMF PQ2520 : Field Action (FA) DEMF PQ2520‐en‐05.00 , Rev. 05.00  DWAG PQ2011 : Screening of Repair and Service Notifications DWAG‐PQ2011‐en‐00.00 , Rev. 00.00  Records:  PSUR Babyleo  PSUR Perseus A500 11249101 rev. 00 Axxx family, covering 2022-01-01 to 2022-12-31  Includes internal data sources: Incidents (Perseus 384), serious incidents without harm (25)  Inputs are generated by referenced documents  - Post Production Information report PPI\_ECRI\_2022 Rev.00 from 2022-03-30   PMCF Plan 101-12 MDR Perseus A500 2022-03-25  - - PMCF Plan atlan 2022-07-04  - Axxx\_PMS\_Plan 2022-04-02  11100333 Rev. 00 Axxx PMS Plan  PMS Plan Babyleo (Thermoregulation) 2023-06-11  PMS Report Babyleo (Thermoregulation) 2023-08-01  Number of Vigilance reports FDA – Trackwise Export 2023-09-13, including 416 reportable Events to FDA.  Number of Complaints worldwide – Trackwise Export 2023-09-13, including 4311 complaints in general Vigilance Contact List (updated 2023-07-21) includes contact data of each potentially involved organisation |
| Names and titles of persons  interviewed | Sonja Hillmer (Head of Post Market Surveillance)  Sven Mamerow (Post Market Surveillance Manager)  Dorothee Neitzel (scribe) (Post Market Surveillance Manager) Christine Rafalzik (scribe) (Post Market Surveillance) |
| Products,  components, or projects  reviewed | Babyleo  Perseus A500 |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for this subsystem | ☒ This process is effectively implemented and conforms to requirements.  ☐ Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 29 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.5 | Design and Development |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
| Audit trail  records of | Martin Szepannek / George Pavlov / Gabriele Mousset / Honorata Donnermair / Melanie Gaßen |
| Area(s) visited (location, e.g., site visited) | Location # 10578  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Design and Development: Identification of Devices Subject to Design and Development Procedures; Technical Documentation (MDSAP Chapter 5, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.1, 4.2.1, 7.1, 7.3.10 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 7.5.3, 8.1, 8.4 + MDSAP - Australia - TG(MR)R Schedule 3, Part1, (excluding or including clause 1.6) + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.7, 4.2 + MDSAP - Canada - CMDR 9, 10 to 20 + MDSAP - Japan - MO169: 5-1, 6, 26, 36-2; [Old: 5, 6, 26] + MDSAP - USA - 21 CFR 820.30(a) + MDR - Article 10.1, 10.2, 10.9 ¶3 (e, g); Annex IX 2.2 ¶2 (c2) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  Design and Development: Selection of a Completed Design and Development Project (MDSAP Chapter 5, Task 2, Site: 10578  "Design and Development: Design and Development Planning (MDSAP Chapter 5, Task 3, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.1, 7.3.2 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.3.2 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(4)&(5)(c) + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.2, 4.1.11 + MDSAP - Canada - CMDR 32 + MDSAP - Japan - MO169: 6, 26, 30 + MDSAP - USA - 21 CFR 820.30(b), 820.30(j) + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Design and Development: Implementation of the Design and Development Process (MDSAP Chapter 5, Task 4, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.3.1, 7.3.10 + (DIN)(EN) ISO 9001 - 7.5.1, 7.5.3, 8.3.1 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(4)&(5)(c) + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.1 + MDSAP - Japan - MO169: 6, 30, 36-2; [Old: 6, 30] + MDSAP - USA - 21 CFR 820.30(a), 820.30(c), 820.30(j) + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2)"  "Design and Development: Design and Development Input (MDSAP Chapter 5, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 5.2, 7.2.1, 7.3.3, 8.2.1 + (DIN)(EN) ISO 9001 - 5.1.2, 7.5.1, 8.2.2, 8.3.3, 8.5.5, 9.1.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(2)&(5)(c), Sch 3 P1 1.4(3)(a)&(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.3, 4.1.11 + MDSAP - Canada - CMDR 10-20, 21-23, 66, 67, 68 + MDSAP - Japan - MO169: 6, 11, 27, 31, 55-1; [Old: 6, 11, 27, 31, 55] + MDSAP - USA - 21 CFR820.30(c), 820.30(g) + MDR - Article 10.9 ¶1 s2, 10.9 ¶3 (b), 10.11; Annex IX 2.2 ¶2 (c2, c6, c8); Article 1 (3), Article 1 (4, 6, 7, 8, 9), Article 2 (1) + MDD - Annex II (3.2)"  "Design and Development: Completeness, Coherence, and Unambiguity of Design and Development Input (MDSAP Chapter 5, Task 6, Site: 10578); (DIN)(EN) ISO 13485 - 7.3.3 + (DIN)(EN) ISO 9001 - 8.3.3 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.3 + MDSAP - Japan - MO169: 31 + MDSAP - USA - 21 CFR820.30(c)"  "Design and Development: Design and Development Output and Design Verification (MDSAP Chapter 5, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.3.4 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.5 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(5)(c) + MDSAP - Brazil - RDC ANVISA 16/2013:4.1.5, 4.1.4, 4.1.11 + MDSAP - Japan - MO169: 6, 7-2, 32; [Old: 6, 32] + MDSAP - USA - 21 CFR 820.30(d), 820.30(f) + MDR - Article 10.9 ¶3 (b); Annex IX 2.2 ¶2 (c5) + MDD - Annex II (3.2)"  "Design and Development: Risk Management Activities Applied Throughout the Design and Development Project (MDSAP Chapter 5, Task 8, Site: 10578); (DIN)(EN) ISO 13485 - 4.2.1, 7.1, 7.3.3, 7.3.4 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.3.3, 8.3.5 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(5)(c)(iii) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.11, RDC ANVISA 56/2001 + MDSAP - Canada - CMDR 10, 11, 15, 16 + MDSAP - Japan - MO169: 6, 26, 31, 32 + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.9 ¶3 (e) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Design and Development: Design Verification or Design Validation to Confirm Effectiveness of Risk Control Measures (MDSAP Chapter 5, Task 9, Site: 10578); (DIN)(EN) ISO 13485 - 7.1, 7.3.6, 7.3.7 + (DIN)(EN) ISO 9001 - 8.1, 8.3.4 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(5)(c) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.4, 4.1.8, 4.1.11 + MDSAP - Canada - CMDR 10,11, 15, 16 + MDSAP - Japan - MO169: 26, 34, 35-1, [Old: 26, 34, 35] + MDSAP - USA - 21 CFR 820.30(f), 820.30(g) + MDR - Annex IX 2.2 ¶2 (c5) + MDD - Annex II (3.2)"  "Design and Development: Design Validation (MDSAP Chapter 5, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.3.7 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.4 + MDSAP - Australia - TG(MD)R Sch1 P1 2; Sch3 P1 Cl1.4(5)(d) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.8, 4.1.11 + MDSAP - Canada - CMDR 12, 18, 19 + MDSAP - Japan - MO169: 6, 35-1; [6, 35] + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.3, 10.9 ¶3 (f); Annex IX 2.2 ¶2 (c5); Annex XIV, Article 61, and Annex XIV part A + MDD - Annex II (3.2)"  "Design and Development: Clinical Evaluation and/or Evaluation of Medical Device Safety and Performance (MDSAP Chapter 5, Task 11, Site: 10578); (DIN)(EN) ISO 13485 - 4.2.1, 7.3.7 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.4 + MDSAP - Australia - TG(MD)R Reg 3.11, Sch1 EP14, Sch3 P1 Cl 1.4(5)(c)(vii), Sch3 P8 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.8, 4.1.11, RDC ANVISA 56/2001 + MDSAP - Canada - CMDR 12, 18, 19 + MDSAP - Japan - MO169: 6, 35-1; [Old: 6, 35] + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.3, 10.9 ¶3 (f); Annex IX 2.2 ¶2 (c5); Annex XIV, Article 61, and Annex XIV part A + MDD - Annex II (3.2)"  "Design and Development: Software Design and Development (MDSAP Chapter 5, Task 12, Site: 10578);  (DIN)(EN) ISO 13485 - 7.3.2, 7.3.10 + (DIN)(EN) ISO 9001 - 7.5.3, 8.3.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch1 EP12.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.8, 4.1.11 + MDSAP - Canada - CMDR 20 + MDSAP - Japan - MO169: 30, 36-2; [Old: 30] + MDSAP - USA - 21 CFR 820.30(g) + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Design and Development: Design and Development Change (MDSAP Chapter 5, Task 13, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.1, 7.3.9, 7.3.10, 8.2.1 + (DIN)(EN) ISO 9001 - 7.5.1, 7.5.3, 8.1, 8.3.6, 8.5.5, 8.5.6, 9.1.2 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 4.1.4, 4.1.8, 4.1.10, 4.1.11, Brazilian Law 6360/76 - Art. 13 + MDSAP - Canada - CMDR 1, 34 + MDSAP - Japan - As required by MDSAP AU P0002 + MDSAP - USA - 21 CFR 820.30(i), 807 + MDR - Article 10.9 ¶1 s2, 10.9 ¶3 (a); Annex IX 2.2 ¶2 (c1, c8); Article 8, Article 9 + MDD - Annex II (3.2)"  "Design and Development: Design Review (MDSAP Chapter 5, Task 14, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.3.2, 7.3.5 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.2, 8.3.4 + MDSAP - Australia - TG(MD)R Sch3 P1 C1.4(5)(c)(i) + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.6, 4.1.11 + MDSAP - Japan - MO169: 6, 30, 33 + MDSAP - USA - 21 CFR 820.30(e) + MDR - Article 10.9 ¶3 (b); Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2 + MDD - Annex II (3.2)"  "Design and Development: Impact Review of Design and Development Changes on Previously Made and Distributed Devices (MDSAP Chapter 5, Task 15, Site: 10578);  (DIN)(EN) ISO 13485 - 7.3.9 + (DIN)(EN) ISO 9001 - 8.3.6, 8.5.6 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.10 + MDSAP - Japan - MO169: 36-1; [Old: 36] + MDSAP - USA - 21 CFR 820.30(i) + MDR - Article 10.9 ¶1 s2, 10.9 ¶3 (a); Annex IX 2.2 ¶2 (c1, c8); Article 8, Article 9 + MDD - Annex II (3.2)" "Design and Development: Design Transfer (MDSAP Chapter 5, Task 16, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.3.8 + (DIN)(EN) ISO 9001 - 7.5.1, 8.3.4 + MDSAP - Brazil - RDC ANVISA 16/2013: 4.1.7, 4.1.9, 4.1.11, 4.2 + MDSAP - Japan - MO169: 6, 7-2, 35-2; [Old: 6, 30] + MDSAP - USA - 21 CFR 830.30(h) + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2)"  "Design and Development: Top Management Commitment to Design and Development Process (MDSAP Chapter 5, Task 17, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.3, 5.1, 5.5.1 + (DIN)(EN) ISO 9001 - 4.4, 5.1.1, 5.3, 8.4 + MDSAP - Australia - TG(MD)R Sch3 P1 Cl 1.4(5)(b)(ii) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1 + MDSAP - Japan - MO169: 5, 10, 15 + MDR - Article 10.9 ¶3 (c) + MDD - Annex II (2, 3.1)"  EN ISO 18562 (Biocompatibility evaluation of breathing gas pathways) |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | \*\*\*\*\*\*\*Trails (GP)  D&D #1 - &Identification of devices subject to design and development procedures; technical documentation (GP) The processes are defined and documented as set of procedures : DWAG IN 4200 is established ad applicable to medical and non-medical devices.  The stage -gate is process is defined with 8 stages, whereas first 3 stage-gates form pre-design concepts phase. All design changes are following SOP Design Change Process.  Start with Gate 3.0 Preparation ==> 4.0 Definition ==> 4.1 Design ==> 5.0 Realization ==> 6.0 Validation ==> 7.0 CE / Ramp-up / Market Launch ==> 7.1 Serial Production ==> Gate 8.0 Life Cycle/Change  Changes are managed according to Design Change Process  The system used for documentation for Design requirements is IBM Engineering Requirements Management Tool DOORS.  The procedure defines criteria, as applicable for  • new product development  • module development  • Upgrades and product change  • Introduction of OEM or private label  • Intro. Trading goods  • Transfer of development, production or other disciplines |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 30 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | SOPs for design and development were demonstrated and assessed during the audit – ref to list of documents for Designee and Development chapter.  Additional country-specific requirements:  Australia / Brazil / Canada / Japan  - the organisation has identified no exclusion from Design control. All product families are controlled by the top-level design process.  D&D #2 - Selection of a completed design and development project (GP)  1. Smart Pilot View was selected based on the sampling plan to cover the product range of the company, as product with direct impact to safety and performance which was not yet evaluated during the surveillance cycle. The product was chosen as linkage to the on-going Technical Documentation review.  2. The product Connected Lung Protective Ventilation Analytics was chosen as verification if this can be a medical product in MDSAP scope. It was observed, the product is not a Medical Device, and therefore is out of scope for this audit.  The introduction product performed: Smart Pilot View is monitoring and predication software for an Anesthesia application. The software displays and logs the dosage of intravenous and volatile drugs administered in human being. Additionally, it calculates the drug effect based on pharmacokinetic models and the drug interaction as guidance for treatment. Current release is 3.03  The devices classification is IIb according to MDR and MDD. The Device is currently MDD , and under MDR TD review.  Classification Codes SmartPilot View 11213764\_00  IfU\_SPV\_SW\_3.03.n\_9512901\_1\_2022-11\_en Instruction for Use Smart Pilot view  IfU\_Supplement\_SPV\_SW\_3.0n\_9054332\_11\_2022-12 Compatibility with other devices Smart Pilot View  D&D #11 - Clinical evaluation and/or evaluation of medical device safety and performance (GP)  Smart Pilot View   Clinical evaluation and clinical investigation processes are established. CE is performed as a part of design and validation process and is documented in CER. CERs are organized to be grouped in “CER-families” if only possible. Aspects for a CER family: Similar or same intended purpose (similar literature search) etc. The process is set up with a main SOP DCS IN4250-110-en-03.00\_Clinical Evaluation is the main SOP for MDR compliance, a separate SOP is available for the products under MDD IN 4251.  Clinical performance and clinical benefit are mainly processed by the Clinical Affairs Team whereas clinical risks and clinical safety is assessed in the frame of the RM in close collaboration with the clinical / medical expert, this assessment is then fed back into the CEP/CER.  Literature searches are conducted for the state of the art and the MDuE, for performance / benefit and safety. Search criteria are defined in the CEP and are generated according to the PICO approach.  Preclinical data based on applicable standards are considered in CEP and CER.  Review of Postproduction Information Report (RPPIR): this assessment is used for updates from the post-market phase on a regular basis.  The complete CER is re-assessed when above listed documents are created to confirm or revise the contents. This approach is described in the main CER SOP.  For the sampled device Smart Pilot View:  Latest clinical evaluation covered by clinical evaluation plan – shown during the audit, Clinical evaluation report was demonstrated: 11149213\_02 11149213 02 Clinical Evaluation Report Released  Confirmation of Applicability (CoA): this assessment is used if new, not clinical information is available it will be integrated into an already existing CER-family with the next periodic update.  PMCF Process:  DWAG IN4250 Clinical Evaluation explains the process and documentation for PMCF Report established for that process. In step 17 od CE Process the decision on PMCF activities is done. There is PMCF Plan Template, PCF Checklist and  PMCF plan includes need for PMCF, objectives, type of activity, description, rationale for appropriateness, timeline, summary of activities, evaluation of clinical data relating to equivalent or similar products, risk management report.  In case of sampled product Smart Pilot View, PSUR contains statement that PMCF is fully based on PMS surveillance there is no need on active PMCF apart from Routine PMS  It was explained that the SSCP process is not applicable as there are no class III devices manufactured.  Post-market phase: update of CERs, the frequency depends on risk class and innovation status. Frequency is 2 to 5 years until end of production plus 7 years, or end of service and 2 more years.  Additional country-specific requirements:  Australia (TGA):  Clinical Evaluation Reports includes the clinical evidence based on PMS history of the device. This can be presented by Literature search in line with IN4250 - Template - Literature Search  D&D #12 - Software design and development (GP)  The Development of Software follows the V-Model approach. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 31 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | From design and development plan, software requirements, software architecture, detailed design, implementation of software units, the process includes the Software classification (medical devices) DWAG-IN42\_A05 – specific requirements for software.  Most of the Software are class C, with some exceptions in class B,  Unit testing is done by code review (by at least 2 people based on the Code Guidelines), Static Code Analysis, and automated unit tests.  After the unit test have been completed, the Software will be integrated, which is continuously happening. When more items are affected by the change, there will be additional tests performed to prove correct functionality.  The system tests will be then performed, to prove that the Software Requirements have been implemented and are fulfilled.  After the Software System test is closed, and additional system tests which are performed together with the Hardware components. The results of the verification will be documented in a report, for the Software, also for the whole system.  After the release of the Software, a regulatory check will be done to determine if additional activities with regards to normative requirements should be performed.  Cybersecurity is also included in the Software development. There will be a thread analysis performed. The inputs for this analysis TR 60601-4, thread analysis template, system architecture, among others. The output for the process is the thread analysis which flows into the risk analysis process of the device, where the corresponding measures will be set. Verifications of cybersecurity measures follow the risk management and software development process.  Anomalies are classified as serious, significant, important, noticeable or no effect. CIN-Classification critical important notable.  Example ///SW Smart Pilot View -design change to Rev 3.03///  The Software designed is perfumed in line with requirement of ISO62304. INSPECTION REPORT  IEC 62304 process inspection by the accredited test lab Product Qualification, Drägerwerk AG & Co.KGaA was demonstrated during the audit.  Software Class according IEC 62304 is determined Class B (According to the risk assessment table, the expected harm that could result from software failure is limited to “minor”). – observed in 5.1 Product Risk Management Report - 11149328\_03  The process was performed under the guidance of design change process DWAG IN4230 Design Changes, the changes were followed by verification and validation prior to release, which was sampled and assessed during this audit.  The devices validation is defined in design Process IN4200. The step is performed between the Gate 6.0 and gate 7.0  Following inputs and outputs were regarded for the Validation stage  - Usability evaluation  - Validation plan  - Validation summary report  - Reliability Review  - User requirements DR-00072766 Product requirement’s Smart pilot base Line 2022-11-24T  Particular examples of product requirements were sampled during the audit and implementation was verified PR-SPV\_309 mart Pilot shall support Wierda PK Model for the Muscle relaxant Rocuronium  PR\_SPV \_ \_297 Emanating patient data  Clinical User requirements - -  PR\_SRV-543 The user shall be able to determine the patients current and future hypnotic and analgesic level related to the leveled intended by user.  Verification process linked to user requirements via  - Standards  - Provision of clinical evidence that TSR matches the user requirement’s - Comparison with similar devices  - Usability Evaluation Formative and summative reports  DOORs system is in use for Traceability for of Inputs and outputs  The Validation summary report: 11149414 Rev 00 Validation Summary report V00 2023-02-24 demonstrated during the audit.  D&D #13 - Design and development change (GP)  The process flow id defined in SOP IND 4200  The process is implemented as a workflow in Pro-X.  A change request is prepared and evaluated by quality assurance, project manager and the product manager, these changes could be improvement of changes triggered by post-production feedback.  In the case the change influences materials, and these materials are used for other products, the change needs to be assessed by other PSB .Product Manager and/or other functions decide on the DCR (accept or decline).  After the design change has been accepted, the design change project will be created. This includes the design change plan, change project, pre-tailoring investigation (central document about which components are affected, recommended solution and which design reviews should be met), Object List (components which are going to be change), List of deliverables (which documents should be change  Example – design change to Rev 3.03  The change for the design was summarized as PKG-2021-002776 Pre-tailoring investigation 18.02.2021 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 32 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | The changes were accumulated as following:  DCR-2019-002082 labeling amassing - change of the labels size – SW only DCR-2021-002127 ISM-IEC TR60601-4-5  DCR-20201 003730 - approval of the Zeus IE  The package summary is in process of implementation and is not accomplished as a packages, therefore this cannot be used for the full assessment.  The example of the changes was assessed during the audit:  The reports rare maintain in SAP in controlled way.  11134555 Design change review report - for the release 3.02n PKF-202-003043 The changes contained – addition IFU languages / languages added  The design change evaluation review report  DCR-2020-002999 IFU Translation for Slovakia 2020-06-02  Verified that the DCR was suitably documented, implemented and verified Validation Form PID Printing process 2020-12-17  The printed documentation report  The complete Design change documented , the new tool ARAS used  Australia, Brazil, Canada, Japan, US)  The regulatory affairs department is also including in the pre-tailoring investigation considering the requirements for each country where the device is marketed and the notifications to be done previous to the approval of the change.  D&D #14 - Design review (GP)  The design reviews are established and the content for each review is defined accordingly. For medical devices the reviews are performed according to DWAG IN4200-en-01.00 Design.  The Design Sub Process contains five major Design Reviews on system level: • System Requirements Review  • System Architecture Review  • System Integration Review (for each integration loop).  • Verification Readiness Review  • System Validation Review  Besides these major Design Reviews on system level, there are additional Design Reviews that are part of other process steps that are required as completion criteria. Design Reviews have to be  conducted according to IN4204. Design Review reports are records and have to be filed into the DHF.  Example – Example ///SW Smart Pilot View -design change to Rev 3.03///  As this design project was controlled as design change , standard design review requirements were not applicable. The project was released as 11134555 Design change review report  US  Procedures ensure that participants include representatives of all functions concerned with the design stage being reviewed and an individual(s) who does not have direct responsibility for the design stage being reviewed.  D&D #15 - Impact review of design and development changes on previously made and distributed devices (GP) An evaluation of the impact of the changes on already delivered devices is included in the template for Pre-Tailori8ng Investigation PTI. For the examples taken, it was possible to follow the impact analysis and the corresponding activities to be performed on the devices on the field.  Example ///SW Smart Pilot View -design change to Rev 3.03///  Drager has demonstrated PTI PKG-2021-002776 from 23.05.2022, which encompasses charges for Smart Pilot View such as DCR-2022-002200 and DCR-2022-002214  D&D #16 - Design transfer (GP)  For Software products, the process for Design Transfer of medical software is performed according to DWAG IN4206 Software Approval and Design Transfer and is documented in DCS IN4206-110  The release and transfer includes the following steps:  - Check software development plan and deliverables  - Check software verification  - Check list of non-conformities  - Check Software Build  - Assure reliable delivery -Assure reliable delivery of the released software without corruption or unauthorized change, and where media are used that contain the released software, address their replication, media labeling, packaging, protection, storage, and delivery. Documented as Plan for malware-free shipping  - Create and upload Software Archive according to IN4206 ARAS Manual  Logistically relevant software needs to be transferred from development to production and service. The software executables become part of the DMR, stored in PLM SYSTEM, on DVDs or on a server with controlled access and configuration control. The following documentation structure is fully supported by PLM SYSTEM but is also applicable to other storage concepts.  Example ///SW Smart Pilot View -design change to Rev 3.03///  Elements of approval and design transfer records as required by DCS IN4206 were requested and assessed during the audit:  Verification summary report – 11149420 verification summary report Rev 08 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 33 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | SW 3.03 List of No-conformities after release 11149233 List of Non-conformities Ver 05  Usability evaluation Summary report – 11149411 Usability summary report Rev 00  Statement – no formative usability test report was performed after change – as no changes affected the to the product 11149378 Smart Pilot Usability Summative Test Rev 01  Smart Pilot View Suability Specification – 111494 Rev 01 usability Specification  – 11149378 Rev 01 Summative Usability Evaluation test report Ver 01  Product risk management report -  11143145 PSUR Ver 01 2022-10-12  Brazil  The product is released and electronically signed via SAP system  D&D #17 - Top management commitment to design and development process (GP)  Based on the assessment of Smart Pilot View Update design project, Top management has demonstrated the commitment or design and development by providing the resources, systems and process.  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  Trails of (HD)  D&D 13 - Design and development change (HD)  The process is established and documented in DWAG IN 42 30 design change.  A change request is prepared and evaluated by quality assurance, project manager and the product manager, these changes could be improvement of changes triggered by post-production feedback. In the case the change influences materials, and these materials are used for other products, the change needs to be assessed by other PSB. Product Manager and/or other functions decide on the DCR (accept or decline).  After the design change has been accepted, the design change project will be created. This includes the design change plan, change project, pre-tailoring investigation (central document about which components are affected, recommended solution and which design reviews should be met), Object List (components which are going to be change), List of deliverables (which documents should be change).  Additional country-specific requirements:  (Australia, Brazil, Canada, Japan, US)  The regulatory affairs department is also including in the pre-tailoring investigation considering the requirements for each country where the device is marketed and the notifications to be done previous to the approval of the change.  The design package needs to be approved, from quality and project management, and then it will be implemented (documented in DHR, DHF, work items).  A design review will be performed when all the changes are ready for release. This includes an evaluation of the status of the changes and the documentation that was generated (quality and regulatory affairs). It will be proved at the end if regulatory changes have been done, and if the country organizations should be informed.  At the end the materials/components will be released and finalized (Quality Assurance).  Example Flow sensor:  The product was previously purchased and delivered as a finished medical device and is now manufactured on Revalstraße. It have been a strategic decision. Additionally, the color of the hose was change and the shape of hose slightly modified.  DCR 2020-001379 dd. 31 05.2020 / PKG 2020 000943  Flow sensor classification:  It is not active device as pressure measurement device per se is in the connected device itself (Oxylog). The flow sensor has no energy source (does not need it) and is non active as per MDR definition. The pressure is transfer to the end device (Oxylog) and is measured based on volume converting.  The classification process and assignment of the EMND codes presented during the audit seems plausible and appropriate.  D&D 14 - Design review (HD)  The design reviews are established and the content for each review is defined accordingly. For medical devices the reviews are performed according to DWAG IN4200-en-01.00 Design.  The Design Sub Process contains five major Design Reviews on system level: • System Requirements Review  • System Architecture Review  • System Integration Review (for each integration loop).  • Verification Readiness Review  • System Validation Review  The issuing authorities for release including Tester, products owner, Quality and regulatory.  USA: There are a process in place (DWAG IN4200-en-01.00 Design). The competences and roles reviewers are defined in DWAG IN4230 and DWAG IN4200. Design review have been audited (Verification and Design Change review).  D&D 15 - Impact review of design and development changes on previously made and distributed devices (HD) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 34 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | An evaluation of the impact of the changes on already delivered devices is included in the template for PTI. For the examples taken, it was possible to follow the impact analysis and the corresponding activities to be performed on the devices on the field. The impact of DCR was reviewed during the audit for biocompatibility test report and usability test report (Inspection Report No 21 -00620)  D&D 16 - Design transfer (HD)  At the end of design and development the design has been transferred to the production site at Revalstrasse at Dräger. The design change steps are signed/ released in SAP by the click on the checklist status is visible who and when has releases each step.  Additional country-specific requirements:  (Brazil) The devices are released for production only after correct approval from the corresponding personnel, which includes quality assurance. The release is documented and signed accordingly.  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  EN ISO 18562 (Biocompatibility evaluation of breathing gas pathways) (GM)  See document: ISO 18562\_questions for audit\_v1\_2023-07-14 filled on 20.09.2023 !!!  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  \*\*\*\*\*\*\*\*\*\*\*\*\*(MSz)  DD11 - Clinical evaluation and/or evaluation of medical device safety and performance (MSz) Verified that clinical evaluation was performed as part of design validation.  Supplier Novinion GMBH Tübingen and Neanatologe Dr. Trips as Mitauthor des CER.  Australia (TGA):  Clinical Evaluation Report Babyleo TN500 SW1.05 -2020-01-08 Review of Post Production Information Report (Clinical) 2022-05-19 PMCF Plan Babyleo TN500 2022-07-25  PMCF Report not yet available  PSUR Thermoregulation 2023-08-01  DD12 - Software design and development (MSz)  Software design and development  Since medical device contains software, verified that the software was subject to the design and development process. It could be confirmed that the software was included within the risk management process.  DD13-15 - Design and development change Babyleo TN300 (MSz)  Verified that design and development changes were controlled, verified (or where appropriate validated), and approved prior to implementation.  It also could be confirmed that any new risks associated with the design change have been identified and mitigated to the extent practical.  DRÄGER Babyleo TN500  Both radiant warmer and neonatal incubator  Introduced 2017 to the market, already MDR upgraded.  ProX (SAP tool) is used for documenting Lifecycle Management changes.  PKG-2021-001689 Q-Improvement Nozzle Opening  PTI Pre-Tailoring Investigation PKG-2021-001689 closed 2022-01-24 Regulatory relevance of this change:  - material stays the same;  - Intended Use stays the same;  - Production process sstays the same;  - Production tool gets an update  - Current standard report remains valid  - EN-60601-2-19 testings stay valid  Product CAPA 97813 Humidifier leakage via pressure release port during operation assessed the need for a Field Action; result: no, therefore nozzles with existing diameter could be used up.  Change Overview 2021-11-15 Assessment on Significance resultetd in EU no, US Letter to File, CA annual renewal;  Letter to File: AMD 20, 2022-03-02, RCA Chamge of the Diameter of the opening of the humidifier nozzle to a larger size.  Changes are handled via DCR Design Change Request to PSB Product Steering Board  Product Steering Board consist of interdisciplinary team and manages the product changes latest after design transfer by selecting them combining and planning product changes according to the business objectives. Attendees are at east: Product Manager, Project Manager , Quality Assurance and Regulatory affairs; depending of the nature of the design change project, the PSB mits be supporte by subject matter experts.  DD16 - Design transfer (MSZ)  Determined that the design was correctly transferred to production.  Work package “Industrial Engineer – Update production process” and Quality Engineer – update production quality process” and “Material Ressource planner” have been completed as documented in Design Change Summary page 9. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 35 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | \*\*\*\*\*\*\*\*\*\*\*\*\*GM  DD13 - Design and development change ATLAN (GM)  Changes have to be verified and approved prior to implementation, which is done in the selected project.  Requests can be triggered from anyone. Handling of change evaluation will be done in the tool “ProX”. Changes have to be approved by Product -Manager/ProjectManager/Quality assurance.  Design changes processing in general is defined in DWAG IN4230.  After approval the change request will be transferred into change project with related evaluation and list of deliverables.  Out put document of evaluation is: Pre-Tailering investigation which serves for definition of mayor needed info and definition of responsibilities and needed reviews.  It have to be evaluated whether additional input into risk analysis must be performed and effects on delivered products are checked for each request.  Change to ATLAN 2.0 SW version was audited.  USA:  Verify that the organization obtained a new 510(k) or supplement to the pre-market approval if required [21 CFR 807].  519 k for ATLAN 2.0 is available:  510 k FDA 2023, 07.23, K 230931, approved by James J. Lee S ( ATLAN change 2.0) Canada:  Verify that the manufacturer has a process or procedure for identifying a “significant change” to a Class III or IV medical  device. Verify that information about “significant changes” is submitted in a medical device license amendment application [CMDR 1, 34].  All changes will be presented at a steering Board (weekly meeting) Members of the steering board are also from R&A. In this steering board it will be decided whether the changes are singificant. Quality assurance (also part of the steering board and change process handling) is responsible that the regulatory decision will be taken. This is defined in DWAG IN4230. A checklist for decisoon is available DWAG PQ2110 regulatory approval to market product.  For the audited sample no Canada approval is planned.  Australia:  Verify that the manufacturer has a process or procedure for notifying the auditing organization of a substantial change to the design process or the range of products to be manufactured [TG(MD)R Sch3 Cl1.5].  Verify that the manufacturer has a process or procedure for identifying a proposed substantial change to the design, or the intended performance, of a Class AIMD or Class III device, and to notify the assessment body prior to implementing the change [TG(MD)R Sch3 P1 Cl 1.6(4)].  If the Manufacturer is also a holder of a TGA Conformity Assessment Certificate, then the Manufacturer is also required to notify the TGA of these changes.  Verify that Manufacturer has taken into account post-production feedback as an input to monitoring and maintaining product requirements and improving product realization processes.  All changes will be presented at a steering Board (weekly meeting) Members of the steering board are also from R&A. In this steering board it will be decided whether the changes are singificant. Quality assurance (also part of the steering board and change process handling) is responsible that the regulatory decision will be taken. This is defined in DWAG IN4230. A checklist for decisoon is available DWAG PQ2110 regulatory approval to market product.  PMS PLAN ATLAN/PSUR ATLAN have been audited.  Market Clearance MC Form AUST(New Zealand), 09.06.2023 ATLAN X, 2.0  Japan:  For the Marketing Authorization Holder, confirm if the Marketing Authorization Holder has submitted a new application, a change application, or a change notification to PMDA/ a Registered Certification Body, when applicable.[PMD Act 23-2-5.1, 23-2-5.11, 23-2-5.17, 23-2-23.1, 23-2-23.6, 23-2-23.7].  For the Registered Manufacturing Site, confirm if the site has a mechanism to communicate with the Marketing Authorization Holder about device modifications, so the Marketing Authorization Holder can take appropriate actions. If a critical medical device modification has happened in the Registered Manufacturing Site, confirm if the Registered Manufacturing Site has communicated with Marketing Authorization Holder about the change [MHLW MO169: 29]. All changes will be presented at a steering Board (weekly meeting) Members of the steering board are also from R&A. In this steering board it will be decided whether the changes are singificant. Quality assurance (also part of the steering board and change process handling) is responsible that the regulatory decision will be taken. This is defined in DWAG IN4230. A checklist for decisoon is available DWAG PQ2110 regulatory approval to market product.  Market Clearance MC Form Japan, 20.01.2023 ATLAN X, 2.0  Brazil:  If the medical device evaluated is already registered/notified with ANVISA, verify that the design change was correctly and promptly submitted to ANVISA for approval, when applicable [Brazilian Law 6360/76 - Art. 13].  All changes will be presented at a steering Board (weekly meeting) Members of the steering board are also from R&A. In this steering board it will be decided whether the changes are singificant. Quality assurance (also part of the steering board and change process handling) is responsible that the regulatory decision will be taken. This is defined in DWAG IN4230. A checklist for decisoon is available DWAG PQ2110 regulatory approval to market product.  It is not planned to get the market approval for the audited change sample for Brazil.  DD14 - Design review (GM)  Design review for Design changes is described in the procedure DWAG IN4230 and implemented in the design and development plan of the selected project.  The Review steps are individually defined in PKG-2021-003936.  After completion of specific design phases a design review is performed and approved by defined personnel (including add. independent and competent members).  Participants in the reviews of the selected project include representatives of functions concerned with the design and development stage being reviewed, as well as any specialist personnel needed. These were in the selected case |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 36 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | :System Designer and Leader of Verification approve Verification Review, Change Review will be approved by Project Leader, Quality asssurance and Regulatory Affairs.  USA:  Verify that procedures ensure that participants include representatives of all functions concernedwith the design stage being reviewed and an individual(s) who does not have direct responsibility for the design stage being reviewed, as well as any specialists needed [21 CFR 820.30(e)].  The competences and roles reviewers are defined in DWAG IN4230 and DWAG IN4200.  Two samples of Design review have been audited (Verification and Design Change review).  DD15 - Impact review of design and development changes on previously made and distributed devices (GM) Assessment of Design Changes is defined in DWAG IN4230  Design changes are reviewed for effects on products already delivered. This will be doumented and approved in PKG-2021-003936, Pretailoring investigation. This document ave been audited for ATLAN 2.0.  Impact review of design and development changes on previously made and distributed devices.  See PTI PKG-2021-001689 Section assessments  DD16 - Design transfer (GM)  The design change ATLAN 2.0 was correctly transferred into production.  Design change transfer is defiend in DEMF GM2110 and includes checks for availability of all needed material. The check will be documented in OA.  Brazil:  Confirm that the manufacture ensures that the design is not released for production until its approval by the persons assigned by the manufacturer and that the persons assigned review all records required to the design history file in order to ensure it is complete and the final design is compatible with the approved plans, prior to its release. Confirm that this release, including date and manual or electronic signature of the responsible is documented [RDC ANVISA 16/2013: 4.1.9, 4.1.11].  Approval of OA (change transfer) will be performed by Quality assurance.  The OA includes the check of all needed deliverables . The OA ATLAN 2.0 have been audited. Triggered by the Change package and specifically for SW changes amog others e.g. the IFU have been adjustsed.  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  Tasks from MGa  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  D&D #1 (MGa)  Process Description:  [ISO 13485:2016: 4.1.1, 4.2.1, 7.1, 7.3]  Devices that are, by regulation, subject to design and development procedures are identified. Main process is DCS IN4200 that regulates the development of new devices. All design changes are following SOP Design Change Process.  Gate 1 and 2 of main process are research phases, e.g. marked investigation, which is optional. Technical documentation in terms of Medical Device History is conducted, at each gate appropriate reports are provided. The fulfillment of the GSPRs are planned and considered.  For the development of Humidstar 2+LL the design and development phase started in gate 3.0. Technology and market are already known.  Start with  Gate 3.0 Preparation: Design and development will be specified; the product requirements finalized,  Gate 4.0 Definition: e.g. technical system requirements, Usability, plan validation; finalized with System requirement review (SRR)  Gate 4.1 Design: Detail Q Targets based on SA (system architecture) freeze of requirements.  Gate 5.0 Realization: system integration review, implementation of design; VRR Verification readiness Review, Finalize Design Transfer  Gate 6.0 Validation: System validation review, official end of development  Gate 7.0 CE marking: Ramp-up / Market Launch: monitoring, in a narrow scheme  Gate 7.1 Serial Production: final production site/ one line and one tool for the device Humidstar 2+LL  Gate 8.0 Life Cycle/Change: targets in quality, financial, on market  The process for Humidstar 2+LL had been defined as a new development:  The Humidstar 2+LL had been designed as new product development.  The Humidstar 2+LL is classified as class IIa product under MDR,  The filter and HMES are currently registered in the following MDSAP countries:  - Australia  - Brasilia  - Canada  The regulatory department confirms that the Humidstar 2+LL are not registered in Japan and USA.  The procedure defines criteria, as applicable for  • new product development  • module development  • Upgrades and product change  • Introduction of OEM or private label  • Introduction of Trading goods  • Transfer of development, production or other disciplines  Changes are managed according to Design Change Process  According to DWAG IN 4230 Design Changes, design change request (DCR) can be issued by anyone. Project Manager with team of QM and R&D the request will be assessed.  Change process flow will be individually decided depending on the request. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 37 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | Australia:  The technical documentation will be issued in parallel to the development phase, end with the successful CE marking.  Brazil/ Canada/ Japan:  In general a List of applicable standards, depending on which countries included in product requirements, is available.  Key process documents reviewed:  DWG In4200en 01.00 Design, 2021-10-01  Process describes the Stage gate approach:  Gate 3.0-8.0  DWAG IN 4230 Design Changes, en, 05.00, 2023-06-30  \*\*\*\*\*  Specific Personnel Competency and Training  ISO 13485: 6.2  Roles profiles are defined for each role. The roles are implemented in the electronic training tool, the appropriate training are linked to the required competence trainings matrix. Training needs are identified.  Training can be conducted external, classroom training or self-training.  The training pensums are monitored annually.  Documents:  DEALL HR3400 Employee Qualification Process, 2021-10-15  Records:  TC Manager Records (Qualification Matrix) for  M.H.: Screenshot Training tool “TC Manager”: personalized:  Roles: Betriebsmittelbeauftragter; Leader Verification; Verification engineer is finalized Planned training: Project Management trainer planned 2023-11-09  S.B.: Roles: Lifecycle manager, Medical Device Acts, ( Training completed)  L.L: RA: Special and General Work instruction  Training on ISO 13485; MDR, MDSAP-all completed.  \*\*\*\*\*\*\*\*  D&D #2 (MGa)  ISO 13485:2016: 4.1.1, 4.2.1, 7.1, 7.3.]  Design and Development Project “Air Force One” (AFO) had been in scope of the audit, especially for Humidstar 2+LL, as this device is regarded as a new development. The device is dedicated for neonates.  The UDI system had been used and a Basic UDI is dedicated to the device.  The device under review is the HME (heat and moister exchanger): Humidstar 2+LL  The HME parts are supplied by supplier from Sweden ULAX.  The HME consist of the two parts of the case (top and bottom) and the medium “foam”, which is impregnated. The example had been selected due to transfer of production.  The device was not in scope of an audit and it is listed on MEDF0325.01, Rev. 11 and is certified under MDR certificate G10 010578 0039 Rev. 09 as R0401 - VENTILATION FILTERS: HME HumidStar 2 Plus Luer-Lock - MP05840 0404867512080436K19T010SC R0401 MDN 1201  D&D #3 (MGa)  ISO 13485:2016: 4.2.1, 7.1, 7.3.2  Process Description:  The process DWG In4200en 01.00 Design, 2021-10-01 requires 5 design reviews at the end of the gate phases 3.0-8.0.  For the project of HME  SRR: System requirement reviews  SAR: System Architecture (not applicable for the HME project ) SIR: System integration review (not applicable for the HME project) VRR: Validation requirement review  SVR: System validation review  Description of requirements:  Process steps and reference to tools are listed in attachment A02, including rolls of participants.  Templates for reviews are implemented-  Australia:  Effective planning for the design and development steps are documented, as verified in task DD-1.  Canada:  As the device under review is not a class IV device this had not been reviewed in particular. However, the process outlines the specific quality practices, resources and sequence activities relevant to the device.  Key process documents reviewed:  DWG In4200en 01.00 Design, 2021-10-01  D&D #4 (MGa)  ISO 13485:2016: 4.2.1, 7.3.1,  Process Description:  The sampled project meets the requested requirements. All sampled product designs follow the global DMS IN4200 development process. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 38 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | List of applicable standard for the HME device are listed within the PTS. “Production and test specification for medical breathing filters and HME” US:  A process is in place to identify the applicable requirements.  D&D #5 (MGa)  ISO 13485:2016: 4.2.1, 5.2, 7.2.1, 7.3.3;  Process Description:  Design Inputs are for example user needs, customer functional, performance and safety requirements, intended use and regulatory requirements. For each project there is an applicable list of standards documented which needs to be applied within the development phase. Regulatory, functional and safety requirements as well as intend use are subject to SOP and are also addressed in the design change by tailoring of the development process. Requirements are checked for conflicts in the system requirements review report. Risk management outputs serve as design input.  For US:   No 510k is applicable for the selected device  D&D #6 (MGa)  ISO 13485:2016: 7.3.3  Process Description:  The Design Inputs are unambiguous and do not conflict with each other. Requirements are checked for conflicts in the system requirements review report. All requirements are checked and approved within the SAR.  For Humidstar 2+LL project no Management commitment and Kick off meeting was not requested as the product portfolio AFO was already approved. For the development process of Humidstar 2+LL as part of the portfolio the gates 1 & 2 had been skipped.  The list of deliverables (required records) had to be fulfilled.  Australia:  Relevant Medical Device Standards are considered and in scope of the development process for Humidstar 2+ LL  D&D #7 (MGa)  ISO 13485:2016: 4.2.1,4.2.3, 7.3.4  Process Description:  Design and development outputs (e.g. device specifications) are traceable to the design and development inputs.  Specifications are also traceable to the verifications. Traceability description for the change project reviewed.  For the Medical Device File a documentation matrix is available which shows the locations of the applicable specification, bill of material, applicable tests.  DEALL PQ3130 Control of Documents and Records, Rev.4, 2023-07-06: A 02, 2023-09-12: Dokumentationsmatrix: Device master record (DMR): Parts of DMR predefined for design transfer.  Partial specification, and other specification are listed.  The cross functional team decided supplier ULAX, Motala Sweden, producer of the HME foam.  D&D #8 (MGa)  ISO 13485:2016: 4.2.1, 7.1, 7.3.3, 7.3.4;  Process Description:  General the risk management is applied,.  A complete Risk Management process according to ISO 14971 is implemented and is part of the design and development. Risk acceptance criteria are defined. Risk management has been adapted for change and is up-to-date. The risk management includes the identification of risks, its assessment and the definition of measures to counteract those risks.  Companywide risks are assessed; Severity and Probability are defined, and measurable with results in defined classes “frequent, occasional, low, impossible”.  US: Identified risks are reduced as far as possible, reduction of risks are dedicated to a new assessment to avoid implementation of new hazards.  D&D #9 (MGa)  ISO 13485:2016: 7.1, 7.3.6, 7.3.7;  Process Description:  In the design and development verification/validation the effectiveness of the risk control measures are verified. Verification testing is a central part of the design process and is typically conducted in an independent design verification department. These activities include testing against international standards.  D&D #10 (MGa)  ISO 13485:2016: 4.2.1, 7.3.7;  Process Description:  The development validation phase shows that the design meets the intended use.  Australia:  environmental conditions are considered and described within the IFU, e.g. temperature, re. humidity and ambient pressure, see DD-1 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 39 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | D&D #11 (MGa)  ISO 13485:2016: 4.2.1, 7.3.7;  Process Description:  The clinical evaluation is part of the technical documentation.  The process IN 4250 is outlined in BIC process management system:  1. Step: new or existing product change-for new  2. Clinical development plan necessary, including initial literature review, clinical study necessary  3. Pre clinical investigation necessary  Design change:  Via DC request=> significant change, nonsignificant changes results in an Amendment => assessment results in new clinical evaluation  Literature search report: separate as output document of clinical evaluation  • CEP  • CDP  • PSURs  • PMCF plan=>activities=> evaluation report  • SSCP necessary=> not available at Dräger  D&D #12 - n/A (MGa)  D&D #13 (MGa)  Process Description:  The Design and Development Change is described in DMS IN 4230 Design Change Process. The reviewed project “Air Force One” was conducted as a new product development.  General description of Design changes:  DCR design change request will be submitted  Each employee can submit this, at the Review a decision will be made if the project will be started or not DCR (design change request) will be proceeded with Pro X, plug in of SAP deliverables,  Object changes, e.g. drawings, specs,  Change specific review, market approvals  Market authorization will be handled by RA  Change accepted and implementation  Key process documents reviewed:  DMS IN 4230 Design Change Process  D&D #14 (MGa)  ISO 13485:2016: 4.2.1, 7.3.2, 7.3.5;  Process Description:  After completion of specific design phases a design review of defined personnel (independent) has been performed. A formal design review needs be conducted and documented before closure of a specific Design Phase.  US:  Applicable representatives are involved in the development process and approval process.  For further description, please see also task DD-3  D&D 15 (MGa)  ISO 13485:2016: 7.3.9;  Process Description:  The Design and Development Change is described in DMS IN 4230 Design Change Process. The reviewed project “Humidstar 2+LL” was conducted as a new product development.  D&D #16 (MGa)  ISO 13485:2016: 4.2.1, 4.2.3, 7.3.8  Process Description:  At the end of design and development the design has been transferred to the production site at ULAX, contracted supplier.  Approved part specification are mandatory an OA (Object Approval) can be issued.  OA difference between new products, changes, prototype or logistical changes. Responsibility matrix is given. OA is implemented in OX -change tool in SAP.  All relevant activities have to be finalized before OA started.  Review by D&D: complete and correct  Australia:  The release, includes date and signature of the responsible (manual or electronic )is documented MRP Material resource planning: all data in SAP  Buy workflow has to be finalized before outsourced manufacturing starts  Part  FAI required=> quality confirms FAI is ok  Label data: release of label department  Confirm end of OA: released by R&D, RA & Quality  D&D 17 (MGa) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 40 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | ISO 13485:2016: 4.1.3, 5.1, 5.5.1  Process Description:  Based on the assessment of the development process the management provides the necessary commitment to the design and development process. Management provides commitment, independent reviews are required by process. A compliance procedure does exist.  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  MDR  Clinical Evaluation Report Babyleo TN500 SW1.05 -2020-01-08  PMCF Plan Babyleo TN500 2022-07-25  Clinical evaluation and performance evaluation in line with the state of the art (PSUR Thermoregulation 2023-08-01)  MDR  Software development process takes into account the principles of development life cycle, risk management, including information security, verification and validation.  EU MDD / MDR  MDD Annex II 3.2, 3rd paragraph (c), 9th indent  MDR 2017/745 - Article 10(3), 61 and Annex XIV  Completion of clinical evaluation / performance evaluation including PMCF / PMPF  Clinical evaluation report was demonstrated: 11149213\_02 11149213 02 Clinical Evaluation Report Released  MDR 2017/745 - Article 10(3), 61.9  Clinical evaluation for products under Annex XVI. – n/a  MDR 2017/745 - Article 10(3), 62 and Annex XIV  Clinical evaluation and performance evaluation in line with the state of the art (PSUR)  PSUR is established and documented, according to PSUR, the PMCF is limited to the PMS process only.  11143145 PSUR Smart Pilot View Ver 01 2022-10-12  MDR 2017/745 - Article 32 – Class III and implantable medical devices  Summary of safety and clinical performance (SSCP) – N/A, the are no class III devices manufactured.  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  Clinical evaluation and/or evaluation of medical device safety and performance (GP)  FOLLOW UP of point 7 to project 1990804: CC 300 - Response DR2 Dräger  The action item was reviewed during the audit. The CEP Template, CEP and CER including CV of CC 300 device were reviewed.  The statement checked and accepted by TDA in the deficiency report (Order No 713298423) has been included in new CE Procedure IN 4250 , CEP template, CEP of CC 300 and updated CER of CC 300 device. The qualifications of evaluators are documented in section 9, qualifications are documented according to the MEDDEV 2.7/1 revision 4.  Records:  DWAG IN 4250 Clinical Evaluation -en-04.00 dd 26.06.2023 DWAG IN 4250 en. 04.00 CEP Template  CEP DWAG IN 4250 en. 04.00 Connectivity Converter CC 300 CEP -CC 300 ID 11224385 revision 01 released 2023- 09-13 CER-CC300 ID 11224384 revision 01 signed 2023-09-15. |
| Reviewed  documents  and records (identification and revision) | GP  DWAG IN 4250 Clinical Evaluation -en-04.00 dd 26.06.2023 DWAG IN 4250 en. 04.00 CEP Template  CEP DWAG IN 4250 en. 04.00 Connectivity Converter CC 300 CEP -CC 300 ID 11224385 revision 01 released 2023- 09-13 CER-CC300 ID 11224384 revision 01 signed 2023-09-15.  \*\*\*\*\*\*\*GP  DWAG IN4000: Develop Product, Rev. 14.00  DWAG IN 4200-en01.00 Design  DWAG IN4202 Usability Evaluation  DWAG IN4203 Product Verification  DWAG IN4204 Design Related Product Reviews Rev 02.00  DWAG IN4100: Project Management\_en\_02.00  DWAG IN4300: New Product Introduction, Rev. 09.00  Classification Codes SmartPilot View 11213764\_00  IfU\_SPV\_SW\_3.03.n\_9512901\_1\_2022-11\_en Instruction for Use Smart Pilot view |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 41 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | IfU\_Supplement\_SPV\_SW\_3.0n\_9054332\_11\_2022-12 Compatibility with other devices Smart Pilot View  DWAG IN4250 Clinical Evaluation Rev.04.00  DWAG IN4251 Clinical Evaluation (MDD) Rev 00  111494913 Smart Pilot View Standalone Validation Plan Ver 01  11149213\_02 11149213 02 Clinical Evaluation Report Released  11143145 PSUR Smart Pilot View Ver 01 2022-10-12  4.1 GSPR -11233802\_00 Smart Pilot View  DDWAG IN4205-en 02.00 Software design  DWAG IN4206 Software Approval and Design Transfer Ver 02.00  11149414 Rev 00 Validation Summary report V00 2023-02-24  Product Risk Management Report - 11149328\_03  Product Risk Assessment Table - 11221004\_03  Validation Summary Report - 11149414\_00 2  6.2 SPV\_IEC62304 - 11244067\_00 INSPECTION REPORT IEC 62304 6.2 SPV\_IEC62366\_1 - 11245524\_00 TEST REPORT IEC 62366-1:2015 6.2 SPV\_IEC82304 - 11244450\_00 Test Report IEC 82304-1:2016  UUser manual Ver 2.02  DR-00072766 Product requirements Smart pilot base Line 2022-11-24T  DCR-2019-002082 labeling amassing - change of the labels size – SW only DCR-2021-002127 ISM-IEC TR60601-4-5  DCR-20201 003730 - approval of the Zeus IE  11134555 Design change review report - for the release 3.02n PKF-202-003043 DCR-2020-002999 IFU Translation for Slovakia 2020-06-02  Validation Form PID Printing process 2020-12-17  PTI PKG-2021-002776 from 23.05.2022  11149233 List of Non-conformities Ver 05 Smart Pilot View SW 3.03  11149420 verification summary report Rev 08 Smart Pilot View  11149411 Usability summary report Rev 00  11149378 Smart Pilot Usability Summative Test Rev 01  111494 Rev 01 usability Specification Smart Pilot View  11149378 Rev 01 Summative Usability Evaluation test report Ver 01  11143145 PSUR Ver 01 2022-10-12  DWAG IN4230 : Design Changes DWAG IN4230‐en‐05.00 , Rev. 05.00 , reviews defined, and OA (design transfer) „start creation and change material MASTER data”, responsibilities defined.  DWAG IN4200 : Design DWAG IN4200‐en‐01.00 , Rev. 01.00  DEMF GM2110 : Creation and Change of Material Master Data for Global Portfolio DEMF‐GM2110‐en‐01.00 , Rev.  01.00  DWAG IN4250 : Clinical Evaluation DWAG IN4250‐en‐04.00 , Rev. 04.00  DEMF PQ2000 : Post Market Surveillance System DEMF PQ2000‐en‐02.00 , Rev. 02.00 DWAG IN4230 : Design Changes DWAG IN4230‐en‐05.00 , Rev. 05.00  DWAG IN4200 : Design DWAG IN4200‐en‐01.00 , Rev. 01.00  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐03.00 , Rev. 03.00  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐03.00 , Rev. 03.00  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*  Records  DD11 (MSz)  Clinical Evaluation Report Babyleo TN500 SW1.05 -2020-01-08 Review of Post Production Information Report (Clinical) 2022-05-19 PMCF Plan Babyleo TN500 2022-07-25  PMCF Report not yet available  PSUR Thermoregulation 2023-08-01  DD12 (MSz)  Softwareänderung SW1.06 PKG2020-003896  Change Specific Design Review Report TN500 SW1.06  Product Risk Management report RM 37, T500\_HA 1.42  DD13 (MSZ)  PKG-2021-001689 Q-Improvement Nozzle Opening  PTI Pre-Tailoring Investigation PKG-2021-001689 closed 2022-01-24  Approval Design Change Package 2022-05-06  CSDRR Change Specific Design Review Report for PKG-2021-001689 2022-05-03 Design Change Summary Final PDF PKG-2021-001689\_PKG Export\_2022-05-06\_MT3.pdf DCR-2020-001820 “Vergrößßerung des Nozzles zur Wasserdampfauslassöffnung“  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*(HD)  DWAG IN 4250 Clinical Evaluation -en-04.00 dd 26.06.2023 DWAG IN 4250 en. 04.00 CEP Template  CEP DWAG IN 4250 en. 04.00 Connectivity Converter CC 300 CEP -CC 300 ID 11224385 revision 01 released 2023- 09-13 CER-CC300 ID 11224384 revision 01 signed 2023-09-15. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 42 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | DDWAG4230-en-05.00 design changes  PQ 2010 Regulatory Affairs Zulassungprocess  MDR 108 – 030 1.1.6 Classification \_codes Carina & Oxylog Breathing Circuit  PQ 2010 Regulatory Affairs- Zulassungprocess  MDR 108 – 030 1.1.6 Classification \_codes Carina & Oxylog Breathing Circuit  DCR 2020-001379 dd. 31 05.2020 / PKG 2020 000943  PTI - PSB 242 created 11.003.2020  BioComp Report -ID 11228066 Carina and Qxylog BC PrM Report 29.11.2022. Inspection Report No 21 -00620 – PR 001 Rev 01.  DCR Approval record from SAP 18.02.2022 signed by PO/ QA  System Validation Review Report Breathing 30-11-2022 ID - 11 221639 IFU - 9511030 version edition 4  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* (GM)  DD13 (GM)  Design change Request DCR -2021-006006 (“Cyber Anteil ATLAN 2.0”), status changed in pro X from Z00 to Z06 (which serves as signature), accepted by Kirstner (Product Manager as required in process), date 14.01 2022, assessment of change evaluation and decision regarding significant change is documented in this document.  PKG-2021-003936, Pretailoring investigation, ATLAN SW upgrade (2.0) last update 14.01 2022, functional  enhancement : Cyber Sec, bug fixes, recruitment features, Improvement of GUI, Insp Exp rate , Auto on and others, Design review steps are defined. Influence assessment on products in the market, products and stocks not affected, Cyber updates state of the art( MDR only for ATLAN 2.0)   electronic signature on:  Design Change Package Export, 14.10.2022, signed by Project Leader and Quality assurance including Design Change plan ATLAN and Pretailoring investigation.  510 k FDA 2023, 07.23, K 230931, approved by James J. Lee S  Market Clearance MC Form Japan, 20.01.2023 ATLAN X, 2.0  Market Clearance MC Form AUST(New Zealand), 09.06.2023 ATLAN X, 2.0  11100333 PMS Axxx family, rev 0, approved 25.08.2023, yearly evaluation also ATLAN.  11249101 PSUR Axxx Familiy, rev 0, chapter 6.2, data from 2022, conclusion, benefit risk ratio not attached, approved 30.03.2023.  Risk assessment table has updated during 2022, Hazard analysis ATLAN 2.0 , 6.22 approved 05.01.2023, Cyber included, typos , some acceptance rationales adjusted.  DD14/15/16 (GM)  Verification Readiness Review Report ATLAN 2.0, approved by System Engineering and Verifiction Leader 12.05.2021.  11159497 Change specific design Review Report ATLAN 2.0, v 00, approved 12.07.2022 by Project Leader, Quality assurance An R&A responsible person.  Design transfer OA specific Object List 2022-MT-1426, approved 16.06.2022.  PKG-2021-003936, Pretailoring investigation, ATLAN SW upgrade (2.0) last update 14.01 2022, functional  enhancement : Cyber Sec., bug fixes, recruitment features, Improvement of GUI, Insp Exp rate , Auto on and others, Design review steps are defined. Influence assessment on products in the market, products and stocks not affected, Cyber updates state of the art( MDR only for ATLAN 2.0)   electronic signature on:  Design Change Package Export, 14.10.2022, signed by Project Leader and Quality assurance including Design Change plan ATLAN and Pretailoring investigation.  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*MGa  TC Manager Records (Qualification Matrix) for  M.H.: Screenshot Training tool “TC Manager”: personalized:  Roles: Betriebsmittelbeauftragter; Leader Verification; Verification engineer is finalized Planned training: Project Management trainer planned 2023-11-09  S.B.: Roles: Lifecycle manager, Medical Device Acts, ( Training completed)  L.L: RA: Special and General Work instruction  Training on ISO 13485; MDR, MDSAP-all completed.  Regulatory approval plan Air Force One, Rev.03 , 2021-11-30 Simon Barz: product management In planning: Humidstar 2+LL with rev.03; approved function:  Part no for Humidstar 2+LL: MP05840, in chapter 1.5.2: planned to be marketed.  • Europe CE  • USA  • Canada  • Japan  • Brazil  Not planned for Australia  MDR: G10 010578 0039 Rev. 07, valid until 2025-03-17, MDR 2017/745 Annex IX, class IIa, Humidstar 2+LL is currently marketed only in CE area  Australia: -  Brasilia: HME Humidstar 2+LL New medical device registration incl Inmetro Cert. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 43 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | Canada: new class II medica device license  USA: HME class I, 510 (k) exempted,  Japan: Approval procedure acc. to MHLW Pharmaceutical Affairs Law.  List of regulatory requirements, Rev. 5: 2021-10-16: up date of Humidstar 2+LL Colour coded for standard: orange for product requirements  Requirements for all defined countries: AUS/ JAP/ CAN/ BRA  Version change of standards will be implemented via design change control  Design and Development plan 101039\_12:  Roles are defined  Change control: when changes will be identified during the project.  TSR Technical system requirements V18, 2022-10-13,  Environmental requirements. Ergonomic aspects, biocompatibility, anesthetic agents, ISO 18562, usability time 30days, Condensate contact (indirect contact to patient, not sterilized,  Technical mechanical: requirements: conical shape for both cylinders, luer lock requirement are considered  risk management  Functional requirements: EN ISO 9360-1:2009  Shelf life requirements: 5 years  Regulatory requirements: list of standards  Production requirements: RCM (risk control measure): requirements of risk management: free of visible particle >100µm/ leakage  Transport/shipping/ Packaging requirements  Label requirements: inner outer/ IFU: not electronic  DWG In4200en 01.00 Design, 2021-10-01  AFO System requirement reviews report, Rev.08, 2021-11-30  Applicable documents: as described above in DD-1  Checklist are approved:  System Design,  Risk manager  Verification leader  DDesign and development Plan, ARAs doc no. 1010139, will be up dated constantly.  In development phase: Humid 2 plus Luer lock  Released by qualification department Mr Schimpf and production: Mathias Ahrens  Design input: economical & sustainable reasons: the production of filter and HME will be implemented at the qualified supplier ULAX. This supplier is already manufacturing Humidstar 2+.  Purpose and scope:  Inhouse and external produced filter at Ulax  List of applicable docs:  Project Medical filter Inhouse Document Status report ARAs:  Including Requirements of  - Incl. Clinical evaluation  - Chemical analysis  - Mechanical drawings  - Design and development plan  - Usability  - List of regulatory requirements: applicable standards, Filter Pus, requirements input; 101067, 2021-02-16, rev. 4  E.g. ISO 18562-q:2017  IOS 5356-1  ISO 80368  ISO 9360-2  ISO 13328-1  - PSUR  - List of non conformities  - Validation report  Materials of device:  Drawing: 11066204, rev.02 released 2022-10-14 for Humidstar 2+LL, 2 parts: Part Specification, rev. 03: Humidstar 2+LL MP05840 (included in design transfer): foam MP12054,  plastic part 05843 (housing)  Supplier decision: part of purchasing process:  Medical Filter AirForce ONE Supplier Descison report Gate 6, 2022-10-27  Risk management DWAG IN 4210  Risk management: Please see DD-8  Kick off meeting: Gate 3.0 review report Medical filter inhouse, reversion 1.0; 2016-04-14, signed 2016-04-22, Including management decision: resources, budget  Humidstar 2+LL: screenshot of document management system: justification for start at gate 3: Product is added via scope change to an existing project. Deliverables will be up dated but no Gate Reviews will performed only for this project. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 44 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | Despite this the development route is considered as a new development and all applicable steps had been conducted. -List of regulatory requirements: applicable standards, Filter Pus, requirements input:  E.g.  ISO 18562-1:2017  IOS 5356-1  ISO 80368  ISO 9360-2  ISO 13328-1  ISO 10993  Drawing: 11066204, rev.02 released 2022-10-14 for Humidstar 2+LL, 2 parts: Part Specification, rev. 03: Humidstar 2+LL MP05840 (included in design transfer): foam MP12054,  plastic part 05843 (housing)  Supplier decision: part of purchasing process:  Medical Filter AirForce ONE Supplier Descison report Gate 6, 2022-10-27  Risk management DWAG IN 4210, Rev. 03.0, 2023-04-16  \_A06: Risk Policy and Acceptance Criteria, rev. 03.00:  Risk management plan and team are defined.  Annex A17 defines the Risk management team: e.g. Product manager, project manager, production expert, Product Quality Manager Clinical engineer  Identify hazard, situation, assess and control the risks, is assessed at each gate of D&D, in frame of market monitoring, etc.  After gate 8=> transfer to lifecycle management. Risk management is also implemented within the post production review. Depending on product class the PPR will be performed annual or biannual. For Humidstar 2+LL it will be performed biannual.  Post market surveillance plan  Periodic Safety Update Report,PSUR, 2022-08-01  For HME, data evaluated form 04/2020-03/2022, including incidents, trends, scientific search, etc. General conclusion: risk management update not necessary.  Risk management plan, AirForce ONE Products, Rev.00, 2022-03-10  Archive Design History file  RM team: Independent reviewer, clinical expert, Risk manager, CFTM Product Manager, CFTM System engineer, usability expert  Risk Assessment table (Hazard analysis for HME), 2022-03-16 Contents is predefined:  probability is defined with the defined words.  Mechanical damage: HME\_RM\_575 unambiguous numbering of risks: product shall withstand droptest  Considerable: HME\_RM\_1456 Hazard situation due to ignition: IFU shall contain a warning (protective measures are not possible, reason is named  Traceability from risk analysis is given to the TSR technical system requirement. TSR technical system requirement  Humidstar 2+LL specific risk: HME\_RM\_421 evaluation of lung gases: IFU shall contain a warning, that device shall be used uncuffed\_ residual risk: considerable: benefit risk ratio.  3.1.18 Risk related to manufacturing process  HME\_RM\_1135 wrong parts used/ incorrectly supplied goods=> incoming inspection Foam manufacturing: Recticell, Belgium  RMR:  Air Force One Products Product Risk Management Report, Rev11, 2022-03-23: at the stage of development Clinical benefit: They are universally used of conditioning and filtering of respiratory gases within the limits of the respective devices”  Benefit risk Analysis  Traceability between verification results and risk controls is provided by TMTA  New hazardous situations are included in the risk assessment table  Overall residual risk  The clinical benefit outweigh the residual risk. Monitoring during life time is assured.  TMTA: Traceability Matrix Traceability Analysis), 2023-07-18, linkage of requirements  TSR: F-HME\_TSR\_787: IFU : used only with uncuffed tubes=> input in the IFU checklist  IFU Checklist: Test report of requirement 787: AFO Checklist reports, Rev.1 , example: test AFO Checklist IFU Humidstar Plus, including Humidstar 2+LL. Beneath others:F-HME\_TSR\_787: requirements is passed and accepted. IFU: 9055971, edition 9, 2023-03 HME Humidstar 2+ including Humidstar 2+LL: warning is included.  Risk management report will be assessed after each gate. Finally, a risk management process review will be performed by an independent reviewer:  AFO RM Process review report, Rev.04, 2023-07-19: |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 45 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | RMP had been implemented, all risk considered, control measures evaluated-whether they introduced new hazards or situation, risk are traceable, deficiencies had been reviewed  System Validation review report, Rev.00. 2023-08-24  To determine if conducted validation and verification measures were appropriate to demonstrate fulfills the defined requirements, intended use and TSR.  Review items all V&V activities fulfilled, no deviation of the checklist=> accepted  For the device under review: Australia is not chosen for marketing, if Australia will be chosen, RA will initiate a change request.  DWAG IN 4250 clinical evalution, rev.04, 2023-06-26  CEP:  AirForce ONE Products Clinical Evaluation Plan, Rev.02, 2021-04-22 Filter are considered accessories for medical devices: input documents.  MDN 1201  Basic UDI: Humidstar 2+LL and Humidstar 2+ identical, but different to the other HMEs  Intended use: Heat and moisture exchanger for humidifying respired gases for the patient. (Intended purpose and intended use are considered the same as per MDCG 2022-6.)  Patient population: for neonates, with volume of 10-15ml  User group: clinical user  Claim: per webside : no claim about gas analyses  Standards listed.  Stages according to MEDDEV 2.7.1 rev4, & MDR  Internal and external resources are defined, e.g. Prof. Dr Michael Imhof  Clinical performance due to technical specification, literature search required and will be substantiated SOTA.  GSPR: defined GSPRs are listed in the new template: DWAG IN 4250 CEP , chapter  CER:  AirForce ONE Products Clinical Evaluation Report, Rev.02, 2021-07-29  Class IIa, rule 2,  STED fie is input for CER  Analysis: clear clinical benefit form the use of HME  Conclusion: including conclusion from risk management: clinical benefit outweigh overall residual risks PMS process is in place and will be used.  Next clinical evaluation is planned no later than 31st of May 2024  DMS IN 4230 Design Change Process  Not applicable, as reviewed as project was no change project  Currently Humidstar 2+LL is marketed only in EU.  DCS GM2110 Creation and Change of Material Master Data for Global Portfolio, Version 1.00, 2018-07-31  Initial transfer of Humidstar 2  Screenshot of SAP:  PRO X Oberfläche:  PT OA:  PKG-2020-000145 MP05840 HME 2 Plus mit LuerLock  Pre tailoring: Luerlock höhe 8.3, in drawing 8.4mm= change of drawing (in stage of Prototype process)  Change Package: PKG-2022-003894 Update MP05840 HME 2 Plus mit LuerLock drawing. MP05840= linked with ARAs (program for control of drawing)  Data transfer per Mail or via SAP export  Humidstar 2+LL launched in August 2023: batch record for tomorrow |
| Names and titles of  persons  interviewed | Marcel Clute Simen  Carolin Nonberg (R&A Country Expert)  Ann Katrin Hilmer (BA Manager Anästhesie/scribe)  Malte Zeuner ( Test-Manager)  Sebastian Gerlich (Risk Manager ATLAN 2.0)  Annalena Brückmann (Testlabor Biocomp)  Thomas Schoop (Product Owner BabyLeo)  Delia Rähder (Quality Assurance (RC, T))  Ulf Hagedorn (Head of Integrated Management Systems Audit Management) Angela Schober (Clinical Affairs Manager);  Tobias Scotti (scribe) (Product Quality Manager - BU Therapy)  Schoop (Product Owner Babyleo)  Holger Wagner, Head of RA, business unit HCA  Sebastian Henning, Product Manager , Filter  Dr Janis Vogt, clinical affairs  Jan Utmeyer, Skript  Luise Lanng, RA, Manager portfolio HCA |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 46 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Design and Development** |
|  | Alexandra Kreimeyer, Product manager ; Research and development Business Unit HCA Medical Devision Max Hünnert, Leaderverification HCA  Dr Stefan Schimpf, Head of Product Qualification; Research and development Business Unit HCA Medical Devision, Qualification |
| Products,  components, or projects  reviewed | HME filters - Humidstar 2+LL  Project ATLAN 2.0  Biocomp ISO 18562  Babyleo TN500  Smart Pilot View |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | This process is effectively implemented and conforms with requirements |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 47 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.6 | Design and Development (non-medical Software ISO9001 only) |

|  |  |
| --- | --- |
| Subsystem | **Design and Development**  **(Non-Medici Device SW , ISO 9001 only)** |
| Audit trail  records of | G. Pavlov |
| Area(s) visited (location, e.g., site visited) | Location # 1 HQ: Moislinger Allee  For more details related to Audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | Only ISO 9001:2015 – Cl 8.3 |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | Selection of the product / project for assessment  SW package *Connect Lung Protective Ventilation Analytics – Anesthesia (LPVA)* was selected for this audit in line with an audit sampling plan.  Additional action items for the audit was to confirm that this SW can be considered as non-medical device  Evaluation if the sampled Software is a non-medical device  Marketing presentation Connected – Lung protective Ventilation Analytics Hospital-data-analytics was demonstrated and assessed during the audit: The software offers following functionality:  - Shows Ventilation Quality indicators to improve the team ventilation performance  - Analysis of parameters, ventilation modes and recruitment maneuvers  - Enables a consistent implementation of lung protective ventilation practices  - Provides benchmarking of Ventilation performance against pre-defined goals  The function of demo Software was demonstrated.  The data are collected once a day from each connected anesthesia devices, the connection assured via additional Infrastructure software Drager Gateway, which assures the connectivity of Drager devices and Darger SW application devices  The data are requested retrospectively from the use case perfume ate pervisu period  Ventilation parameters: which are demonstrated are following: VT / IBW, ml / kg  PEEP - pressure  The results are indicating with red / amber / green indication for the visuals demonstration of not-recommended / possible and recommended parameters areas, while the outcome from the date transfer show the actual statistical evaluation of the past uses of the anesthesia device.  The patient data are not transferred and not process by the software.  The SW cannot control or impact medical device. The data are collected after the Anastasia session (the Anesthesia medical device shall be in standby after completion of clinical procedure) and therefore does not deliver information which can be and input to immediate use for the handling of the individual patient.  Therefore , the auditor concluded that the abovementioned Software is not a Standalone Medical device software and not software with is integrated in Medical device Hardware.  Design and development process  The Software is developed under ISO9001:2015 requirements, according the Software Design Process.  Draeger has established the process for Design and develpment  The processes are defined and documented as set of procedures : DWAG IN 4200 is established ad applicable to medical and non-medical devices.  The stage -gate is process is defined with 8 stages, whereas first 3 stage-gates form pre-design concepts phase.  All design changes are following SOP Design Change Process.  Start with Gate 3.0 Preparation ==> 4.0 Definition ==> 4.1 Design ==> 5.0 Realization ==> 6.0 Validation ==> 7.0 CE / Ramp-up / Market Launch ==> 7.1 Serial Production ==> Gate 8.0 Life Cycle/Change  At the same time, the designated process DEMF IN6000 is documented design and development of non-medical software:  The process DEMF IN6000-en-00 Development of non-medical device software has been developed and laid from May 2023, however was not used during the design and development of LPV software. It also contains the requirements for the changes. The change to the new process is planned to be completed by may 20224  In the absence of documented process for non-medical device software, the process IN4200 for MD-Software was partly applied , however according to design and development plan – the  DWAG IN4200 : Develop Product was used only to make the plane, the plans however contained the statement that DWAG was only used for the panning stage.  8.3.2 Design and development planning  Design and development plan Rev 3.7 was demonstrated.  The roles and resources are defined - the product management teams is demonstrated.  The stages are defined as  Issue – Iteration.  Product release approval |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 48 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | For each release, the stages include  - Planning  - Sprint development  - Release  - Deployment  8.3.3 Design and development inputs  S1000000063642212594 DDB External requirement 2022-08-11 Following defined as design inputs  External requirements:   |  |  | | --- | --- | | - - - - - | Functional and performance requirements  Normative requirement 9001:2015  Data protection security 2016 /679  Functional and performance requirements – the  The required verification and validation activities – validation in each sprint is performed as automatic test |   Backlog – as list of internal requirements  Note from the auditor: it was observed that the EN 82304 Health Software is potentially applicable and shall be regarded as mandatory design input. It was explained by Draeger that this standard family is considered in the new edition of the DEMF IN6000, started from V02, and will be applied after  implementation of the procedure.- accepted as QMS continuous improvement process  8.3.4 Design and development controls  According to new process, DEMF IN6000 A05 List of implemented Work Items Minimum Content Security requirements demonstrated – documented in DMC -107301 product security whitepaper The stages include  Creation of Source Code  Verification of Source Code and building Software  8.3.5 Design and development outputs  Building Release Candidate  - List of implemented Work Items  - Product approval  - Software Bill of Materials  - Approval of the released candidate - approval document was demonstrated  8.3.6 Design and development changes  No particular change process is defined, the changes are understood as repetition of the Sprint cycle |
| Reviewed  documents  and records (identification and revision) | Marketing presentation Connected – Lung protective Ventilation Analytics  Hosppital-data-analytuics-cp-DMC-107167-en master Aug 2023  LPV- A Rational for medical device is non-medical device product Ver 0 2023.090  DEMF IN6000 Development of non-medical SW products Ver 00 01.05.2023  DWAG IN4200 : Design Rev. 01.00  IN4200-en-01 design Ver 02  DMC 106527 Lung Protective Ventilation analytics Anesthesia Data Driven solutions Marketing Brochure Design and development plan Rev 3.7  S1000000063642212594 DDB External requirement 2022-08-11  DMC -107301 product security whitepaper  The device approval document 2023-04-26 |
| Names and titles of  persons  interviewed | Room: F05-E1-356  Connect LPV:  Fiorian Zichlin – QA/RA  René Carolus Product Owner CDA  Andreas Weng Head of Tech. & Dev. Global Services  Kevin Dornau   Director Quality & Regulatory Affairs Business Unit Therapy Markus Hielscher Quality System Manager Auditing  Mark Schenk Product Manager  Marcel Clute-Simon Head of Product Quality - BU Therapy  Leona Schneider (scribe) EHS Manager |
| Products,  components, or projects  reviewed | Connect Lung Protective Ventilation Analytics – Anesthesia (LPVA) |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | ☒ This process is effectively implemented and conforms to requirements.  ☐Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 49 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.7 | Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23) | |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
| Audit trail  records of | Gabriele Mousset |
| Area(s) visited (location, e.g., site visited) | Location # 10578 (Service Center)/ # 90464 (ATLAN Series B23)  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | ISO 13485:2016, 7.5  ISO 9001  MDR PRODUCTION AND  PROCESS CONTROLS Annex  IX.2.2d) & e), XI.6.2  **Specific Personnel Competency and Training**  **ISO 13485:** 6.2  **ISO 9001:** 7.2, 7.3, 7.5.1  **MDR:** Annex IX 2.1, 2.2 (a), Article 15, [MPDG §83]  **MDD:** Annex II (3.1, 3.2), Annex V (3.1, 3.2), Annex VI (3.1) |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | Planning of product realization (7.1)  PSC1 production planning (GM) 7.1; 7.5.1  ///Revalstr. – “Line 2 – ATLAN ”///  Production Revalstrasse Anästhesia consists of two pillars: ”Linie” and “components”.  Every ATLAN device will be produced after concrete order of customer have been placed. No stock production of finished devices.  Once a month a forecast meeting will be performed and ordering of material and planning of resources will be adjusted.  It is verified that the product realization processes are planned, including any necessary controls, controlled conditions, and risk management activities required for the product to meet the specified or intended uses, the statutory and regulatory requirements related to the product.  It could be confirmed that the planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.  *USA:*  *Confirm that the organization has determined the applicability of unique device identifier requirements per 21 CFR 801 and 21 CFR 830, has obtained the unique device identifiers from an FDA-accredited UDI-issuing agency, and the required data elements have been entered in the Global Unique Device Identification Database (GUDID) [21 CFR 801, 830].*  The organization applies UDI identifier which includes Serial number / Batch number to all devices.  PSC2 Selection of processes (GM) 7.5.1  One or more production processes were selected to audit:  ///Revalstr. – “Line 2 – ATLAN ”///  ATLAN Series have been audited according to audit planning.  Reason for the choice have been the change of ATLAN 300/350 from version 1 to version 2.  During auditing of “Management” and “Measurement Analysis and Improvement” no observation occurred to change the original plan.  Provision of resources (6.1), Infrastructure (6.3)  PSC5 infrastructure requirements (GM) 6.3  ///Revalstr. – “Line 2 – ATLAN ”///  Temperatur /Humidity /Air pressure controls are defined for test places in B23.At each test place sensors are active. The measures will be documented at each test protocol. Furthermore, ESD controls are in place: DEMF SC6700 : Handhabung elektrostatisch gefährdeter Bauteile (ESD)  Every person accessing B23 have to be ESD protected. This is clearly marked with colored lines at the entrance. A test station is located at the entrance of the production hall.  Brazil:  Verify that manufacturing facilities are configured in order to provide adequate means for people flow [RDC ANVISA 16/2013: 5.1.2]  Service facilities are configured in order to provide adequate means for people flow and enough space for correct development of the activities. The B23 hall have been audited. Modern building with comfortable space for flow of personnel as well as devices, components and working areas. Lay out plan have been audited as well.  PSC12 personnel competence (GM) 6.2  It have been verified with samples that personnel in service center and audited production area are competent to implement and maintain the processes in accordance with the requirements identified by the medical device organization.  ///Service Center - Moislinger Alee///  Roles working in Service center is mainly “ Service Mitarbeiter”  Furthermore, employees in service center are dedicated to device types and will be trained accordingly. Two employees in Service Center are technicians for ATLAN devices.  One sample have been audited.  ///Revalstr. – “Line 2 – ATLAN ”///  Audited Evidence:  Training Evidence Sample Jörg Bentin (Gerätemonteur),  Training Evidence Christian Alwert (Gerätemonteur) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 50 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
|  | Work environment and contamination control (6.4)  PSC4 Product cleanliness (GM) 7.5.2  Documented requirements for product cleanliness are established. Following aspects are copnsidered and defined in DEMF SC6330 : -Requirements for particle in the air (class 9)  -General Cleaning plans exists  -pestcontrol  It exists a “Reinigingsplan” for B23 with concrete advices for the external personnel. The cleaning execution will be documented from external company in a table. The cleaning results as well as the documentation will be checked and confirmed regularly by responsible leader of production.  Futhermore it is defined to control particles according to class 9 requirements. There are 35 measure points in B23 and a limit of 1 Mio parts is defined. The measurement will be evaluated every 3 month.  *Brazil:*  *Confirm that a pest control program has been established and where chemicals are used as part of the pest control program, the company must ensure that they do not affect product quality [RDC ANVISA 16/2013: 5.1.3.4].*  *Verify that themanufacturer has established andmaintains housekeeping procedures and schedules for production areas and warehouses, in conformance with production specifications [RDC ANVISA 16/2013: 5.1.3.1].*  Pest control in B 23 will be done on a monthly base from external supplier Bockholdt.  Last report have been audited.  PSC6 work environment conditions; training or supervision of personnel (GM) 6.4  ///Revalstr. – “Line 2 – ATLAN ”///  It exists a “Reinigingsplan” for B23 with concrete advice for the external personnel. The cleaning will be documented from external company in a table. The cleaning results as well as the documentation will be checked and confirmed regularly by responsible leader of production.  Futhermore it is defined to control particles according to class 9. There are 35 measure points and a limit of 1 Mio part is defined. The measurement will be done every 3 month.  *Brazil:*  *Verify that biosafety standards are used, when applicable [RDC ANVISA 16/2013: 5.1.3.6*  See description above no further requirements defined and needed  Control of production and service provision (7.5.1)  PSC7/PSC8 validation of processes (GM) 7.5.6  Generally all processes of ATLAN prodcution are listed and are validated at least partly. Revalidation will be done according to specific triggers which are defined in SOP e.g. move of production or process changes.  The validation of selected ATLAN processes has been done according to IN4300. When steps of validation or process steps haven´t been necessary to evaluate, a justification is given. In general IQ/OQ and PQ will be part of the validation process or a justfication is given for exclusion of one of these aspects from a dedicated process step validation.  No molding no welding or gluing process applicable at ATLAN production.  Sample of validation after move of ATLAN production (2020) and Change project (ATLAN 2.0 ) validation have been audited.  Validation demonstrates the ability of the process(es) to consistently achieve the planned result.  *Australia:*  *Confirm that methods of validation have regard to the generally acknowledged state of the art (e.g. current Medical Device Standard Orders - MDSO, ISO/IEC Standards, BP, EP, USP etc.) [TG Act s41CB, TG(MD)R Sch 1 P1 2(1)].*  Validation of processes are performed according to:  GHTF SG3 N99-10 2004 Quality Management Systems-Process Validation, 02.January 2004 *USA:*  *Process validation is required for sterilization, aseptic processing, injection molding, and welding [21 CFR 820.75; preamble comment 143].*  No sterilization,molding no welding or gluing process applicable at ATLAN production.  *Brazil:*  *Verify that analytical methods, supporting auxiliary systems for production and environmental control that can adversely affect product quality or the quality systemare validated, periodically reviewed and, when necessary, revalidated according to documented procedures [RDC ANVISA 16/2013: 5.5.2, 5.5.3].*  Temeparture/Humidity and pressure measurement equipment will be calibrated acc. to respective SOP requirements. See also PSC 13/14 with respective samples  PSC10 monitoring and measuring of product capable to product conformity (GM) 8.2.6  The system for monitoring and measuring of product characteristics can demonstrate the conformity of products to specified requirements. Test requirements for ATLAN series have been defined. Test specification samples for ATLAN series have been audited.  The product risk is considered in the type and extent of product monitoring activities.  Risk assessment ATLAN product series is performed and will be adjusted with needed input and output as described under D&D (PMS activities, CAPA handling etc.)  Last version of risk assesment ATLAN 2.0 have been audited.  PSC11 monitoring and measuring of product within specified limits risk conrols GM) 8.2.5  The processes used in production and service are appropriately controlled, monitored, operated within specified limits and documented in the product realization records. ATLAN Test samples during production have been audited.  Risk control measures identified by the manufacturer for production processes are implemented, monitored and evaluated.  The product risk is considered in the type and extent of product monitoring activities. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 51 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
|  | Risk assesment ATLAN product series is performed and will be adjusted with needed input/output as described under D&D (PMS activities, CAPA handling etc.)  Last version of risk assesment ATLAN 2.0 have been audited.  Records of in production- and final tests have been audited.  PSC15 Validation of software used in production (GM) 7.5.6  In production are parts of SAP in usage. Whole SAP tool with all used modules are validated from SW validation officers ( see also docu Pavlov).  Main used SAP Modul in productionis: PLESS validation protocol have been audited  Furthermore some teststations with SW are in use. Here the whole test sttion will be validated. One sample have been audited.  PSC16 product file (GM) 4.2.3; 7.5.9.1  Conduction of product file is defined in:  DEMF SC6200 : Produktherstellung  ATLAN 300/350 configurations are documented in SAP; based on the customer order specification an individual product test specification is created in SAP which leads to test plans. The individual product file will be completed during production steps up to the final testing in SAP. Each test step can only be processed when the step before has been finished and confirmed in product file.  It could be determined within samples that the medical device organization has established and maintained a file for each type of device that includes or refers to the location of device specifications, production process specifications, quality assurance procedures, traceability requirements, and packaging, labelling specifications, and when applicable requirements for installation and servicing.  It could also be confirmed via auditing samples of product files that the medical device organization determined the extent of traceability based on the risk posed by the device in the event the device does not meet specified requirements.  ///Revalstr. – “Line 2 – ATLAN ”///  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnumer 62730423, Arbeitsplan all workplaces beginning with workplace1216/ BUM until 750240/ PQMO.  *USA:*  *If a control number is required for traceability, confirm that such control number is on or accompanies the device throughout distribution [21 CFR 820.120(e)].*  Every device gets a label with the serial number at the beginning of assembly. Serial No of device is connected to order No and the DHS in .At the end the final label is put on the device which includes also the same serial number. This serial number is also used for the packaging label.  *Canada:*  *Verify that the manufacturer maintains objective evidence that devices meet the safety and effectiveness requirements of the CMDR [CMDR 9(LA)].*  *Verify that devices sold in Canada have labeling that conforms to Canadian English and French language requirements*  *and contains the manufacturer’s name and address, device identifier, control number (for Class III and IV devices), contents of packaging, sterility, expiry, intended use, directions for use and any special storage conditions [CMDR 21-23].*  *Verify that the manufacturer maintains distribution records in respect of a device that will permit a complete and rapid withdrawal of the device from the market [CMDR 52-56].*  All devices are designed to meet the safety and effectiveness requirements of the CMDR. The type tests (testing of IEC 60601-1 family) are done while design and development phase. The technical documentation is checked while the regular technical file review according to MDR. Additionally, the passed final test (see respective task documentation: “accaptence”) makes sure that essential safety aspects are verified. All final labels of the device and packaging contain: manufacturer’s name and address, device identifier and any special storage conditions. The language is English, or symbols are used on the label. User manuals in several languages (also French) are available and will be distributed together with device that are sold to Canada. The DHR includes all information about distribution (in case of withdrawal from the market).  *Brazil:*  *Verify that the manufacturer has established and maintains procedures to ensure integrity and to prevent accidental mixing of labels, instructions, and packaging materials [RDC ANVISA 16/2013: 5.2.2.1].*  *Confirm that the manufacturer has ensured that labels are designed, printed and, where applicable, applied so that they remain legible and attached to the product during processing, storage, handling and use [RDC ANVISA 16/2013: 5.2.2.2].*  Components (e.g. PCB, Screen) and enclosure have a separate label with their serial number. All these components are documented in the DHR per each device in the ERP System so that accidental mixing is prevented according to DCS GM2150-013.Additionally, scan checks of correct IFU`s and labels will be performed. If system gets a wrong scan check the task can´t be closed. At the end the final label is put on the device. All final labels are designed and printed that way that they withstand storage, handling and use which is required by IEC 60601-1. The labels are tested according to IEC 60601-1 family.  *Australia:*  *Verify that the design and location of information to be provided with a medical device, including labelling and instructions for use, comply with Essential Principle 13 and implant cards and leaflets with Essential principle 13A*  See Canada/Brazil  PSC17 approve of batch releases GM) 7.5.1; 8.2.6  It could be determined that the medical device organization has established and maintained a record of the amount manufactured and approved for distribution. The release will be performed and documented for each medical device (ATLAN series). The record is verified and approved, the device is manufactured according to the file referenced in Task 16, and the requirements for product release were met and documented. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 52 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
|  | ///Revalstr. – “Line 2 – ATLAN ”///  Following samples have been audited:  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnummer 62730423,  Herstellerprotokoll A 300 SN ASSK-0001 Auftragsnummer 62727913  *USA:*  *Verify that labeling is not released for storage or use until a designated individual has examined the labeling for accuracy including, where applicable, the correct unique device identifier (UDI) or Universal Product Code (UPC), expiration date, control number, storage instructions, handling instructions, and any additional processing instructions [21 CFR 820.120(b)].*  *Confirm that labeling is stored in a manner that provides proper identification and prevents mix-ups. Verify labeling and packaging operations are controlled to prevent labeling mix-ups [21 CFR 820.120(c) and (d)].*  *Verify that the label and labeling used for each production unit, lot, or batch are documented in the batch record, as well as any control numbers used [21 CFR 820.120(e), 820.184(e)].*  The labelling is not released for storage or use until a designated individual has examined the labelling for accuracy including, where applicable, the correct unique device identifier (UDI) or Universal Product Code (UPC), expiration date, control number, storage instructions, handling instructions, and any additional processing instructions  Mix up see under PSC 16  *Brazil:*  *Verify that the device history record of the product includes or refers to the following information: date of manufacture; components used; quantity manufactured; results of inspections and tests; parameters of special processes; quantity released for distribution; labeling; identification of the serial number or batch of production; and final release of the product [RDC ANVISA 16/2013: 3.2.1].*  *Verify that labeling has not been released for storage or use until a designated individual has examined the labeling for accuracy. The approval, including the date, name, and physical or electronic signature of the person responsible, must be documented in the device history record [RDC ANVISA 16/2013: 5.2.2.3].*  The device history record of the product includes: date of manufacturer; components used; quantity manufactured; results of inspections and tests; parameters of special processes; quantity released for distribution; labelling; identification of the serial number of production and final release of the product.  Therefore, it is ensured that labeling has not been released for storage or use until a designated individual has examined the labeling for accuracy. The approval, including the date, name, and physical or electronic signature of the person responsible is documented in the device history record.  PSC 18 n/A  PSC 19: product status (GM)  Product status can be identified by the etiquette documentation. Only products which are finally released can be put into the market.  PSC20 - Customer property (GM)  ///Service Center - Moislinger Alee///  ATLAN A300 labeled with red sticker found in third level Service Center - Moislinger Alee, label No 3085421308 Customer Property is identified as such with label when received. The reception of devices from customer is managed using the service and maintenance procedure.  Every devices in Service center are labeled as such with “Meldungs Nummer” /order no in SAP and colored sticker. The red sticker indicates that cleaning procedure have been finished.  PSC21 acceptance activities (including supplier) (A) 7.4.3; 8.2.6  It have been verified by means of audited samples that acceptance activities assure conformity with specifications and are documented.  It have been confirmed based on samples (e.g. leakage testing, pressure tests, electrical safety testing and verifications of individual configurations and accompanying labels and documents) that the extent of acceptance activities is commensurate with the risk posed by the device.  ///Revalstr. – “Line 2 – ATLAN ”///  2 samples from ATLAN series have been audited:  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnummer 62730423  *USA:*  *Verify that the manufacturer establishes and maintains procedures to ensure that sampling methods are adequate for their intended use and ensure that when changes occur, the sampling plans are reviewed [21*  *CFR 820.250(b)].*  *Brazil:*  *Verify that sampling plans are defined and based on valid statistical rationale. Each manufacturer must establish and maintain procedures to ensure that sampling methods are suitable for their intended use and*  *are reviewed regularly. A review of sampling plans should consider the occurrence of nonconforming product, quality audit reports, complaints and other indicators [RDC ANVISA 16/2013: 9.2].*  Acceptance process based on 100% verification, therefore sampling is NA  MDR 2017/745  Description of verification and quality assurance techniques at the manufacturing stage including processes and procedures which are to be used (MDR / IVDR Annex IX\_2.2 (d) , MDR Annex XI 6.2)  Herstelleranweisung ATLAN series have been audited.  Description of appropriate tests and trial before / during / after manufacture including frequency and test equipment (MDR / IVDR Annex IX 2.2(e), MDR Annex XI 6.2)  Test protocols ATLAN Series have been audited. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 53 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
|  | Control of monitoring and measuring equipment (7.6)  PSC13 monitoring and measuring devices needed (GM) 7.6  The organization has determined the monitoring and measuring devices needed to provide evidence of conformity to specified requirements. Devices are listed in MIMS System.  The monitoring and measuring equipment used in production and service control has been identified, adjusted, calibrated and maintained, and is capable of producing valid results. For verification several samples in Service enter and ATLAN production have been audited.  Calibration of measurement equipment is performed in specific intervals (usually once a year or after 18 months)  Calibration is currently done by “Kalibrierlabor Revalstr.” which counts as provider. In some cases devices can be caibrated with other external partners (e.g. Testo)  All measuring devices are listed and controlled in MIMS with ID-number, last calibration date, next calibration date, calibration evidence.  Responsible persons in Service Center Moislinger Allee and production get once a month an email with status of devices for notification of devices that must be calibrated.  Futhermore, each employee of service center is responsible to check calibration status of used devices which is labeled on each device.  Calibration certificates are stored and maintained in MIMS  Devices are marked with an ID number and the date of the next calibration.  Audited Examples :  ///Moislinger Allee – “Service center”///  Secu Life PS 300 Patienten Simulator MIMS 302658 (Prüfplatz 107) Tempstecker 37.0 Grad Inventarnummer 302658  ///Revalstr. – “Line 2 – ATLAN ”///  Testo 622 (humidity/Temp/pressure) MIMS No 101983,  Manometer 6 bar MIMS 10495,  Flaschendrucksimulation MB01008 MIMS 302777  PSC14 monitoring and measuring devices validity of previous measurements in case of non- confirming measurement devices (GM) 7.6  MDR 2017/745 / IVDR 2017/746  • Test equipment used shall be possible to trace back adequately the calibration of that test equipment. (MDR /IVDR Annex IX\_2.2 (e) , MDR Annex XI 6.2)  The organization assesses (and records) the validity of previous measurements when equipment is found not to conform to specified requirements, and takes appropriate action on the equipment and any product affected. The control of the monitoring and measuring devices is adequate to ensure valid results.  Every device which is processed in “Service Center Moislinger Allee” will be listed in SAP system with incoming date. In SAP the device will be linked to a dedicated work place with ID. Every workspace has a list of measurement equipment used unique at this place.  In production all used test equipment will be documented in every test protocol in SAP. It will be possible to trace back every used device with related time-period and related concrete tests and test results. The status of measurement-device at time of usage can be traced back in MIMS.  Monitoring and measuring devices are protected from damage or deterioration e.g. via limited access to the  “Service Center building Moisslinger Allee” and producstion and the floor where the devices are in usage. Every employee is teached in handling of the measurement equipment.  No such event occurred so far.  Samples for audited Mesurement equipment with rekated status which have bee checked at workplaces and in MIMS find under PSC 13.  Customer property (7.5.10)  PSC20 customer property (GM) 7.5.10  ///Service Center - Moislinger Alee///  ATLAN A300 labeled with red sticker found in third level Service Center - Moislinger Alee, label No 3085421308  Customer Property is identified as such with label when received. The reception of devices from customer is managed using the service and maintenance procedure.  Every devices in Service center are labeled as such with “Meldungs Nummer” /order no in SAP and colored sticker. The red sticker indicates that cleaning procedure have been finished.  Non-confrming product (8.3)  PSC22 identification, control, and disposition of nonconforming products is adequate (LA) 8.3  ///Revalstr. – “Line 2 – ATLAN ”///  There are two areas for storage of non-conforming products. All Non- conforming product is labeled with “Sperraufkleber”, edged with red color. The “Sperraufkleber” contains serial no, product code, order no and reason for blocking.  In case of Non-conforming product components an additional specific cupboard is used.  Samples Non - conforming product handling have been audited:  Meldungs No 810000417804 ATLAN A300XL ASSK-0147  ATLAN A300XL ASSK-0147, order No 62728824  N 5 x Sperrlager 1 piece , MK07201  Arbeitsplatz BUM Sperrbereich Order No 62728313,Material No 8609250 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 54 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
| Reviewed  documents  and records (identification and revision) | Documents  PSC 4  DEMF SC6330 : Instandhaltung und Reinigung DEMF SC6330‐de‐00 , Rev. 0, requirements for cleaning and pest control  PSC5  DEMF SC6700 : Handhabung elektrostatisch gefährdeter Bauteile (ESD) DEMF‐SC6700‐de‐00.01 , Rev. 00.01 PTS ATLAN 8609010- v 16, Arbeitsbedingungen: Temp 15-35 Grad/Luftdruck: 950-1060/ Luftfeuchte 5%-95% PSC 8  IN4300 New product introduction en 09.00, defines for process validation.  PSC 10/PSC11  8609010 Production and Test Specification ATLAN Series, rev 16, Final Test, 3.2.3 and further beginning with leakage etc….  8621500 Herstelleranweisung ATLAN A350, v21 includes all needed test specification for production.  PSC/13/14 (GM)  DWAG PQ8010 : Betriebsmittelüberwachung DWAG PQ8010‐de‐02 , Rev. 2  PSC 12 (GM)  DEALL HR3400 : Employee Qualification Process DEALL HR3400‐en\_de‐05.00 , Rev. 05.00  PSC 15  DEALL IT4120 : Validierung qualitätsrelevanter Prozess Software DEALL IT4120‐de‐02.01 , Rev. 02.01  PSC16  DEMF SC6200 : Produktherstellung DEMF SC6200‐de‐02 , Rev. 2  PSC 20 (GM)  DEMF SE4300 : Factory Services DEMF SE4300‐en‐01.00 , Rev. 01.00 , attribute with regulation for customer property and advice for labeling.  PSC 22  DEMF SC6111 : Lenkung von fehlerhaftem Material DEMF‐SC6111‐de‐00.01 , Rev. 00.01  DEMF SC6110 : Behandlung von Abweichungen in der Produktion DEMF‐SC6110‐de‐00.00 , Rev. 00.00  Records  PSC 1  Presentation production, 21.09.2023  Organigramm BU Therapie/Anästhesia, Admin Anästhesia Head of production Niko Raap, Teamleader Production ( Anja Hidden/Dirk Rowedder/Dirk Sachse)  Leader Components (Dirk Sachse)  Leader Linie (Anja Hidden)  Lay out plan B 23 Anäesthesia  MDR101-035 3.1. design and Manufacturing information/Flow chart Manufacturing  ROFO Chart, 18.09.2023 with forecast planning, upper limit of production 800 pieces, needed pieces per month for profitability 500 pieces.  Layout label ATLAN family Sample US ATLAN A 350 UDI 04048675556176 for US only SN ASSA-9998 (Dummy serial No)  PSC 4/PSC5/PSC6 (GM)  Bockholdt pestcontrol last report done on 06.09.2023 report from 12.09.2023, signed,Werk 3 Revalstr. including lay out plans (incl B23) and results, no pests found.  Reinigungsplan Gebäude B23, BU Therapie, 2023-07-2023, includes advice for cleaning of B23, weekly and monthy cleanings needed. The execution will be confirmed by personnel and documented in lists.  DQS Zertifikat Bockholdt GMbH EN 16636 Zert Nr. 543810 PMS, 08.12.2025  Reinigungsplan B 23 August 2023, filled with confirmation of personnel, 04.03.2023, signed by responsible person in production.  Messprotokoll Partikelmessung B23, class 9, 35 measure points, limit 1 Mio, measures on protocol at all points < 25.000 at all measurements points, 13.09.2023 will be repeated every 3 months.  Überwachungsplan BU Therapy Linie Perseus/ATLAN\_Reiner Bereich, 30.08.2021  Layout label ATLAN family Sample US ATLAN A 350 UDI 04048675556176 for US only SN ASSA-9998 (Dummy serial No)  Herstellprotokoll A 350 SN ASSK-0057., Auftragsnummer 62730423, 12.09.2023 Hentschel (Runin Test) Inspect 0010/0020/0030), PP 3.2, measure temp 24 Grad, humidity 71%, humidity 1012  Training Evidence Sample Jörg Bentin ( 1004324) Gerätemonteur, ESD Training (B70 Prozesstraining) , 27.04 2023  PSC 7/8  Validation master Plan ATLAN 2.0 family, 16.08.2022, v 00 (ARAS transfer, Project Manager Andres Plöger, History: 1.1 ATLAN complete 2019-07-10, 1.2 complete 2019-07-10, 2.1 ATLAN complete 2020-03-05, 2.2 complete 2020-03-05 (compete Validation have been done after move of factory), all defined steps for Change from 1.0 to 2.0 are  documented  Process FMEA 11232750, v01 Final Assembly, all risks rated in acceptable risk  Last Delta Validation MB01987 UNIT RunIN, 11.05.2022  PSC 10/PSC11  Risk assessment table has updated during 2022, Hazard analysis ATLAN 2.0 , 6.22 approved 05.01.2023, Cyber included, typos , some acceptance rationales adjusted.  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnummer 62730423, Prüfpunkt 12.1 start of final test Dichtigkeitsprüfung Messwert > 3,72 ( ZV02 ZV Air), results ZV021,14/ ZVair0,93, 19.09.2023, Christian Alwert  12. 8(1) Mischertypeinstellung wird vorgenommen, confirmed with ja, |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 55 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
|  | 12.08 (9) Leakage and Temp.: Sensor temp test: -4 – +4 Gad / measure -1 Grad, LeakAuto < 100 ml Measurement 10 ml , Leakman spont > 100 ml; measurements 17 ml  12. 8(1) Mischertypeinstellung wird vorgenommen, confirmed with ja,  12.08 (9) Leakage and Temp.: Sensor temp test: -4 – +4 Gad / measure -1 Grad, LeakAuto < 100 ml Measurement 10 ml , Leakman spont > 100 ml; measurements 17 ml  PSC 12  Training Evidence Sample Jörg Bentin ( 1004324) Gerätemonteur, ESD Training (B70 Prozesstraining) , 27.04 2023 Training Evidence Christian Alwert, 05.03 2019, Training of Final test on A300/350 series  Q- Check Christian RAAB ID 1003118, 05.05 2023 incl. evidence for academy training ATLAN A3X0 series. Autorisierungs Freigabe Berechtigung Christian RAAB, ATLAN A3X0 series, signed and approved by employee and team leader on 01.07.2019, 2 parts training : academy and onsite practical advice.  PSC/13/14 (GM)  Multimeter Fluke Reg. 33576/3131 AP 113, last calibration 25.09.2022-expiry date 25.09.2023  Dräger Prüfstand MIMS No 40281/3132 (manueller Prüfstand) (Prüfplatz 113)  Secu Life PS 300 Patienten Simulator MIMS 302658 (Prüfplatz 107)  Kalibrierzertifikat, 16.05 2022, Patienten Simulator Nr. 378483-03 next due date 11.2023 Inventarnummer 302658, in System 07.12.2023  Kalibrierzertifikat, Nr.315489/2022-06 Inventarnummer 302658 Tempstecker 37.0 Grad, Kalibrierung 07.06.2022, due date 07.12.2023  Testo 622 (humidity/Temp/pressure) MIMS No 101983, due date 13.06 2024  Kalibrierzertifikat testo MIMS No 101983,pass 16.06.2023.  Manometer 6 bar MIMS 10495, due date 02.02.2024  Kalibrierzertifikkat Dräger, MIMS 10495, 02.02.2022  Flaschendrucksimulation MB01008 MIMS 302777, due date 16.02.2024  Kalibrierzertifikat Dräger MIMS 302777, 16.02.2023  PSC 15  Validation Report PLESS QPS, 2.3 ID 400, approved without further activities 09.05.2023.  Validation Report Test station A220001 Ventilation Unit Funktionstest (inkl A180039 SW part v 4.1/1.3.0.0FW 3.x), 25.07.2023, under usage of A 200008 as reference measurement tool, result no observations test results are similar to used equivalence.  PSC 16  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnummer 62730423, Arbeitsplan all workplaces beginning with workplace1216/ BUM until 750240/ PQMO.  PSC17  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnumer 62730423, Prüfpunkt 12.1 start of final test Dichtigkeitsprüfung Messwert > 3,72 ( ZV02 ZV Air), results ZV021,14/ ZVair0,93, 19.09.2023, Christian Alwert  12. 8(1) Mischertypeinstellung wird vorgenommen, confirmed with ja,  12.08 (9) Leakage and Temp.: Sensor temp test: -4 – +4 Gad / measure -1 Grad, LeakAuto < 100 ml Mesurement 10 ml , Leakman spont > 100 ml; measurements 17 ml  PZAE technical final approval, 19.09.2023 Herr Allwerth  Herstellerprotokoll A 300 SN ASSK-0001 Auftragsnumer 62727913, PZAE technical final approval, 08.09.2023. Mathias Junghans.  PSC20  ATLAN A300 labeled with red sticker found in third level Service Center - Moislinger Alee, label No 3085421308 PSC 21  Herstellprotokoll A 350 SN ASSK-0057, Auftragsnummer 62730423, Prüfpunkt 12.1 start of final test Dichtigkeitsprüfung Messwert > 3,72 ( ZV02 ZV Air), results ZV021,14/ ZVair0,93, 19.09.2023, Christian Alwert  12. 8(1) Mischertypeinstellung wird vorgenommen, confirmed with ja,  12.08 (9) Leakage and Temp.: Sensor temp test: -4 – +4 Gad / measure -1 Grad, LeakAuto < 100 ml Measurement 10 ml , Leakman spont > 100 ml; measurements 17 ml  PZAE technical final approval, 19.09.2023 Herr Allwerth  PAB2 Freigabe zur Ablieferung des Produktes, Final test and accompanying documents Torsten Adels, 20.09.2023 Herstellerprotokoll A 300 SN ASSK-0001 Auftragsnummer 62727913, PZAE technical final approval, 08.09.2023. Mathias Junghans.  PAB2 Freigabe zur Ablieferung des Produktes, Final test and accompanying documents Torsten Adels, 08.09.2023 BUM Arbeitsplatz 62729265, SN ASSK-0163, A350, tests finished (Typenschild checked, break tested)  Atem System 8609011-06, SN ASRM-3361  VM 4 HIT SW used.  MB01987 UNIT RunIN- Selbstest valid 21.09 2023 06:21  FA 3 Bach Manual mode Label Spanish Version A 621245, test with French not accepted in SAP , Spanish accepted.  Sicherheitsbatt Locktite 601 (Glue used in some work places), Juni 2004, storage between 8- 21 degree  PSC 22  Meldungs No 810000417804 ATLAN A300XL ASSK-0147, 19.09.2023, Bauteil MK07201 O² Flush Ventil  ATLAN A300XL ASSK-0147, order No 62728824, PP 12.2 Dichtigkeitsprüfung 0-27,90 ,measurement -3,33 ml/min, replacement of Bauteil MK07201, retested on 19.09.2023, PP 12.2 pass 0,21 ml/min  N 5 x Sperrlager 1 piece , MK07201  Arbeitsplatz BUM Sperrbereich Order No 62728313,Material No 8609250 Schubladenschrank, labeled with red sticker, Kratzer seitlich |
| Names and titles of  persons  interviewed | Ralf Küster (Indsutrial Engineer, Service center)  Martin Lieber (Medical plant Servcie center Moislinger Allee )  Herr Hagedorn provides rest of participant names and roles |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 56 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center) / # 90464 (ATLAN Series B23)** |
| Products,  components, or projects  reviewed | ATLAN Series 300/350 version 2.0 |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | Actions are needed for this process to conform to requirements. See audit findings list |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 57 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| 2.5.8 | Production and Service Controls - #10578 (Anlauffabrik / Startup Factory) |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Anlauffabrik/Startup Factory)** |
| Audit trail  records of | Martin Szepannek |
| Area(s) visited (location, e.g., site visited) | Location # 10578 (Anlauffabrik/startup Factory)  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Production and Service Controls: Planning of Production and Service Process (MDSAP Chapter 6, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.2.1, 7.5.1 + (DIN)(EN) ISO 9001 - 8.1, 8.2.2, 8.5.1 + MDSAP - Australia - TG(MD)R Sch 1 P1 2, Sch3 P1 Cl1.4(4), Sch3 P1 Cl1.4(5)(d)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1, 2.4, 4.1.2, 4.1.7, 5.1 + MDSAP - Japan - MO169: 26, 27, 40 + MDSAP - USA - 21 CFR 801, 820.30(b), 820.20(a), 820.30(h), 820.70(a), 830 + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2), Annex V (3.2)"  Production and Service Controls: Selection of Production and Service Process(es) (MDSAP Chapter 6, Task 2, Site: 10578  "Production and Service Controls: Infrastructure (MDSAP Chapter 6, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.3, 7.5.1 + (DIN)(EN) ISO 9001 - 7.1.3, 7.5.1, 8.5.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.2, 5.1.5 + MDSAP - Canada - CMDR 14 + MDSAP - Japan - MO169: 6, 24, 40 + MDSAP - USA - 21 CFR 820.70(g), 820.70(f) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Work Environment (MDSAP Chapter 6, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.4 + (DIN)(EN) ISO 9001 - 7.1.4, 7.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 7.2, 8 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.3 + MDSAP - Japan - MO169: 6, 25-1, 25-2; [Old: 6, 25] + MDSAP - USA - 21 CFR 820.70(c), 820.70(d), 820.70(e) + MDR - Annex IX2.2 ¶1; Annex I (11) + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Identification of Processes Subject to Validation (MDSAP Chapter 6, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.1.6, 7.5.6 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 8.4, 8.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 8.2, 8.3; Sch3 P1 1.4(5)(d) + MDSAP - Brazil - RDC ANVISA16/2013: 5.5.2, 5.5.3 + MDSAP - Japan - MO169: 6, 5-6, 45; [Old: 6, 45] + MDSAP - USA - 21 CFR 820.75(a) + MDR - Annex IX 2.2 ¶2 (d); Annex XI 6.2 ¶2, 12"  "Production and Service Controls: Control, Operation, and Monitoring of the Production and Service Process; Risk Controls (MDSAP Chapter 6, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.5 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 5.1.6, 8.2, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 57 + MDSAP - USA - 21 CFR 820.70(a), 820.75(b), 820.250 + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); "  "Production and Service Controls: Competence of Personnel (MDSAP Chapter 6, Task 12, Site: 10578);  (DIN)(EN) ISO 13485 - 6,2 + (DIN)(EN) ISO 9001 - 7.2, 7.3 + MDSAP - Australia - RDC ANVISA 16/2013: 2.3.2 + MDSAP - Japan - MO169: 22 + MDSAP - USA - 21 CFR 820.25, 820.70(d), 820.75(b) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Control of Monitoring and Measuring Device (MDSAP Chapter 6, Task 13, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.1, 7.6 + (DIN)(EN) ISO 9001 - 7.1.5, 8.5.1 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.5, 5.4 + MDSAP - Japan - MO169: 40, 53 + MDSAP - USA - 21 CFR 820.70(g), 820.72 + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Impact Analysis of Monitoring and Measuring Device Found Out of Specifications (MDSAP Chapter 6, Task 14, Site: 10578); (DIN)(EN) ISO 13485 - 7,6 + (DIN)(EN) ISO 9001 - 7.1.5 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.4 + MDSAP - Japan - MO169: 53 + MDSAP - USA - 21 CFR 820.72(a) + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Device Master File (MDSAP Chapter 6, Task 16, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.1, 7.5.8, 7.5.9.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.5.2 + MDSAP - Australia - TG(MD)R, Sch1 EP13, Sch3 P1 1.4(5) (c),(d),(e) & 1.9 + MDSAP - Brazil - RDC ANVISA 16/2013: 1.2.26, 2.4, 4.2, 5.2, 6.4 + MDSAP - Canada - CMDR 9(2), 21-23, 52-56, 66-68 + MDSAP - Japan - MO169: 6, 7-2, 26, 47, 48; [Old: 6, 26, 47, 48] + MDSAP - USA - 21 CFR 820.65, 820.120(e), 820.181 + MDR - Article 10.4 ¶1 , 10.5, 10.9 ¶3 (b), 10.11, 10.15; Annex IX 2.2 ¶2 (c6); Annex XI 6.1 ② & 12 ¶1 + MDD - Annex II (3.2), Annex VI (3.1)"  "Production and Service Controls: Production Record; Evidence of Compliance of Released Devices (MDSAP Chapter 6, Task 17, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.5.1, 7.5.8, 7.5.9.1, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.5.1, 8.5.2, 8.6 + MDSAP - Brazil - RDC ANVISA 16/2013: 3.2, 5.2, 6.4 + MDSAP - Japan - MO169: 6, 40, 47, 48, 58, 59 + MDSAP - USA - 21 CFR 820.120, 820.184 + MDR - Article 10.7, 10.9 ¶3 (h); Annex IX 2.2 ¶2 (c7); Annex XI 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Customer Property (MDSAP Chapter 6, Task 20, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.10 + (DIN)(EN) ISO 9001 - 8.5.3 + MDSAP - Japan - MO169: 51 + MDR - Article 109"  "Production and Service Controls: Acceptance Activities (MDSAP Chapter 6, Task 21, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.4.3, 7.5.8, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.4.2, 8.4.3, 8.5.2, 8.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.3.1, 5.3.2, 5.3.3, 5.3.4, 9.2 + MDSAP - Japan - MO169: 6, 39, 47, 58, 59 + MDSAP - USA - 21 CFR 820.80, 820.250(b) + MDR - Article 10.9 ¶3 (m), Annex IX 2.2 ¶2 (b2, e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" "Production and Service Controls: Identification, Control, and Disposition of Nonconforming Products (MDSAP Chapter 6, Task 22, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.8, 8.3 + (DIN)(EN) ISO 9001 - 8.5.2, 8.7 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 6.5.1, 6.5.2 + MDSAP - Japan - MO169: 47, 60-1, 60-2, 60-3, 60-4; [Old: 47, 50, 60] + MDSAP - USA - 21 CFR 820.60, 820.90(a), 820.86, 820.100(a) + MDR - Article 10.9 ¶3 (k), 10.12; Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" "Production and Service Controls: Review of Customer Requirements, Distribution Records (MDSAP Chapter 6, Task 25, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 5.2, 7.2.2, 7.5.9 + (DIN)(EN) ISO 9001 - 5.1.2, 7.5.1, 8.2.3, 8.2.4, 8.5.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 6.3 + MDSAP - Canada - CMDR 52-53, 55-56 + MDSAP - Japan - MO169: 6, 11, 28, 48, 49 + MDSAP - USA - 21 CFR 820.160(a) + MDR - Article 10.1" "Production and Service Controls: Installation Activities (MDSAP Chapter 6, Task 26, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.3 + MDSAP - Brazil - RDC ANVISA 16/2013: 8.1 + MDSAP - Japan - MO169: 42 + MDSAP - USA - 21 CFR 820.170 + MDR - Article 10.9 ¶3 (g)"  "Production and Service Controls: Servicing Activities (MDSAP Chapter 6, Task 27, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.5.4, 8.4 + (DIN)(EN) ISO 9001 - 7.5.1, 9.1.3 + MDSAP - Brazil - RDC ANVISA 16/2013: 8.2 + MDSAP - Japan - MO169: 6, 43, 61 + MDSAP - USA - 21 CFR 820.200 + MDR - Article 10.9 ¶3 (g) + MDD - No specific requirements"  "Production and Service Controls: Top Management Commitment to the Production and Service Process (MDSAP Chapter 6, Task 29, Site: 10578); (DIN)(EN) ISO 13485 - 5.1, 5.2 + (DIN)(EN) ISO 9001 - 5.1.1, 5.1.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1 + MDSAP - Japan - MO169: 10, 11 + MDR - Article 10.9 ¶3 (c) + MDD - Annex II (2, 3.1)" |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | PSC #1 Planning of production and service process  Verified that the product realization processes are planned, including any necessary controls, controlled conditions, and risk management activities required for the product to meet the specified or intended uses, the statutory and regulatory requirements related to the product, and (when applicable) unique device identifier requirements.  Confirmed that the planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.  Andreas Plöger  Anlauffabrik/Start-up factory is a production area jointly used by R+D and Production for the assembly of new products from the first integration samples to series production. It provides the complete infrastructure for medical device manufacturing.  Development phases:  4.0 definition  4.1 Design  5.0 Realisation  6.0 validation  7.0 Ramp-Up + Market launch  7.1 Serial Production  8.0 Stable Installed Base / abschluss New product Intgeration  Activities of Ramp-up-Factory range from 5.0 to 7.1 (that mesns, it may include production of actually placed on the market devices. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 58 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Anlauffabrik/Startup Factory)** |
|  | 900 m²production Space  140m² Albus Production Space  NPI – New Product Introduction  United States (FDA):  Confirmed that the organization has determined the applicability of unique device identifier requirements per 21 CFR 801 and 21 CFR 830, has obtained the unique device identifiers from an FDA-accredited UDI-issuing agency, and the required data elements have been entered in the Global Unique Device Identification Database (GUDID) [21 CFR 801, 830].  PSC#2 Selection of production and service process(es)  Reviewed production processes considering the following criteria and selected several production processes to audit.  Priority criteria for selection:  • Use of production processes that directly impact the ability of the device to meet its essential design outputs • New production processes or new product to be introduced in future (Albus Ventilation System (0-Series planned for 2027).  PSC#5 Infrastructure  Verified that the organization has determined and documented the infrastructure requirements to achieve product conformity, including buildings, workspace, process equipment, and supporting services.  Confirmed that buildings, workspaces, and supporting services allow product to meet requirements.  Verified that there are documented and implemented requirements for maintenance of process equipment where important for product quality, and that records of maintenance are maintained.  Brazil (ANVISA):  Verified that manufacturing facilities are configured in order to provide adequate means for people flow. [RDC ANVISA 16/2013: 5.1.2].  PSC#6 Work environment  Verified that documented requirements have been established, implemented and maintained for:  - health, cleanliness, and clothing of personnel that could have an adverse effect on  - product quality  - monitoring and controlling work environment conditions that can have an adverse effect on product quality - training or supervision of personnel who are required to work under special environmental conditions - controlling contaminated or potentially contaminated product (including returned products) in order to prevent contamination of other product, the work environment, or personnel.  Brazil (ANVISA)  No specific Biosaftey Standards applicable  PSC#7 Identification of processes subject to validation  Determined if the selected process(es) and sub-process(es) have been reviewed, including any outsourced processes, to determine if validation of these processes is required. At the stage being, no process validation is required (100% individual end control of finished medical devices.  Brazil (ANVISA):  n/a  United States (FDA):  Process validation n/a  PSC #10 Monitoring and measurement of product conformity  Verified that the system for monitoring and measuring of product characteristics is capable of demonstrating the conformity of products to specified requirements.  It could be confirmed that product risk is considered in the type and extent of product monitoring activities.  PSC#11 Control, operation, and monitoring of the production and service process; risk controls  Verifed that the processes used in production and service are appropriately controlled, monitored, operated within specified limits and documented in the product realization records.  In addition, verifed that risk control measures identified by the manufacturer for production processes are implemented, monitored and evaluated.  At time of audit, Integration System iteration 3 is ongoing with 130 devices to be produced; this is made under as realistic production conditions as possible, however, not yet with finally approved components, parts, work instructions and measuring equipment. Produced devices are not yet labelled with a CE mark, however, rest of label is already as realistic as in this development stage possible. All devices manufacture in this stage will stay internally; they are either provided to R+D for further development input, or to Test center for testing; none of these devices is planned or qualified to be placed on the market, all integration systems will be scrapped later.  Traceability  SAP status ensures that Integration Systems are logistically not able to be placed on the market. This is traced electronically by Revision Index, Serialnumber, material number  Material number and revision index must be released in SAP with status "Serial" to be shippable; Serial number also contains date information that would prevent future erroneous release/marketing.  Production requirements - Albus Production requirements 11028963 rev.02 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 59 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Anlauffabrik/Startup Factory)** |
|  | Produktionskonzept - Albus production Concept 11028978 Rev. 02  Process FMEA 11028980 2023-06-11  Albus NIV Ref. 8430003-05 SN ASSJ-0016  Albus ICU-MID Ref. 8430001-05 SN ASSJ-0016  ➔ Device Status Document (currently in Excel), including Electrical Safety Test values and Final Test Results ➔ Order Card 62728075 from 2023-08-25  Order card contains customer order related specifications (options/variants) and order data.  Order card 62728153 Albus NIV 8430003 ➔ ASSJ-0020  PCB 8430381 Release status SAP: Prototype (which is OK for this Pre-Production State) Leakage Current Tester Elabo 300066/3832 next Cal 03/2024  Tsi Flowmeter 20895/5550 nextCal 07/2024  PSC#12 Competence of personnel  Verified that personnel are competent to implement and maintain the processes in accordance with the requirements identified by the organization.  PSC#13 Control of monitoring and measuring device  Confirmed that the organization has determined the monitoring and measuring devices needed to provide evidence of conformity to specified requirements. Verified that the monitoring and measuring equipment used in production and service control has been identified, adjusted, calibrated and maintained, and capable of producing valid results. Verified that the control of the monitoring and measuring devices is adequate to ensure valid results. Confirmed that monitoring and measuring devices are protected from damage or deterioration.  PSC#14 Impact analysis of monitoring and measuring device found out of specifications  Confirmed that the organization assesses (and records) the validity of previous measurements when equipment is found not to conform to specified requirements, and takes appropriate action on the equipment and any product affected.  n/a for this process, since devices will not be released for marketing/clinical use  PSC#15 Validation of software used for the control of the production and service process  Checked if the selected process are software controlled, or if software is used in production equipment or the quality management system. If so Verified that the software is validated for its intended use.  Software validation may be part of equipment qualification.  Process defines use of Checklist to define if Software is Quality relevant.  A QPS Critically assessment is done – QMS software is classified into categories I, II, or III. Based on that, a test specification is created. Criteria for classification are Software Category (non-configured, Configured, customized), Impact of malfunction and Propability of detection.  At time of audit, 253 Quality relevant Software Tools are listed in the QPS list, of which 67 are categorized to be Class 3.  Screening of Service records for potential events/Complaints has been validated (Tool existing since 2005).  PSC#16 Device master file  Determined that the manufacturer has established and maintained a file for each type of device that includes or refers to the location of device specifications, production process specifications, quality assurance procedures, traceability requirements, and packaging, labeling specifications, and when applicable requirements for installation and servicing.  Confirmed that the manufacturer determined the extent of traceability based on the risk posed by the device in the event the device does not meet specified requirements  Produktionsspezifikation PTS 11201373 Draft Version (will be approved to gate 6 or production readiness review). Contains relevant product and variant specific test requirements.  Australia (TGA):  n/a – not implantable  Brazil (ANVISA):  Drägerwerk has established and maintains procedures to ensure integrity and to prevent accidental mixing of labels, instructions, and packaging materials. Labels are designed, printed and, where applicable, applied so that they remain legible and attached to the product during processing, storage, handling and use.  Canada (HC):  Not yet applicable at thias stage of Design and Development, since products are not to be released to the market yet.  United States (FDA):  Not yet applicable at thias stage of Design and Development, since products are not to be relöeased to the market yet.  PSC#17 Production record; evidence of compliance of released devices  Determined that the manufacturer has established and maintained a record of the amount manufactured and approved for distribution for each batch of medical devices, the record is verified and approved, the device is manufactured according to the file referenced in task 16, and the requirements for product release were met and documented.  Brazil (ANVISA):  Verifed that the device history record of the product includes or refers to the following information: date of manufacture; components used; quantity manufactured; results of inspections and tests; parameters of special processes; quantity released for distribution [not yet recorded since devices are not to be lreleased fto be marketed]; labeling; identification of the serial number or batch of production; and final release of the product all this is recorded and documented already in order to simulate realisticconditions. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 60 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Anlauffabrik/Startup Factory)** |
|  | Not yet all Brazilian labelling handling requirements are not yet implemented within this D+D/Ramp-up project (market release time not before 2027)  United States (FDA):  Not yet all FDA labelling handling requirements are not yet implemented at this stage of D+D/Ramp-up project (market release time not before 2027).  PSC#20 Customer Property  n/a for Startup Factory/Anlauffabrik  PSC#21 Acceptance activities  Verified that acceptance activities assure conformity with specifications and are documented. Confirmed that the extent of acceptance activities i s commensurate with the risk posed by the device.  Brazil (ANVISA) & United States (FDA):  DEMF PQ8050 : Statistical Techniques DEMF PQ8050‐en\_de‐00.00 , Rev. 00.00  PSC#22 Identification, control, and disposition of nonconforming products  Verifed that the identification, control, and disposition of nonconforming products is adequate, based on the risk the nonconformity poses to the device meeting its specified requirements.  Drägerwerk ensures that products manufactured in the current state of D+D/Production Ramp-up are not CE marked and therefore can not be released to the market.  PSC#25 Review of customer requirements, distribution records  Confirmed that the medical device organization performs a review of the customer’s requirements, including the purchase order requirements, prior to the medical device organization’s commitment to supply a product to a customer.  It also was verified that the medical device organization maintains documentation required by regulatory authorities regarding maintenance of distribution records.  However, within Startup factory these processes are simulated only (no real customer orders, no distribution of non-CE-marked devices restricted to onsite the facility (Design+Developmen department) only.  Brazil (ANVISA):  Verified that the manufacturer maintains distribution records which include or make reference to: the name and address of the consignee, the identification and quantity of products shipped, the date of dispatch, and any numerical control used for traceability; However, within Startup factory these processes are simulated only (no real customer orders, no distribution of non-CE-marked devices restricted to onsite the facility (Design+Developmen department) only.  Canada (HC):  Verified that the manufacturer maintains distribution records that contain sufficient information to permit complete and rapid withdrawal of the medical device from the market; However, within Startup factory these processes are simulated only (no real customer orders, no distribution of non-CE-marked devices restricted to onsite the facility (Design + Development department) only.  United States (FDA):  Verify that the manufacturer maintains distribution records which include or refer to the location of the name and address of the initial consignee, the identification and quantity of devices shipped; and any control numbers used; However, within Startup factory these processes are simulated only (no real customer orders, no distribution of non-CE-marked devices restricted to onsite the facility (Design + Development department) only.  PSC#26 Installation activities  Installation and respective verification activities are not applicable to this Product Line (Albus/Anesthesia devices).  PSC#27 Servicing activities  Servicing activities are not applicable to this Product Line (Albus/Anesthesia devices) in Startup factory.  Brazil (ANVISA):  Servicing activities are not applicable to this Product Line (Albus/Anesthesia devices) in Startup factory.  United States (FDA):  Servicing activities are not applicable to this Product Line (Albus/Anesthesia devices) in Startup factory.  PSC#29 Top management commitment to the production and service process  Based on the assessment of the production process in Startup-Factory overall, it could be determined that management provides the necessary commitment to the production and service control process to ensure devices meet specified requirements and quality objectives. |
| Reviewed  documents  and records (identification and revision) | DEMF SE4300 : Factory Services DEMF SE4300‐en‐01.00 , Rev. 01.00  DEMF SC6700 : Handhabung elektrostatisch gefährdeter Bauteile (ESD) DEMF‐SC6700‐de‐00.01 , Rev. 00.01 DWAG IN4300 New Product Introduction Rev. 09:00  DWAG IN4320 : Process FMEA / Prozess FMEA DWAG IN4320‐en\_de‐08.00 , Rev. 08.00  DEALL IT4120 : Validation of Quality Process Software DEALL IT4120‐en‐02.01 , Rev. 02.01  DEALL-IT4120\_A03-en-02.00 Checklist for Quality Process Software  Backup and Archive Plan Template  QPS Criticality Assessment.xls  **Records:** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 61 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Anlauffabrik/Startup Factory)** |
|  | Albus Production Project Plan Operations 11028941 Rev. 00  MTN Kalibrierschein Leakage Current Tester Elabo 300066 2023-03-15  Kalbrierschein TSI Flow Meter 20895 2023-07-26  ESD Training Record Assembly Line Colleage Jonas Spahrbier  ESD Training Record 2022-07-06 ESD-Unterweisung Jonas Spahrbier (TC Manager correctly shows red flag for extinguisehd training; however, employee is planned for next upcoming training 2023-10-13; repeated training).  Global\_Qality\_Process\_Software\_List.xls (ongoing)  QPS 219 RI04 Complete ValidationReport for Update of SAP from SAP R/3 to S/4HANA  Software Specification QPS\_ID219\_FSP\_Aenderung Langtext und BZW\_2.0  Risk analysis and Validation Plan QPS\_ID219\_RA\_Aenderung Langtext und BZW\_2.0  Test Specification QPS\_ID219\_TS\_Aenderung Langtext und BZW\_2.0  Test Report QPS\_ID219\_TR\_Aenderung Langtext und BZW\_2.0  User Trainings CHG0044933\_Conversion from from SAP R/3 to S/4HANA (no Trainings, since no functional Changes) QPS ID019 RI09 Compelete Validation report “Übersichtsreport für Meldungen“ |
| Names and titles of  persons  interviewed | Andreas Plöger (Kostenstellenleiter Anlauffabrik/startup Factory)  Daniel Sell (Projektmanager NPI)  Ulf Hagedorn (scribe) (Head of Integrated Management Systems Audit Management) Tritscher (Systems Engineer)  Reimann (Project Manager)  Yvonne David (Software Validation Officer + Process Owner IT4120)  Michael Blanke (Software Valiation Officer) |
| Products,  components, or projects  reviewed | Albus / Anesthesia |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | |  |  | | --- | --- | | ☒ ☐ | This process is effectively implemented and conforms to requirements.  Actions are needed for this process to conform to requirements. See audit finding list. | |

2.5.9

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 62 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.10 Production and Service Controls - #90464 (Revalstraße / Ambia)

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße/Ambia)** |
| Audit trail  records of | Martin Szepannek |
| Area(s) visited (location, e.g., site visited) | Location # 90464 (Revalstraße)  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Production and Service Controls: Planning of Production and Service Process (MDSAP Chapter 6, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.2.1, 7.5.1 + (DIN)(EN) ISO 9001 - 8.1, 8.2.2, 8.5.1 + MDSAP - Australia - TG(MD)R Sch 1 P1 2, Sch3 P1 Cl1.4(4), Sch3 P1 Cl1.4(5)(d)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1, 2.4, 4.1.2, 4.1.7, 5.1 + MDSAP - Japan - MO169: 26, 27, 40 + MDSAP - USA - 21 CFR 801, 820.30(b), 820.20(a), 820.30(h), 820.70(a), 830 + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2), Annex V (3.2)"  Production and Service Controls: Selection of Production and Service Process(es) (MDSAP Chapter 6, Task 2, Site: 10578  "Production and Service Controls: Infrastructure (MDSAP Chapter 6, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.3, 7.5.1 + (DIN)(EN) ISO 9001 - 7.1.3, 7.5.1, 8.5.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.2, 5.1.5 + MDSAP - Canada - CMDR 14 + MDSAP - Japan - MO169: 6, 24, 40 + MDSAP - USA - 21 CFR 820.70(g), 820.70(f) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Work Environment (MDSAP Chapter 6, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.4 + (DIN)(EN) ISO 9001 - 7.1.4, 7.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 7.2, 8 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.3 + MDSAP - Japan - MO169: 6, 25-1, 25-2; [Old: 6, 25] + MDSAP - USA - 21 CFR 820.70(c), 820.70(d), 820.70(e) + MDR - Annex IX2.2 ¶1; Annex I (11) + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Identification of Processes Subject to Validation (MDSAP Chapter 6, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.1.6, 7.5.6 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 8.4, 8.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 8.2, 8.3; Sch3 P1 1.4(5)(d) + MDSAP - Brazil - RDC ANVISA16/2013: 5.5.2, 5.5.3 + MDSAP - Japan - MO169: 6, 5-6, 45; [Old: 6, 45] + MDSAP - USA - 21 CFR 820.75(a) + MDR - Annex IX 2.2 ¶2 (d); Annex XI 6.2 ¶2, 12"  "Production and Service Controls: Monitoring and Measurement of Product Conformity (MDSAP Chapter 6, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.6 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 8.6, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 58, 59 + MDSAP - USA - 21 CFR 820.70(a), 820.250(a) + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Control, Operation, and Monitoring of the Production and Service Process; Risk Controls (MDSAP Chapter 6, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.5 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 5.1.6, 8.2, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 57 + MDSAP - USA - 21 CFR 820.70(a), 820.75(b), 820.250 + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); "  "Production and Service Controls: Competence of Personnel (MDSAP Chapter 6, Task 12, Site: 10578);  (DIN)(EN) ISO 13485 - 6,2 + (DIN)(EN) ISO 9001 - 7.2, 7.3 + MDSAP - Australia - RDC ANVISA 16/2013: 2.3.2 + MDSAP - Japan - MO169: 22 + MDSAP - USA - 21 CFR 820.25, 820.70(d), 820.75(b) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Control of Monitoring and Measuring Device (MDSAP Chapter 6, Task 13, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.1, 7.6 + (DIN)(EN) ISO 9001 - 7.1.5, 8.5.1 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.5, 5.4 + MDSAP - Japan - MO169: 40, 53 + MDSAP - USA - 21 CFR 820.70(g), 820.72 + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Impact Analysis of Monitoring and Measuring Device Found Out of Specifications (MDSAP Chapter 6, Task 14, Site: 10578); (DIN)(EN) ISO 13485 - 7,6 + (DIN)(EN) ISO 9001 - 7.1.5 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.4 + MDSAP - Japan - MO169: 53 + MDSAP - USA - 21 CFR 820.72(a) + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Device Master File (MDSAP Chapter 6, Task 16, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.1, 7.5.8, 7.5.9.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.5.2 + MDSAP - Australia - TG(MD)R, Sch1 EP13, Sch3 P1 1.4(5) (c),(d),(e) & 1.9 + MDSAP - Brazil - RDC ANVISA 16/2013: 1.2.26, 2.4, 4.2, 5.2, 6.4 + MDSAP - Canada - CMDR 9(2), 21-23, 52-56, 66-68 + MDSAP - Japan - MO169: 6, 7-2, 26, 47, 48; [Old: 6, 26, 47, 48] + MDSAP - USA - 21 CFR 820.65, 820.120(e), 820.181 + MDR - Article 10.4 ¶1 , 10.5, 10.9 ¶3 (b), 10.11, 10.15; Annex IX 2.2 ¶2 (c6); Annex XI 6.1 ② & 12 ¶1 + MDD - Annex II (3.2), Annex VI (3.1)"  "Production and Service Controls: Production Record; Evidence of Compliance of Released Devices (MDSAP Chapter 6, Task 17, Site: 10578); (DIN)(EN) ISO 13485 - 4.2.1, 7.5.1, 7.5.8, 7.5.9.1, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.5.1, 8.5.2, 8.6 + MDSAP - Brazil - RDC ANVISA 16/2013: 3.2, 5.2, 6.4 + MDSAP - Japan - MO169: 6, 40, 47, 48, 58, 59 + MDSAP - USA - 21 CFR 820.120, 820.184 + MDR - Article 10.7, 10.9 ¶3 (h); Annex IX 2.2 ¶2 (c7); Annex XI 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Acceptance Activities (MDSAP Chapter 6, Task 21, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.4.3, 7.5.8, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.4.2, 8.4.3, 8.5.2, 8.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.3.1, 5.3.2, 5.3.3, 5.3.4, 9.2 + MDSAP - Japan - MO169: 6, 39, 47, 58, 59 + MDSAP - USA - 21 CFR 820.80, 820.250(b) + MDR - Article 10.9 ¶3 (m), Annex IX 2.2 ¶2 (b2, e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" "Production and Service Controls: Identification, Control, and Disposition of Nonconforming Products (MDSAP Chapter 6, Task 22, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.8, 8.3 + (DIN)(EN) ISO 9001 - 8.5.2, 8.7 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 6.5.1, 6.5.2 + MDSAP - Japan - MO169: 47, 60-1, 60-2, 60-3, 60-4; [Old: 47, 50, 60] + MDSAP - USA - 21 CFR 820.60, 820.90(a), 820.86, 820.100(a) + MDR - Article 10.9 ¶3 (k), 10.12; Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | AMBIA Medical Supply Units Manufacturing Line  6 Order manager  6 Admin for 2 Lines  14 HC Technische Klärer (Product Engineering)  4 CAD Zeichnerinnen  28 Employees Light, Gas management Systems + Components, Arbeitsplatzkomponenten 94 Employees Supply Units  Pull-Process: Sales defines priorities  3D-Tool Part of the Production processes (input)  Delivery Reliability is crucial, since most deliveries have to align with Hospital (re)building projects.  Medical Supply Units (Production Capacity >10.000 p.a.)  Medical Lighting Systems (Production Capacity >6.000 p.a.)  Gas Supply Units (Production Capacity >200.000 p.a.)  Production Planning Heijunka-Board  Durchlaufzeit pro Ambia ca. 6-20 Std.  Dräger Interservice is internal and external Logistics Servoice Provider (Material Supply and shipping)  Interservice checks Goods to be shipped for completeness, Drägerwerk checks for Conformity/Merkmalsausprägung 3D-Planner ➔ Technische Klärung (regulatory, technische Machbarkeit) ➔ Angebot  PSC-1 Planning of production and service process  Verified that the product realization processes are planned, including any necessary controls, controlled conditions, and risk management activities required for the product to meet the specified or intended uses, the statutory and regulatory requirements related to the product, and (when applicable) unique device identifier requirements.  Confirmed that the planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.  Risk management in production process  Risk assessment Table Ambia 11175385 rev. 01 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 63 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße/Ambia)** |
|  | Hazardous Situation RM-SUS 4178 Contamination of parts in contact to the gas flow during transport, storage, production, installation and service  Risk Control Measures  RCM RM\_SUS\_4869 Production: gas leading hoses must be packed clean and free from impurity, protected against contamination (Hoses Ends must be sealed)  RCM\_SUS\_4910 Production: Gas hoses shall be visibiliy checekd by an incoming inspection  RCM\_SUS\_5417 Production FMEA shall evaluate the risk of soiling hoses or tubes during production.  RCM\_SUS\_5515 Warnig in Service Instructions “Gas and electrical installations may only be carried out by trained service personell; Do not allow any contamination (especially oil, grease, or flammable liquids) into the lines or in the terminal unit.”  United States (FDA):  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00 DEMF SC6440: Labeling DEMF‐SC6440‐de‐00 , Rev. 0  PSC-2 Selection of production and service process(es)  Complete Production has been audited including several processes that directly impact the ability of the device to meet its essential design outputs.  PSC-5 Infrastructure  Verified that the organization has determined and documented the infrastructure requirements to achieve product conformity, including buildings, workspace, process equipment, and supporting services.  Confirmed that buildings, workspaces, and supporting services allow product to meet requirements.  Verified that there are documented and implemented requirements for maintenance of process equipment where important for product quality, and that records of maintenance are maintained.  Brazil (ANVISA):  Verify that manufacturing facilities are configured in order to provide adequate means for people flow.  PSC-6 Work environment  Verified that documented requirements have been established, implemented and maintained for:  - health, cleanliness, and clothing of personnel that could have an adverse effect on  - product quality  - monitoring and controlling work environment conditions that can have an adverse effect on product quality - training or supervision of personnel who are required to work under special environmental conditions - controlling contaminated or potentially contaminated product (including returned products) in order to prevent contamination of other product, the work environment, or personnel  PTS Chapter 1.1.1 Umweltanforderungen:  PTS\_509: 5°-35°  5%-95%  950 - 1060hPa  These conditions are confirmed during Gas Test  Brazil (ANVISA)  No specific Biosafety Standards applicable  PSC-7 Identification of processes subject to validation  Determined if the selected process and sub-process have been reviewed, including any outsourced processes, to determine if validation of these processes is required.  Process Validation Report Production Ambia Aras 11044209 Rev. 0.0  Attachment 01 to Process Validation Report Production Ambia 1200113578 POS 20 EM 2021-08-19  Key Targets of Process Validation have been reached; however, unacceptable PFR (production Failure Rate) has been adressed during Gate 7.0 meeting to be adressed in Product Steering Board. It is also monitored on a daily basis by the Project Engineer and reported weekly into PSB and biweekly into PQB; LCE (Life Cycle Engineering is responsible for further improvement.  Brazil (ANVISA):  Verified that analytical methods, supporting auxiliary systems for production and environmental control that can adversely affect product quality or the quality system are validated, periodically reviewed and, when necessary, revalidated according to documented procedures.  United States (FDA):  Not applicable  PSC-10 Monitoring and measurement of product conformity  Verified that the system for monitoring and measuring of product characteristics is capable of demonstrating the conformity of products to specified requirements.  It could be confirmed that product risk is considered in the type and extent of product monitoring activities.  PSC-11 Control, operation, and monitoring of the production and service process; risk controls  Verifed that the processes used in production and service are appropriately controlled, monitored, operated within specified limits and documented in the product realization records.  In addition, verifed that risk control measures identified by the manufacturer for production processes are implemented, monitored and evaluated.  PSC-12 Competence of personnel |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 64 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße/Ambia)** |
|  | Verified that personnel are competent to implement and maintain the processes in accordance with the requirements identified by the organization.  PSC-13 Control of monitoring and measuring device  Confirmed that the organization has determined the monitoring and measuring devices needed to provide evidence of conformity to specified requirements. Verified that the monitoring and measuring equipment used in production and service control has been identified, adjusted, calibrated and maintained, and capable of producing valid results. Verified that the control of the monitoring and measuring devices is adequate to ensure valid results. Confirmed that monitoring and measuring devices are protected from damage or deterioration.  PSC-14 Impact analysis of monitoring and measuring device found out of specifications  Confirmed that the organization assesses (and records) the validity of previous measurements when equipment is found not to conform to specified requirements, and takes appropriate action on the equipment and any product affected.  Rückmeldebericht RMB417351 2022-08-18: Drehmomentschlüssel 13NM, regg.-Nr. 417351 found out of spec during kcalibration 2022-08-18 (Result: Fail/Pass); Analysis showed, that Product or material approvals are not to be questioned, since Tolerance is higher than measured deviation.  PSC-16 Device master file  Determined that the manufacturer has established and maintained a file for each type of device that includes or refers to the location of device specifications, production process specifications, quality assurance procedures, traceability requirements, and packaging, labeling specifications, and when applicable requirements for installation and servicing. Confirmed that the manufacturer determined the extent of traceability based on the risk posed by the device in the event the device does not meet specified requirements  Australia (TGA):  n/a  Brazil (ANVISA):  Verify that the manufacturer has established and maintains procedures to ensure integrity and to prevent accidental mixing of labels, instructions, and packaging materials.  Confirm that the manufacturer has ensured that labels are designed, printed and, where applicable, applied so that they remain legible and attached to the product during processing, storage, handling and use.  Canada (HC):  Verify that the manufacturer maintains objective evidence that devices meet the safety and effectiveness requirements of the CMDR.  United States (FDA):  Fertigungsauftrag 62730484 2023-09-11 /2023-09-20  Herstellprotokoll 62730484 2023-09-21, SN ASSJ-0476  Fertigungsauftrag 62730492 2023-09-12 /2023-09-20  Herstellprotokoll 62730492 2023-09-21, SN ASSJ-0484  PSC17 Production record; evidence of compliance of released devices  Determined if the manufacturer has established and maintained a record of the amount manufactured and approved for distribution for each batch of medical devices, the record is verified and approved, the device is manufactured according to the file referenced in task 16, and the requirements for product release were met and documented.  Order Confirmation Kundenauftrag 1200338274 2023-09-01, Customer Dräger Nederland B.V.  - Fertigungsauftrag 62730484 2023-09-11 /2023-09-20  - Herstellprotokoll 62730484 2023-09-21, SN ASSJ-0476  - Fertigungsauftrag 62730492 2023-09-12 /2023-09-20  - Herstellprotokoll 62730492 2023-09-21, SN ASSJ-0484  Brazil (ANVISA):  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00  United States (FDA):  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00  PSC-21 Acceptance activities  Verified that acceptance activities assure conformity with specifications and are documented. Confirmed that the extent of acceptance activities i s commensurate with the risk posed by the device.  Brazil (ANVISA):  DEMF PQ8050 : Statistical Techniques DEMF PQ8050‐en\_de‐00.00 , Rev. 00.00  United States (FDA):  DEMF PQ8050 : Statistical Techniques DEMF PQ8050‐en\_de‐00.00 , Rev. 00.00  PSC-22 Identification, control, and disposition of nonconforming products  Verifed that the identification, control, and disposition of nonconforming products is adequate, based on the risk the nonconformity poses to the device meeting its specified requirements. |
| Reviewed  documents | DEMF SE4300 : Factory Services DEMF SE4300‐en‐01.00 , Rev. 01.00  DEMF SC6700 : Handhabung elektrostatisch gefährdeter Bauteile (ESD) DEMF‐SC6700‐de‐00.01 , Rev. 00.01 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 65 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße/Ambia)** |
| and records (identification and revision) | DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00 DEMF SC6440: Labeling DEMF‐SC6440‐de‐00 , Rev. 0  DEMF GM2150 : Traceability of products and components DEMF GM2150‐en\_de‐03.00 , Rev. 03.00  DEMF SC6110 : Behandlung von Abweichungen in der Produktion DEMF‐SC6110‐de‐00.00 , Rev. 00.00  DEMF SC6120 : Qualitätskennzahlen in der Produktion DEMF‐SC6120‐de‐00.00 , Rev. 00.00  DEMF SC6130 : Produktionsstopp und Lieferstopp DEMF‐SC6130‐de‐00.00 , Rev. 00.00  DEMF SC6200 : Produktherstellung DEMF SC6200‐de‐02 , Rev. 2  DEMF SC6500 : Dokumentation von Produktionsprozessen DEMF SC6500‐de‐00 , Rev. 0  DEMF SC6720 : Schutz vor elektromagnetischen Einflüssen in der Produktion DEMF SC6720‐de‐00 , Rev. 0  DWAG IN4203 : Product Verification DWAG IN4203‐en‐02.00 , Rev. 02.00  DWAG OF5213 : Produktverpackung DWAG‐OF5213‐de‐01 , Rev. 1  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐03.00 , Rev. 03.00  Records  FMEA Schneiden von Schläuchen und Kabeln 11206117 2022-09-14, Pkt. 2.18 Verschließend von Schläuchen mit Endkappen  „Grundlegende Sicherheitshinweise“ in Service Connect 1.10 „Umgag mit Sauerstoff und Lachgas“ Overview of all FMEAs is kept in PLM Aras  BU Work Place Infrastructure OPS Overview PPT  Detail Layout House 10 EG  Organisation Structure 2023-09-01  PRRC Marcus Vorwerk (Product Specific Responsibilities)  Tätigkeitsbeschreibung PRRC Vorwerk\_Marcus-01\_2020.pdf  Table of Content Sted File 11173409 rev. 04  Product Risk Management Report 111044055 Rev. 09  DOC Ambia MDR103-029-2304-002-0 2023-04-27 Rev04  Product Test Specification Ambia PTS Electric Components GG53280 Rev.01  Marvin Möller, Unterweisung am Arbeitsplatz „Prozessablauf Endmontage“, z.B. 2022-03-02 Uwe Golla, Unterweisung am Arbeitsplatz „Prozessablauf Gas- und Elektroprüfung“, z.B. 2022-02-18 René Groß, Unterweisung am Arbeitsplatz „Armsysteme“, z.B. 2021-08-18  MIMs-Data Base as used and audited in Moislinger Allee  MIMS Druckmessgerät 405821, nextCal 2024-11  Kalibrierschein Dichtprüfgerät Bremse 405821\_20221104\_WKSPErev00  Order Confirmation Kundenauftrag 1200338274 2023-09-01, Customer Dräger Nederland B.V.  Fertigungsauftrag 62730484 2023-09-11 /2023-09-20  Herstellprotokoll 62730484 2023-09-21, SN ASSJ-0476  Fertigungsauftrag 62730492 2023-09-12 /2023-09-20  Herstellprotokoll 62730492 2023-09-21, SN ASSJ-0484  IFU Supplement 9052924 Ed. 3 |
| Names and titles of  persons  interviewed | Marcus Vorwerk (Head of Q&RA sowie Purchasing WPI)  Sönke Behrens (PQM für MSS)  Benjamin Krüger (Quality Engineer)  Joachim Rochel (Director Operations BU WPI)  Markus Hielscher (Quality System Manager Auditing)  Alexej Agibalow (Regulatory Affairs)  Tim Sennholz (Risk Manager)  Matthias Brauer (Industrial Engineer)  Bastian Stender (Technical Product Manager)  Tim Sennholz (remote) (Risk Manager)  Heiko Senz (Project Management Operations Business Unit Workplace Infrastructure") David Binder (Scribe) (Product Quality WPI)  Marvin Müller (Gerätemonteur) |
| Products,  components, or projects  reviewed | AMBIA |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | |  |  | | --- | --- | | ☒ ☐ | This process is effectively implemented and conforms to requirements.  Actions are needed for this process to conform to requirements. See audit finding list. | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 66 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.11 Production and Service Controls - #90464 (Revalstraße / Central Supply Hoses)

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / Central Supply Hoses)** |
| Audit trail  records of | Martin Szepannek |
| Area(s) visited (location, e.g., site visited) | Location # 90464 (Revalstraße)  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Production and Service Controls: Planning of Production and Service Process (MDSAP Chapter 6, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.2.1, 7.5.1 + (DIN)(EN) ISO 9001 - 8.1, 8.2.2, 8.5.1 + MDSAP - Australia - TG(MD)R Sch 1 P1 2, Sch3 P1 Cl1.4(4), Sch3 P1 Cl1.4(5)(d)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1, 2.4, 4.1.2, 4.1.7, 5.1 + MDSAP - Japan - MO169: 26, 27, 40 + MDSAP - USA - 21 CFR 801, 820.30(b), 820.20(a), 820.30(h), 820.70(a), 830 + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2), Annex V (3.2)"  Production and Service Controls: Selection of Production and Service Process(es) (MDSAP Chapter 6, Task 2, Site: 10578  "Production and Service Controls: Infrastructure (MDSAP Chapter 6, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.3, 7.5.1 + (DIN)(EN) ISO 9001 - 7.1.3, 7.5.1, 8.5.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.2, 5.1.5 + MDSAP - Canada - CMDR 14 + MDSAP - Japan - MO169: 6, 24, 40 + MDSAP - USA - 21 CFR 820.70(g), 820.70(f) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Work Environment (MDSAP Chapter 6, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.4 + (DIN)(EN) ISO 9001 - 7.1.4, 7.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 7.2, 8 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.3 + MDSAP - Japan - MO169: 6, 25-1, 25-2; [Old: 6, 25] + MDSAP - USA - 21 CFR 820.70(c), 820.70(d), 820.70(e) + MDR - Annex IX2.2 ¶1; Annex I (11) + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Identification of Processes Subject to Validation (MDSAP Chapter 6, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.1.6, 7.5.6 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 8.4, 8.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 8.2, 8.3; Sch3 P1 1.4(5)(d) + MDSAP - Brazil - RDC ANVISA16/2013: 5.5.2, 5.5.3 + MDSAP - Japan - MO169: 6, 5-6, 45; [Old: 6, 45] + MDSAP - USA - 21 CFR 820.75(a) + MDR - Annex IX 2.2 ¶2 (d); Annex XI 6.2 ¶2, 12"  "Production and Service Controls: Monitoring and Measurement of Product Conformity (MDSAP Chapter 6, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.6 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 8.6, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 58, 59 + MDSAP - USA - 21 CFR 820.70(a), 820.250(a) + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Control, Operation, and Monitoring of the Production and Service Process; Risk Controls (MDSAP Chapter 6, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.5 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 5.1.6, 8.2, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 57 + MDSAP - USA - 21 CFR 820.70(a), 820.75(b), 820.250 + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); "  "Production and Service Controls: Competence of Personnel (MDSAP Chapter 6, Task 12, Site: 10578);  (DIN)(EN) ISO 13485 - 6,2 + (DIN)(EN) ISO 9001 - 7.2, 7.3 + MDSAP - Australia - RDC ANVISA 16/2013: 2.3.2 + MDSAP - Japan - MO169: 22 + MDSAP - USA - 21 CFR 820.25, 820.70(d), 820.75(b) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Control of Monitoring and Measuring Device (MDSAP Chapter 6, Task 13, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.1, 7.6 + (DIN)(EN) ISO 9001 - 7.1.5, 8.5.1 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.5, 5.4 + MDSAP - Japan - MO169: 40, 53 + MDSAP - USA - 21 CFR 820.70(g), 820.72 + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Impact Analysis of Monitoring and Measuring Device Found Out of Specifications (MDSAP Chapter 6, Task 14, Site: 10578); (DIN)(EN) ISO 13485 - 7,6 + (DIN)(EN) ISO 9001 - 7.1.5 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.4 + MDSAP - Japan - MO169: 53 + MDSAP - USA - 21 CFR 820.72(a) + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Device Master File (MDSAP Chapter 6, Task 16, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.1, 7.5.8, 7.5.9.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.5.2 + MDSAP - Australia - TG(MD)R, Sch1 EP13, Sch3 P1 1.4(5) (c),(d),(e) & 1.9 + MDSAP - Brazil - RDC ANVISA 16/2013: 1.2.26, 2.4, 4.2, 5.2, 6.4 + MDSAP - Canada - CMDR 9(2), 21-23, 52-56, 66-68 + MDSAP - Japan - MO169: 6, 7-2, 26, 47, 48; [Old: 6, 26, 47, 48] + MDSAP - USA - 21 CFR 820.65, 820.120(e), 820.181 + MDR - Article 10.4 ¶1 , 10.5, 10.9 ¶3 (b), 10.11, 10.15; Annex IX 2.2 ¶2 (c6); Annex XI 6.1 ② & 12 ¶1 + MDD - Annex II (3.2), Annex VI (3.1)"  "Production and Service Controls: Production Record; Evidence of Compliance of Released Devices (MDSAP Chapter 6, Task 17, Site: 10578); (DIN)(EN) ISO 13485 - 4.2.1, 7.5.1, 7.5.8, 7.5.9.1, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.5.1, 8.5.2, 8.6 + MDSAP - Brazil - RDC ANVISA 16/2013: 3.2, 5.2, 6.4 + MDSAP - Japan - MO169: 6, 40, 47, 48, 58, 59 + MDSAP - USA - 21 CFR 820.120, 820.184 + MDR - Article 10.7, 10.9 ¶3 (h); Annex IX 2.2 ¶2 (c7); Annex XI 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Acceptance Activities (MDSAP Chapter 6, Task 21, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.4.3, 7.5.8, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.4.2, 8.4.3, 8.5.2, 8.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.3.1, 5.3.2, 5.3.3, 5.3.4, 9.2 + MDSAP - Japan - MO169: 6, 39, 47, 58, 59 + MDSAP - USA - 21 CFR 820.80, 820.250(b) + MDR - Article 10.9 ¶3 (m), Annex IX 2.2 ¶2 (b2, e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" "Production and Service Controls: Identification, Control, and Disposition of Nonconforming Products (MDSAP Chapter 6, Task 22, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.8, 8.3 + (DIN)(EN) ISO 9001 - 8.5.2, 8.7 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 6.5.1, 6.5.2 + MDSAP - Japan - MO169: 47, 60-1, 60-2, 60-3, 60-4; [Old: 47, 50, 60] + MDSAP - USA - 21 CFR 820.60, 820.90(a), 820.86, 820.100(a) + MDR - Article 10.9 ¶3 (k), 10.12; Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | 21 Employees in Production for Kits and accessories  BU Therapy as Manufacturer within DRÄGER Medical  BU HCA as marketing organisation  PSC-1 Planning of production and service process  Verified that the product realization processes are planned, including any necessary controls, controlled conditions, and risk management activities required for the product to meet the specified or intended uses, the statutory and regulatory requirements related to the product, and (when applicable) unique device identifier requirements.  Confirmed that the planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.  Risk management in production process  United States (FDA):  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00 DEMF SC6440: Labeling DEMF‐SC6440‐de‐00 , Rev. 0  PSC-2 Selection of production and service process(es)  Complete Production has been audited including several processes that directly impact the ability of the device to meet its essential design outputs.  PSC-5 Infrastructure  Verified that the organization has determined and documented the infrastructure requirements to achieve product conformity, including buildings, workspace, process equipment, and supporting services.  Confirmed that buildings, workspaces, and supporting services allow product to meet requirements.  Verified that there are documented and implemented requirements for maintenance of process equipment where important for product quality, and that records of maintenance are maintained.  Brazil (ANVISA): |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 67 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / Central Supply Hoses)** |
|  | Verify that manufacturing facilities are configured in order to provide adequate means for people flow.  PSC-6 Work environment  Verified that documented requirements have been established, implemented and maintained for:  - health, cleanliness, and clothing of personnel that could have an adverse effect on  - product quality  - monitoring and controlling work environment conditions that can have an adverse effect on product quality - training or supervision of personnel who are required to work under special environmental conditions - controlling contaminated or potentially contaminated product (including returned products) in order to prevent contamination of other product, the work environment, or personnel  Brazil (ANVISA)  No specific Biosafety Standards applicable  PSC-7 Identification of processes subject to validation  Determined if the selected process and sub-process have been reviewed, including any outsourced processes, to determine if validation of these processes is required.  Brazil (ANVISA):  Verified that analytical methods, supporting auxiliary systems for production and environmental control that can adversely affect product quality or the quality system are validated, periodically reviewed and, when necessary, revalidated according to documented procedures.  United States (FDA):  Not applicable  PSC-10 Monitoring and measurement of product conformity  Verified that the system for monitoring and measuring of product characteristics is capable of demonstrating the conformity of products to specified requirements.  It could be confirmed that product risk is considered in the type and extent of product monitoring activities.  Raumedic Gas Supply Hose Air 200m 5000782 (no Caps)  14bar-Test Formblatt Weekly Prüfanweisung/Prüfplan 8608533 2016-10-13  Filled Form Weekly 14bar-Test Prüfplan for Hose Sample M36011 3m 2023-09-18 Defines a weekly 14bar test, however, test equipment is neither specified nor recorded.  Measurement-/Test Equipment not documented in record - see Findings List internal Calibration  FMEA/Risk nalysis  CS Hoses Risik asessemnt V2.3 2023-07-04  Production Risk Control measure: CS\_RM-566 The product shall be delivered Clean but not sterile  CS-TSR-432 The Product shall not have a level of hydrocarbon greater than 550mg/spm and be free from particles acc.  To ISO15001  Verification report CS\_TRS\_156\_TR3  Test report 14-00128-PR-004 rev. 0 ➔ Test Result: Particle measureent, Oils Content, Ignition temperature passed.  PSC-11 Control, operation, and monitoring of the production and service process; risk controls  Verifed that the processes used in production and service are appropriately controlled, monitored, operated within specified limits and documented in the product realization records.  In addition, verifed that risk control measures identified by the manufacturer for production processes are implemented, monitored and evaluated.  PSC-12 Competence of personnel  Verified that personnel are competent to implement and maintain the processes in accordance with the requirements identified by the organization.  PSC-13 Control of monitoring and measuring device  Confirmed that the organization has determined the monitoring and measuring devices needed to provide evidence of conformity to specified requirements. Verified that the monitoring and measuring equipment used in production and service control has been identified, adjusted, calibrated and maintained, and capable of producing valid results. Verified that the control of the monitoring and measuring devices is adequate to ensure valid results. Confirmed that monitoring and measuring devices are protected from damage or deterioration.  PSC-14 Impact analysis of monitoring and measuring device found out of specifications  Confirmed that the organization assesses (and records) the validity of previous measurements when equipment is found not to conform to specified requirements, and takes appropriate action on the equipment and any product affected.  PSC-16 Device master file  Determined that the manufacturer has established and maintained a file for each type of device that includes or refers to the location of device specifications, production process specifications, quality assurance procedures, traceability requirements, and packaging, labeling specifications, and when applicable requirements for installation and servicing. Confirmed that the manufacturer determined the extent of traceability based on the risk posed by the device in the event the device does not meet specified requirements  Australia (TGA):  n/a |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 68 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / Central Supply Hoses)** |
|  | Brazil (ANVISA):  Verify that the manufacturer has established and maintains procedures to ensure integrity and to prevent accidental mixing of labels, instructions, and packaging materials.  Confirm that the manufacturer has ensured that labels are designed, printed and, where applicable, applied so that they remain legible and attached to the product during processing, storage, handling and use.  Canada (HC):  Verify that the manufacturer maintains objective evidence that devices meet the safety and effectiveness requirements of the CMDR.  PSC17 Production record; evidence of compliance of released devices  Determined if the manufacturer has established and maintained a record of the amount manufactured and approved for distribution for each batch of medical devices, the record is verified and approved, the device is manufactured according to the file referenced in task 16, and the requirements for product release were met and documented.  Brazil (ANVISA):  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00  United States (FDA):  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00  PSC-21 Acceptance activities  Verified that acceptance activities assure conformity with specifications and are documented. Confirmed that the extent of acceptance activities i s commensurate with the risk posed by the device.  Brazil (ANVISA):  DEMF PQ8050 : Statistical Techniques DEMF PQ8050‐en\_de‐00.00 , Rev. 00.00  United States (FDA):  DEMF PQ8050 : Statistical Techniques DEMF PQ8050‐en\_de‐00.00 , Rev. 00.00  PSC-22 Identification, control, and disposition of nonconforming products |
| Reviewed  documents  and records (identification and revision) | DEMF SE4300 : Factory Services DEMF SE4300‐en‐01.00 , Rev. 01.00  DWAG PQ2140 : International Labeling Requirements ‐ for Medical Devices DWAG PQ2140‐en‐04.00 , Rev. 04.00 DEMF SC6440: Labeling DEMF‐SC6440‐de‐00 , Rev. 0  DEMF GM2150 : Traceability of products and components DEMF GM2150‐en\_de‐03.00 , Rev. 03.00  DEMF SC6110 : Behandlung von Abweichungen in der Produktion DEMF‐SC6110‐de‐00.00 , Rev. 00.00  DEMF SC6120 : Qualitätskennzahlen in der Produktion DEMF‐SC6120‐de‐00.00 , Rev. 00.00 DEMF SC6130 : Produktionsstopp und Lieferstopp DEMF‐SC6130‐de‐00.00 , Rev. 00.00  DEMF SC6200 : Produktherstellung DEMF SC6200‐de‐02 , Rev. 2  DEMF SC6500 : Dokumentation von Produktionsprozessen DEMF SC6500‐de‐00 , Rev. 0  DWAG OF5213 : Produktverpackung DWAG‐OF5213‐de‐01 , Rev. 1  DWAG PQ2110 : Regulatory Approval to Market Product DWAG PQ2110‐en‐03.00 , Rev. 03.00  Records:  Raumedic Gas Supply Hose Air 200m 5000782 (no Caps)  14bar-Test Formblatt Weekly Prüfanweisung/Prüfplan 8608533 2016-10-13  Filled Form Weekly 14bar-Test Prüfplan for Hose Sample M36011 3m 2023-09-18  PTS 8608533 ZV-Schläuche Rev. 03  Hardcopy IFU 9053929 Ed. 6 2021-02 in Production  Lagerzugangsschein zu Fertigungsauftrag 65580704  Wartungsprotokoll der Produktlinie ZV-Schläuche 2023 (hardcopy record template signed 2022-12-22, filled) Weekly measurement length angles table week 38  Calibration Certificate MIMS 412258/3808 FC0750 Leak Detector nextCal 2024-09 412258\_20230915\_WKSPErev00 internal Calibration  03\_1801\_MB01593\_Kalibrieranforderungen MB01593  Kalibrierprotokoll MIMS Grenzlehre 4222340 ID 331773/2023-09-14 MTN Calibation Services, including assessment of Calibration Certificate and signature (2023-09-19) gemäß Calibration Routine KA MB01593 Rev. 02 from2019-09-10  Non-conforming Product example  3 Examples 08/2023 09/2023  Fertigungsbegleitende Qualitätsmeldungen  810000410409 (for 5002096, Winkelstecker, Oberfläche beschädigt), with refernce to Fertigungsauftrag (65557194, M36011; Air-ZV-Schlauch)  810000412481 (for 2002085 Stecker, kauttes Gewinde) with refernce to Fertigungsauftrag (65357, M36020 Air-ZV-Schlauch)  810000412456 (for M36772 Aufkleber verklebt, unansehnlich)) with refernce to Fertigungsauftrag (65565331, M36026, Air-ZV-Schlauch)  FMEA/Risk nalysis |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 69 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / Central Supply Hoses)** |
|  | CS Hoses Risik asessemnt V2.3 2023-07-04  Production Risk Control measure: CS\_RM-566 The product shall be delivered Clean but not sterile  CS-TSR-432 The Product shall not have a level of hydrocarbon greater than 550mg/spm and be free from particles acc.  To ISO15001  Verification report CS\_TRS\_156\_TR3  Test report 14-00128-PR-004 rev. 0 Test Result: Particle measureent, Oils Content, Ignition temperature passed. |
| Names and titles of  persons  interviewed | Dirk Geisteier (Head of Production Line Respiratory Care/ Warming Therapy)  Frank Wehde (Teamleiter Monitoring & IT, Kits and Accessories)  Hannes Fabig (Quality Engineer - BU Therapy)  Andreas Maresch (Industrial Engineer / Pre-installation Manager Monitoring & IT, Kits and Accessories) Alexandre Barette (Product Quality Manager)  Jochen Meyn (Quality Manager Operations - BU Therapy)  Alexander Kühn (Industrial Engineer)  Andre Möller (Quality Engineer)  Tony Vertein (Toby Vertein Entw. OPT)  Axel Bürger (Industrial Engineer)  Markus Hielscher (scribe) (Quality System Manager Auditing) |
| Products,  components, or projects  reviewed | Central Supply Hoses |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | ☒Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 70 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.12 Production and Service Controls - #10578 (Moislinger Allee / Service Center)

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center)** |
| Audit trail  records of | Honorata Donnermaier |
| Area(s) visited (location, e.g., site visited) | Location **#10578 (Moislinger Allee)**  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | MDSAP Tasks: #1-3, #5-7, #9, #18, #19-20, #24-#26, #28-#29  ISO 13485:2016, 7.5  ISO 9001  MDR PRODUCTION AND  PROCESS CONTROLS Annex  IX.2.2d) & e), XI.6.2 |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | SC1 - Planning of production and service process  ///Service Centre - Moislinger Allee/// (HD)  Global Service Centre Lübeck is responsible for performing repairs on the devices, approx. 65 employees in the Service Centre in Lübeck are working of Medical Devices. There are three groups, dosage & Sensors, Intensive Care &WPI and Spare Parts. Last year approx. 9200 orders regarding medical devices were received.  The activities that are performed in the service center include: - Maintenance.  - Repair.  - Investigation.  - Calibration.  - Upgrade.  The service orders planning is done via SAP, each construction group has a specific target date for repairs. The order is assigned to technicians based on availability. The principle of first come first serve is applied. This planning process was demonstrated in SAP during the audit (Workplace/ capacities/ formula constant).  Service process is monitored and reported on monthly base including service KPIs. The one of the top devices by services are M540 patient monitor and Vapor 2000 anesthetic evaporates.  Logistic center C45 and IS4 inbound, outbound, storage, packaging (HD)  For the warehouse following applicable processes were identified: preservation, traceability, incoming inspection and infrastructure including Pest control. Those processes are established and implemented.  US  The organisation applies UDI identifier and Serial number / Batch number to all devices.  PSC 2 - Selection of production and service process(es)  ///Service Centre - Moislinger Allee/// (HD)  The service process was selected to audit. The criticality of the process is considered as the part pf the process is outsource to the external supplier. The initial cleaning and disinfection of the devices sent for service are outsourced. The service order of Perseus A500 class IIb ( Prüfkarte 308450914) was selected.  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD)   Logistics centrum / warehouse - the area included the material supply, Incoming inspection area, vertical automated storage / Commissioning of the parts and components for all production lines.  NLZ – material warehouse / commissioning for production.  ES4 – distribution centrum ES4  PSC 3 - Controls for the implementation of selected production and service process(es) Logistic center C45 and S4 inbound, outbound, storage, packaging (HD)  It has been verified by the auditor that logistic process follows defined procedures and SOPs.  PSC 4 - ///Service Centre - Moislinger Allee/// (HD)  There are no specific requirements for the cleanliness in the repair centre. The general hygiene plan PQ 8830 is applicable.  The most important standard for repair centre infrastructure is an ESD procedure, this applies to all areas in which the electrostatically sensitive components, assemblies or product are unprotected.  Brazil:  Pest control in B 23 will be done on a monthly base from external supplier Bockholdt. Last report have been audited.  PSC 5 - Infrastructure  ///Service Center - Moislinger Alee/// (HD)  Requirements for ESD were taken as an example in the Service Center. The maintenance of the workplaces is done based on a documented procedure. There is a regular monitoring of the values in the workstations, if there are some deficiencies found, measures should be taken. As demonstrated for the workplace MAZ 3OG.  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 71 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center)** |
|  | The process is defined according to SOP DEMF SC6330 Instandhaltung und Reinigung.  Cleaning is performed on the regular basis by external supplier. During the audit in the warehouse / logistics it was observed that all structures are very clean. There are no areas sensitive to cleaning impact and no areas with special requirements for cleanliness.  It was verified that the pest traps are in pace in indicated on the Pest control plan (Traps 77 and 78 opposite to the commissioning area), the fly traps are located near large goods doors. Pest control is outsourced to An Bockholdt a service agreement is in place. The plan and protocol were demonstrated during the audit ref to document at records section.  Temperature and humidity are monitored, and records are provided on monthly base. There are 4 temperature sensors installed west, east, south and north.  Additional country-specific requirements:  Brazil  The facility is configured in order to provide adequate means for people flow and enough space for the manufacturing activities to be performed. Work spaces are identified and provided with the necessary tools for the production step to be performed. Confirmed by observation during the audit  Service facilities are configured in order to provide adequate means for people flow and enough space for correct development of the activities.  PSC6 - Work environment conditions; training or supervision of personnel (HD)  It exists a “Reinigingsplan” for B23 with concrete advice for the external personnel. The cleaning will be documented from external company in a table. The cleaning results as well as the documentation will be checked and confirmed regularly by responsible leader of production.  Futhermore it is defined to control particles according to class 9. There are 35 measure points and a limit of 1 Mio part is defined. The measurement will be done every 3 month.  Brazil:  See description above no further requirements defined and needed  Control of production and service provision (7.5.1)  PSC7/PSC8 - Validation of processes (HD)  no validation for process in service area.  Australia / USA / Brazil:  No sterilization,molding no welding or gluing process applicable.  PSC 9 - Validation of sterilization process (HD)  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD)  According to the information from Head of Production supply there are no materials delivered in sterile conditions.  PSC 10 - Monitoring and measurement of product conformity (HD)  Product conformity is monitored and measeured during in process controls. Test methods, test plan and test records were available, verified by the etiquette documentation.  PSC 11 - Control, operation, and monitoring of the production and service process; risk controls ///Service Center - Moislinger Alee/// (HD)  Service activities are documented in SAP and accompanied from test protocols which are link to the order.  Australia  Risk control measures exist, see risk management.  PSC12 - Personnel competence (GM)  It have been verified with samples that personnel in service center and audited production area are competent to implement and maintain the processes in accordance with the requirements identified by the medical device organization.  ///Service Center - Moislinger Alee///  Roles working in Service center is mainly “ Service Mitarbeiter”  Furthermore, employees in service center are dedicated to device types and will be trained accordingly. Two employees in Service Center are technicians for ATLAN devices.  One sample have been audited.  PSC13 - Monitoring and measuring devices needed (GM)  The organization has determined the monitoring and measuring devices needed to provide evidence of conformity to specified requirements. Devices are listed in MIMS System.  The monitoring and measuring equipment used in production and service control has been identified, adjusted, calibrated and maintained, and is capable of producing valid results. For verification several samples in Service enter and ATLAN production have been audited.  Calibration of measurement equipment is performed in specific intervals (usually once a year or after 18 months) Calibration is currently done by “Kalibrierlabor Revalstr.” which counts as provider. In some cases devices can be caibrated with other external partners (e.g. Testo)  All measuring devices are listed and controlled in MIMS with ID-number, last calibration date, next calibration date, calibration evidence. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 72 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center)** |
|  | Responsible persons in Service Center Moislinger Allee and production get once a month an email with status of devices for notification of devices that must be calibrated.  Futhermore, each employee of service center is responsible to check calibration status of used devices which is labeled on each device.  Calibration certificates are stored and maintained in MIMS  Devices are marked with an ID number and the date of the next calibration.  Audited Examples :  ///Moislinger Allee – “Service center”///  Secu Life PS 300 Patienten Simulator MIMS 302658 (Prüfplatz 107) Tempstecker 37.0 Grad Inventarnummer 302658  PSC14 - Monitoring and measuring devices validity of previous measurements in case of non- confirming measurement devices (GM)  The organization assesses (and records) the validity of previous measurements when equipment is found not to conform to specified requirements, and takes appropriate action on the equipment and any product affected.  The control of the monitoring and measuring devices is adequate to ensure valid results.  Every device which is processed in “Service Center Moislinger Allee” will be listed in SAP system with incoming date. In SAP the device will be linked to a dedicated work place with ID. Every workspace has a list of measurement equipment used unique at this place.  In production all used test equipment will be documented in every test protocol in SAP. It will be possible to trace back every used device with related time-period and related concrete tests and test results. The status of measurement-device at time of usage can be traced back in MIMS.  Monitoring and measuring devices are protected from damage or deterioration e.g. via limited access to the “Service Center building Moisslinger Allee” and producstion and the floor where the devices are in usage. Every employee is teached in handling of the measurement equipment.  No such event occurred so far.  Samples for audited Mesurement equipment with rekated status which have bee checked at workplaces and in MIMS find under PSC 13.  PSC15 - Validation of software used in production (GM)  In production are parts of SAP in usage. Whole SAP tool with all used modules are validated from SW validation officers ( see also docu Pavlov).  Main used SAP Modul in productionis: PLESS validation protocol have been audited  Furthermore some teststations with SW are in use. Here the whole test sttion will be validated.  One sample have been audited.  PSC16 - Product file (HD)  ///Service Center - Moislinger Alee/// (HD)  Technical documentation for medical device was reviewed during this audit, including risk management process, labelling, specification, Standard List, Biocompatibility Testing, etc. During design and development the design change review takes place. Please see also correspnding tasks of Design and Development chapter.  PSC 17 - Production record; evidence of compliance of released devices  ///Service Center - Moislinger Alee/// (HD)  The cleaning of the devices in that are received in the workshop is done by Dräger Interservice GmbH. the employees of the Service Center (sales) receive the devices and assigns them an identifier based on the Serial and Material number as well as the customer documents that are sent together with the device.  The Service order will be set in SAP, the description of the service, for the Interservice employees and the service technicians to be able to start the failure diagnosis.  The traceability of the whole process is ensured via SAP system. The service devices are registered and each service step is documented in SAP based on the service need e.g. code 1150 received in der service center, 1690 service start in repair center, 1700 end of service, ready to send 4000 etc. The device status in repair center is traceable at any time also service and spare parts provided are visible to the client via SAP documentation.  The Service Connect tool (www.serviceconnect. dreager.com) will be used for the compilation of the whole service strategies of the devices, including diagrams and parts list. Maintenance documents which are used for factory services can be found on the Share Point. The service process is documented and released via SAP.  Brazil and US requirements are full filled, the example above.  PSC 18 - Traceability applied to life-supporting or life-sustaining medical devices  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD)  The process is defined each working step is documented in SAP system. All materials delivered are registered in the system with incoming good receipt. The status of the goods such as quality inspection, blocked, P01 pellets stock, P03 block stock can be checked via SAP. The back traceability for delivered orders was verified during the audit see the records.  Additional country-specific requirements:  CANADA / US  NA, no implantable devices in scope  PSC 19 - Identification of product status  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 73 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center)** |
|  | All products in outbound logistic center are clearly identified with labeling with the following minimum information: Part Number, Revision, Lot or serial number, expiration date where applicable and acceptance status.  Particular examples assessed.  Order No 1200353210 pos 10 Atlan 300 XL, delivery to Mexico Delivery documents includes unpacking instructions.  The evidence for incoming inspection could be reviewed during the audit. The requirements document in the inspections test plan (In SAP), inspection record for the sampled part was available. The QS inspector can mark the status of incoming goods in SAP as e.g.: F1 release without defect, F4 release with rework, R – rejection, KI– needs clarification.  AB 4900062419 / WE 6009269331 and AB 4900059225/ Name 60009238477 (blocked material) – The sample size for QS inspection is defined in SAP, Incoming inspection plan is saved by each material in SAP.  PSC 20 - Customer property  ///Service Center - Moislinger Alee/// (HD)  Customer Property is identified as such with red label when received. The reception of devices from customer is managed using the service and maintenance procedure. All service orders are entered in SAP and received SAP unique service order No.  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD)  No examples of customer property were observed in the warehouse and logistic center during the audit.  PSC 21:  Test plans and escalation schemes for in process controls, final inspection and final release are defined.  PSC 22 - Identification, control, and disposition of nonconforming products  ///Service Center - Moislinger Alee/// (HD)  The identification, control, and disposition of nonconforming products in the service center is adequate. In case the device cannot be repaired it is marked in SAP with code 1750 end of service / scrap +new.  PSC 23 - no rework  PSC 24 - Preserving the conformity of product during internal processing, storage,  Logistic center C45 and S4 inbound, outbound, storage, packaging (HD)  The preservation limited with temperature and humidity levels defined for some areas of the warehouse.  All products are initially packed at the end of production lines and transported to the Outbound logistic center were they are labeled with delivery documents/ Unpacking instructions and any additional required information. The packaging specification is deposited in material master data in SAP.  PSC 25 - Review of customer requirements, distribution records //Service Center - Moislinger Alee/// (HD)  See Task PSC-1+17  A process to ensure a traceability is established. 0800-GWI-000104[0], Product Block Procedure (from 30-March-2018) was reviewed.  Traceability of two distribution records in ERP System were reviewed. Distribution record: Ref. Service Order No 308574490.  Distribution record: Ref. Order No 2221460420 LS 0175998557.  Distribution record: Ref. Order No 213121773 LS 0175999693. Traceability to end customer for both distribution records was given.  Additional country-specific requirements:  BRA, USA, CAN, EU (Distribution records including name and address of consignee, quantity of products, date of dispatch and numerical control used for traceability): Manufacturer use an ERP System for distribution records, all required information are available.  PSC 26 - installation activities  ///Service Center - Moislinger Alee/// (HD)  Not applicable for service center.  Logistic ( HD)  Not applicable for logistic center the installation take place onsite by customer.  PSC 27 - Servicing activities  ///Service Center - Moislinger Alee/// (HD)  See Task PSC-1+17  Servicing activities are conducted and documented in accordance with defined and implemented instructions and procedures. Service records are used as a source of quality data in the Measurement, Analysis and Improvement process.  (Brazil, US) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 74 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center)** |
|  | Records of servicing activities are kept with the following information: the product serviced; the control number of product serviced; the date of completion of service; identification of the service provider; description of service performed; and results of inspections and tests performed.  Trends of service activities are evaluated during regular meetings, which allows to identify trends.  (US)  Service reports are evaluated to determine if the event should be reported  PSC 28 - Risk controls applied to transport, installation, and servicing Logistic center C45 and S4 inbound, outbound, storage, packaging (HD) There are not installation and servicing activities in logistic center.  For risk controls applied to transport are defined for the product during design & development process and are part of the technical documentation. The Dräger Interservice GmbH is a logistic supplier and has no access to the Risk Management Files of products.  PSC 29 - Top management commitment to the production and service process  Bases on the assessment of the production and service control process, the management provides the necessary commitment to the production and service control process. |
| Reviewed  documents  and records (identification and revision) | PSC-1-29  DDEMF SC6330 Instandahaltung und Reiningung (including Pestcontrol) Rev00.00 DCS SC 5110 Wareneiannahme and Wareneingangs pruefung Rev.01.00  DEMF-SC5120 Incoming inspection planning Rev. 02.00  SC 8901 Wareneingang  SC 8907 QS Prüfung  DEALL PQ 8830 Hygieneplan de. Rev 00  Presentation Dräger Service Center September 2023  Labs Group Vapore Workspace 4248 / 10 14 days  SAP Workspace team ventilation 4248 / 080 14 days.  Planning process retrieved/demonstrate from SAP.  GCS Net Sale Top 10 products.  Logistic Center  Presentation Logistic center inbound.  Presentation Logistic center outbound  Prüfanweisung für Service card IPL L Samos revision 18  Prüfkarte 308450914  Material No NK06000 / Equipment no 1015880062  DDEMF SC6330 Instandahaltung und Reiningung (including Pestcontrol) Rev00.00  DCS SC 5110 Wareneiannahme and Wareneingangs pruefung Rev.01.00  DEMF-SC5120 Incoming inspection planning Rev. 02.00  SC 8901 Wareneingang  SC 8907 QS Prüfung  DEALL PQ 8830 Hygieneplan de. Rev 00  AB 4900062419  WE 6009269331  AB 4900059225  FA 62732117  LS 175995547  LS6009269040  AB 1200353210  DSC SC 6700-013-de-00.01 Handhabung elektrostatisch gefährdeter Bauteile  DDEMF SC6330 Instandahaltung und Reiningung (including Pestcontrol) Rev00.00  DEALL PQ 8830 Hygieneplan de. Rev 00  Service Order 308450914  Service Order 308579966  Material No NK06000 / Equipment no 1015880062Material No NK06000 / Equipment no 1015880062  Prüfanweisung für Service card IPL L Samos Revision 18  Service Order 308450914  Service Order 308579966  Material No NK06000 / Equipment no 1015880062Material No NK06000 / Equipment no 1015880062 PO- a3 9109935 -de 2009- 002  Prüfprotokoll D-Vapor Service Card IPM-L SAMOS revision 3 signed 20Sep2023  Narkosemittel Charge Nummer 23E10 A32 Ablaufdatum 2026-02  DEMF-GM2150-013-en-03.00 DEMF GM2150 : Traceability of products and components FA 62732117  FA. 6273647  LS 175995547  WE 6009269040  AB 1200353210  AB 4900062419 / WE 6009269331  AB 4900059225/ Name 60009238477 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 75 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #10578 (Service Center)** |
|  | PQ 8830 Abläufe zur Behandlung von Reparaturaufträge in Rapair center.  Service Order 308450914  Service Order 308579966  PO- a3 9109935 -de 2009- 002  Red label Service No 000308562202 masimo Set  Prüfanweisung für Service card IPL L Samos revision 18  www.serviceconnect. dreager.com  PQ 8830 Abläufe zur Behandlung von Reparaturaufträge in Rapair center.  SeService Order 308450914  Service Order 308579966  PO- a3 9109935 -de 2009- 002  Packaging specification revision 08 b 87114896 NK 6000  PQ 8830 Abläufe zur Behandlung von Reparaturaufträge in Rapair center.  DMS OF5220-en-091-00 Material returns  Distribution record: Ref. Service Order No 308574490.  Distribution record: Ref. Order No 2221460420 LS 0175998557.  Distribution record: Ref. Order No 213121773 LS 0175999693.  Prüfanweisung für Service card IPL L Samos revision 18  www.serviceconnect. dreager.com  PQ 8830 Abläufe zur Behandlung von Reparaturaufträge in Rapair center.  Service Order 308450914  Service Order 308579966  PO- a3 9109935 -de 2009- 002  Labs Group Vapore Workspace 4248 / 10 14 days  SAP Workspace team ventilation 4248 / 080 14 days.  Planning process retrieved/demonstrate from SAP  Material No NK06000 / Equipment no 1015880062Material No NK06000 / Equipment no 1015880062  DWAG IN4207-de-02 Versand, Transport und Verpackung  DWAGOF5213 revision 1 WI Product packaging  Packaging specification revision 08 b 87114896 NK 6000 |
| Names and titles of  persons  interviewed | Ralf Küster (Indsutrial Engineer, Service center)  Martin Lieber (Medical plant Servcie center Moislinger Allee )  Herr Hagedorn provides rest of participant names and roles  \*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Anlauffabrik / Startup Factory (MSz)  Andreas Plöger (Kostenstellenleiter Anlauffabrik/startup Factory)  Daniel Sell (Projektmanager NPI)  Ulf Hagedorn (scribe) (Head of Integrated Management Systems Audit Management) Tritscher (Systems Engineer)  Reimann (Project Manager)  Yvonne David (Software Validation Officer + Process Owner IT4120)  Michael Blanke (Software Validation Officer) |
| Products,  components, or projects  reviewed | See above |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | ☒Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 76 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.13 Production and Service Controls - #90464 (Revalstraße / BabyLeo)

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
| Audit trail  records of | George Pavlov |
| Area(s) visited (location, e.g., site visited) | Location **#90464 (Revalstraße)**  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Production and Service Controls: Planning of Production and Service Process (MDSAP Chapter 6, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.2.1, 7.5.1 + (DIN)(EN) ISO 9001 - 8.1, 8.2.2, 8.5.1 + MDSAP - Australia - TG(MD)R Sch 1 P1 2, Sch3 P1 Cl1.4(4), Sch3 P1 Cl1.4(5)(d)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1, 2.4, 4.1.2, 4.1.7, 5.1 + MDSAP - Japan - MO169: 26, 27, 40 + MDSAP - USA - 21 CFR 801, 820.30(b), 820.20(a), 820.30(h), 820.70(a), 830 + MDR - Article 10.9 ¶3 (g) + MDD - Annex II (3.2), Annex V (3.2)"  Production and Service Controls: Selection of Production and Service Process(es) (MDSAP Chapter 6, Task 2, Site: 10578  "Production and Service Controls: Infrastructure (MDSAP Chapter 6, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.3, 7.5.1 + (DIN)(EN) ISO 9001 - 7.1.3, 7.5.1, 8.5.1 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.2, 5.1.5 + MDSAP - Canada - CMDR 14 + MDSAP - Japan - MO169: 6, 24, 40 + MDSAP - USA - 21 CFR 820.70(g), 820.70(f) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Work Environment (MDSAP Chapter 6, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 6.4 + (DIN)(EN) ISO 9001 - 7.1.4, 7.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 7.2, 8 + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.3 + MDSAP - Japan - MO169: 6, 25-1, 25-2; [Old: 6, 25] + MDSAP - USA - 21 CFR 820.70(c), 820.70(d), 820.70(e) + MDR - Annex IX2.2 ¶1; Annex I (11) + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Identification of Processes Subject to Validation (MDSAP Chapter 6, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.1.6, 7.5.6 + (DIN)(EN) ISO 9001 - 4.4, 7.5.1, 8.4, 8.5.1 + MDSAP - Australia - TG(MD)R Sch1 P2 8.2, 8.3; Sch3 P1 1.4(5)(d) + MDSAP - Brazil - RDC ANVISA16/2013: 5.5.2, 5.5.3 + MDSAP - Japan - MO169: 6, 5-6, 45; [Old: 6, 45] + MDSAP - USA - 21 CFR 820.75(a) + MDR - Annex IX 2.2 ¶2 (d); Annex XI 6.2 ¶2, 12"  "Production and Service Controls: Monitoring and Measurement of Product Conformity (MDSAP Chapter 6, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.6 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 8.6, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 58, 59 + MDSAP - USA - 21 CFR 820.70(a), 820.250(a) + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Control, Operation, and Monitoring of the Production and Service Process; Risk Controls (MDSAP Chapter 6, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 7.1, 7.5.1, 8.1, 8.2.5 + (DIN)(EN) ISO 9001 - 8.1, 8.5.1, 9.1.1 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 5.1.1, 5.1.6, 8.2, 9.1 + MDSAP - Japan - MO169: 26, 40, 54, 57 + MDSAP - USA - 21 CFR 820.70(a), 820.75(b), 820.250 + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2, e); "  "Production and Service Controls: Competence of Personnel (MDSAP Chapter 6, Task 12, Site: 10578);  (DIN)(EN) ISO 13485 - 6,2 + (DIN)(EN) ISO 9001 - 7.2, 7.3 + MDSAP - Australia - RDC ANVISA 16/2013: 2.3.2 + MDSAP - Japan - MO169: 22 + MDSAP - USA - 21 CFR 820.25, 820.70(d), 820.75(b) + MDR - Annex IX2.2 ¶1"  "Production and Service Controls: Control of Monitoring and Measuring Device (MDSAP Chapter 6, Task 13, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.1, 7.6 + (DIN)(EN) ISO 9001 - 7.1.5, 8.5.1 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.1.5, 5.4 + MDSAP - Japan - MO169: 40, 53 + MDSAP - USA - 21 CFR 820.70(g), 820.72 + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Impact Analysis of Monitoring and Measuring Device Found Out of Specifications (MDSAP Chapter 6, Task 14, Site: 10578); (DIN)(EN) ISO 13485 - 7,6 + (DIN)(EN) ISO 9001 - 7.1.5 + MDSAP - Australia - TG(MD)R Sch3 P1 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.4 + MDSAP - Japan - MO169: 53 + MDSAP - USA - 21 CFR 820.72(a) + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Production and Service Controls: Device Master File (MDSAP Chapter 6, Task 16, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 4.2.3, 7.1, 7.5.8, 7.5.9.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.5.2 + MDSAP - Australia - TG(MD)R, Sch1 EP13, Sch3 P1 1.4(5) (c),(d),(e) & 1.9 + MDSAP - Brazil - RDC ANVISA 16/2013: 1.2.26, 2.4, 4.2, 5.2, 6.4 + MDSAP - Canada - CMDR 9(2), 21-23, 52-56, 66-68 + MDSAP - Japan - MO169: 6, 7-2, 26, 47, 48; [Old: 6, 26, 47, 48] + MDSAP - USA - 21 CFR 820.65, 820.120(e), 820.181 + MDR - Article 10.4 ¶1 , 10.5, 10.9 ¶3 (b), 10.11, 10.15; Annex IX 2.2 ¶2 (c6); Annex XI 6.1 ② & 12 ¶1 + MDD - Annex II (3.2), Annex VI (3.1)"  "Production and Service Controls: Production Record; Evidence of Compliance of Released Devices (MDSAP Chapter 6, Task 17, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.5.1, 7.5.8, 7.5.9.1, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.5.1, 8.5.2, 8.6 + MDSAP - Brazil - RDC ANVISA 16/2013: 3.2, 5.2, 6.4 + MDSAP - Japan - MO169: 6, 40, 47, 48, 58, 59 + MDSAP - USA - 21 CFR 820.120, 820.184 + MDR - Article 10.7, 10.9 ¶3 (h); Annex IX 2.2 ¶2 (c7); Annex XI 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2)"  "Production and Service Controls: Acceptance Activities (MDSAP Chapter 6, Task 21, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.4.3, 7.5.8, 8.2.6 + (DIN)(EN) ISO 9001 - 7.5.1, 8.4.2, 8.4.3, 8.5.2, 8.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d) + MDSAP - Brazil - RDC ANVISA 16/2013: 5.3.1, 5.3.2, 5.3.3, 5.3.4, 9.2 + MDSAP - Japan - MO169: 6, 39, 47, 58, 59 + MDSAP - USA - 21 CFR 820.80, 820.250(b) + MDR - Article 10.9 ¶3 (m), Annex IX 2.2 ¶2 (b2, e); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" "Production and Service Controls: Identification, Control, and Disposition of Nonconforming Products (MDSAP Chapter 6, Task 22, Site: 10578);  (DIN)(EN) ISO 13485 - 7.5.8, 8.3 + (DIN)(EN) ISO 9001 - 8.5.2, 8.7 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(b) + MDSAP - Brazil - RDC ANVISA 16/2013: 6.5.1, 6.5.2 + MDSAP - Japan - MO169: 47, 60-1, 60-2, 60-3, 60-4; [Old: 47, 50, 60] + MDSAP - USA - 21 CFR 820.60, 820.90(a), 820.86, 820.100(a) + MDR - Article 10.9 ¶3 (k), 10.12; Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2, 12 ¶1 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)" |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | PSC1 - Planning of production and service process  Drager has created and implemented the process and procedure related to the production process.  //Production Control device Baby Leo TN500 //[GP]  Production is performed a B23  The production is made order based. Production process is organized as series of workstations, the product is pushed manually from one step to another.  The prodcuation records section is completed electronically after Each work station – based on so called production router records. At each section of production step is limited to 20 minutes.  The Organisation structures, the responsibilities and authorities related to Production were demonstrated - the product belongs to the unit Customer Order execution Waermeterapy  Short product overview was provided on request during the audit  Babyleo TN500 is an incubator and a radiant warmer for use with premature babies and neonates.  The IncuWarmer Babyleo TN500 provides controlled ambient conditions for premature babies and neonates. The following parameters are regulated, according to the intended use:  – Temperature  – Humidity  – Oxygen (option)  Total production quantity is 1600 production a year. The materials supplied to production – based on KANBAN principle (two boxes for the particular par are positioned at each location, the empty box is replenished automatically from the warehouse M5.  Special environment – only maintained in the Functional Test area – the room is Climate controlled – temperature control , humidity – no control , particles – no requirement.  United States (FDA):  The organisation applies UDI identifier and Serial number / Batch number to all devices. The documented UDI DI was demonstrated: |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 77 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
|  | MDR 106091 Babyleo TN500 Document of STED Ver 6 202-11-09  Part No 2M60000 / BabyLeo TN 500  Basic UDI DI 040486751306011VK19Z0008,  Main GTIN (UDI DI) 04048675436607  GTIN is issued by GS1  UDI data Set is documented in Attachment  PSC-2 – Selection of production and service process(es)  Line 1 – Babyleo was sampled in line with overall sampling plan for Drager as new device not audited in respect of production. The selection was defined in line with Sampling plan  Final production and functional test were selected as process with direct impact to safety and performance.  PSC-5. – Infrastructure  The process for control of the infrastructure is defined in DEMF SC6330 Instandhaltung und Reinigung. The decision on the specific requirement for maintenance of the equipment is performed, when the new process or equipment is introduced according to Qualification of Production. The result of initial evaluation of production equipment shall be documented as DEMF SC6330\_A06 Betriebsmittel/- Anlagenbewertung  Based on the areas observed during the audit in production (Building B23), the production areas are well organised and maintained.  The verification in respect of Water supply preparation system was performed – the statement of the manufacturer , no maintenance was planned as the quality of water is measured based on the conductivity meter – conductivity of 2 to 30 mkS/cm was demonstrated , with max permissible level 20 mikes.  The manufacturer instruction was demonstrated – no requirements for periodic maintenance wre defined. Accepted based on observed water conductivity well within defined framework.  ESD measures are applicable across all production area. Those include the conductive flooring, equipotential connections to all equipment, presents of ESD mats on the work benches (observed during the audit at Babyleo production) , use of ESD furniture and closing .  The presence of control station for ESD check uniform foot ware was verified by the auditor.  The periodic inspection of ESD measures is performed twice a year – the last inspection report demonstrated, the reports confirms in-depth testing of the conductivity in production area – including the floor surfaces (conductivity in the region of 22 – 25 MOhm was achived0 and testing of the furniture and work benches.  Brazil  adequate means for people flow. Was assured in production areas – verified by visual inspection during the audit at Building B23  PSC-6. – Work environment  In the audited production area Baby Leo, building 23, no special environmental requirements applied, with exception of Functional test Lab.  In the Functional test area, the control of temperature is implemented. Within the span of 20…25C. The temperature is logged during the active test performance, the calibration of the temperature measurement system was verified during the audit.  Note: the organisation has adopted the cleanroom process , this was verified as part of the audit in another production area  Brazil  Biosafety standards were not applicable in the sample dare of production – no use of chemical was observed. The water used in functional testing is soft water )de-ionized) – not relevant for biosafety.  PSC 7 - Identification of processes subject to validation  The Identification of the process subject for validation is performed as a part of Transfer to production.  The organisation has not identified any production processes subject to validation with Babyleo TN500. This was challenges by the auditor during the observation on the production floor – nevertheless, no process subject to validation were observed in Production area for Baby Leo. The processes is 100%, final assembly does not include gluing, welding or soldering.  Brazil  NA- the processes subject to validation were identified for Babyleo TN500  US  NA – in the sampled and audited production are no sterilization, aseptic processing, injection molding, and welding were observed  PSC 10 - Monitoring and measurement of product conformity  Product conformity is verified during the performance of in-production and final tests, with test procedures documented and available electronically as part of eDMR and were demonstrated during the audit as so called Production steps |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 78 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
|  | (Vorgang), specifically the test steps shall be documented as Prüfanweisung according to DEMF SC6500 Documentation von Produktionsprozessen, the records documented as a part of electronic DHR.  ///Baby Leo Production Building B23 Line 1// [GP]  In the sampled are of production for baby Leo devices, following steps were observed during the audit: Electrical safety Test  Electrical safety test – finished Basis-device with High Voltage Tester: Id 302303(HiPot) and 3032338 (Leakage Current)  Safety test Operating instruction W01-0012  Final Function test (basis-device)  Functional test / incl temperature test for TN500 S/N 2M6001-19-ASSK-0088  Temperture Test was observed in prductaion for Device Order 65577324  Average temperature / Maximum teperature test wasobserved and record verified according to Final performnec AV0-3220 Final / Performance test  Linke to measurement equipment observed for humidty meters ate funstional tes area  1) ID506091 /4214  2) ID505128 /4214  Linkage to the temeparture mesuremnt system observed ID 505278 / 4214  Water preapration station for Humidty generator in funtiona testiing: the de-aionising filter with conductivity meter Water Conductivity meter – identified ID 2800, water prepeartion unut installed 23.01.2016  Operator demosnatrted the Functional /Temperture testing – Marius Wydra  The verfication of skin sensor (externally connected part ) was not observed in final Function prducation – its was explained this test is perfomed at in-process prducation satation. This was verfied for one finished devce based of DHR: Work Plan material Base device TN 500 Planer 5006010 Rev 5  Vorgang 3190 Arbeitsplatz 4214 /012  Test of the skin temperetaure 39.5  PSC 11 - PControl, operation, and monitoring of the production and service process; risk controls  ///Baby Leo Production Building B23 Line 1// [GP]  The pre-production of the assemblies and pre-finished devices is built anonymously to the production assembly warehouse M5 – and completed on the specific production order for individual customer.  5 Assembly Work Stations observed in final production area – Software download - - Electrical safety test – Final performance test (Environment control) -> Local assembly lager (customer neutral devices) - > customizing station – (customization station by the specific customer order) - > Electrical safety test ( repeated) -> Functional test and Language seeing for the client - Internal waiting areas - - >  The final production and release is performed in two stages:  - Production of basic device – customer neutral / unconfigured  - Configuration of finished device, including installation of particular SW / Partial retest and release packaging and dispatch . The packaging B3B – packaging in the separate Building.  After the construction has been finished, the devices go to the hall B3, to be packed and sent to the customer.  There is a working plan, which is distributed according working places, (paperless production) and controlled trough SAP, which indicates which productions steps have been completed and allow the device to continue the assembly. The whole order paper and preparation documents are linked to the order. In the case additional information is needed of has to be provided, the supporting documents are linked to the working place.  The processes used in production are appropriately controlled, monitored, operated within specified limits and documented in the product realization records. The electronic assembly and test instruction were observed. He auditor has observed assembly operation – assessment was performed that operation are performed in lined with defined Work Instructions and defined parameters, following operation selected and observed on production floor 1. Trolley assembly   Installation of Hubsaule LINAK Part Nr 2M60521-08  Production Order records performed in PLESS (Paper les Order system)  Installation of Separation Power supply ZP/N 8421200-09 S/N ASSE-507  Assembly of the trolley – installation of Radiant Heater – checked if toque screwdrivers correctly applied during the prediction operations;  Drawing 2M60600-09 Radian of Radiant Heater assembly  Verified if the Torques screwdrivers correctly identified and used - verified actual Toque screwdrivers to the drawing 1) Screwdriver 1.8 NM – screwdriver ID416048/4217  2) Screwdriver 8NM – ID 415989  The Toque settings were verified against the drawing – found in line with drawing requirements  W01-006Radiant heater assembly work station 4 for Prodcuation Order 6557743 S/N 2 M600-1-19-ASSK-0106  Australia  The production observed in line with required parameters and documented instruction. No devices for Australis were observed, it was explained the devices are manufactured as country-neutral for subsequent labelling and packaging  PSC 12 - Competence of personnel |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 79 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
|  | Competency / Training records verified in respect to the prodcuation operate in the Final Function ? temperature test Babylog TN 500 – train records were demonstrated in relation to the operation performed during the audit.  Training for Final release of production records Arbeits Vorganag 1590 was verified in relation of Operator Dirk Schnoor – who was observed as released DHR at last step of basis Device – demonstrated during the audit  PSC 13 - Control of monitoring and measuring device  It was observed that measurement equipment in production area are identified with individual ID numbers, also the measurement equipment which used as part of production rigs / stations.  The measurement equipment critical for safety and performance was sampled and verified during the audit: Calibration certificate.  US 416581 Torque controlled wrench - Calibration certificate by Test valid 28.10.2020  Electrical screwdriver  Additionally, calibration certificates were verified for Temperature measurement station / Functional test Temperature Measurement Station ID 505278 / 4214. It was confirmed the calibration was performed in time and includes both multichannel station and related thermocouples.  PSC 14 - Impact analysis of monitoring and measuring device found out of specifications  Impact is investigation in relation of the instrument, which failed calibration - investigation demonstrated: the decision to write of the instruments, the analysis of the impact was performed in respect of the medical devices,  According to justification, the toque of the wrench, which failed calibration was within the tolerated are - statement: no additional risk observed, the investigation performed by the device responsible manager.  PSC 16 - Device master file  He DMR is generated according to the DEALL PQ3130\_A02 - Rev 04.02  This document defines the summary of the documentation, which must be prepared as part of the DMR.  ///Example – DMR Baby Leo TN500/// [GP]  The set of documents straws provided during the audit as evidence of the documented DMR.  Element of DMR were produced  9054863\_09 IfU Babyleo TN500 SW 1.0n EN 2021-06-22  2M60003\_17 Produktions- und Test Specification BABYLEO TN500 2023-01-16  2M60002\_11\_Assembly\_TN500 2M60002 – 11 Assembly Drawing top level 2022-12-09  2M60002\_11 Part- Specification for Assembly TN500 2022-12-09  2M60000\_29\_AP\_HA\_HP Druckliste Arbeitsplan – 2M60000 the list for Work Instruction 22.09.2023 2M60000\_29 Part- Specification for Babyleo TN500 2023-02-22  2M60000\_28 Information für Rückverfolgb Rev 28  Australia / Brazil / Canada  DEMF SC\_A6200\_A02-de-01 Erlaueterung und darstellung –  The review- and approval of DHR ASRM 0019 07.11.2022  The release of the Label is documented and approved in DHR  Verification of the Label – according to the to DEMF SC6400\_A01-de-00  The labelling is printed directly in the production and verified as part of the final release according to according to the to DEMF SC6400\_A01-de-00  / US  Each device maintains the Serial Number which is used for traceability  PSC 17 - Production record; evidence of compliance of released devices  The DHR is formed at the production of top-level sub-assemblies and is defined as sub-DHR , the linked to the top-level DHR for Basis device, and subsequently the DHR for the finished configured device via serial numbers of subassemblies and finished device.  DHR was sampled from the distribution list and demonstrated during the audit for the device TN500 ASRL 0056 The auditor has observed the final approval and review stage from production of Babyleo TN500 Basis device – it was explained that DHR is regarded as approved if all sub-DHRs are completed without errors, and accepted this is an automatic step in SAP. The review is confirmed by the electronic signature of the operator  Brazil  Device history record of the product includes date of manufacture; components used; quantity manufactured (usually – 1 pcs as DHR is documented for one device); results of inspections and tests; parameters of special processes; quantity released for distribution; labeling; identification of the serial number or batch of production; and final release of the product [  The approval, including date, name, and electronic signature of the person responsible, must be documented is documented.  US  The process is defined in DWAG PQ2140-en-04.00. Labels are printed and issued to production for each individual device, verification is performed by the Operator in production line.  UDI is established and maintained – verified during the audit:  Part No 2M60000 / BabyLeo TN 500  Basic UDI DI 040486751306011VK19Z0008,  Main GTIN (UDI DI) 04048675436607 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 80 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
|  | GTIN is issued by GS1  UDI data Set is documented in Attachment  PSC 21 - Acceptance activates   The process is defined in DCS SC5120 Incoming Inspection Planning  The process starts with the review of critical parts, for each critical part, the Inspection Plan shall be documented and Inspection characteristics shall be defined. For initial receiving DCS SC5130 First Article Inspection (FAI) shall be performed.  Records of successful inspection demonstrated as following   Example observed for the Part 368451 The test protocol incoming inspection Part 8421200 N 3 parts were checked from overall 192 incoming batch.  Additional country-specific requirements:   United States (FDA): Brazil (ANVISA):  SC 5121 Incoming Inspection Rev 01. – defines the Dynamic rules for the sampling  The AQL sampling according to DIN 2859-1 According to DCS SC5120 Incoming Inspection Planning The rules for inspection severity according to DIN ISO 2859-1 allow a change of the sampling procedure regarding sample size from normal, increased and reduced, depending on the inspection results for lots supplied before.  PSC 22 - Identification, control, and disposition of nonconforming products  SC6110 – Non-confirming material  The NC devices are identified with dedicated red label, the FQ (number (NC- Message) is raised in SAP The list of NC devices was demonstrated – the 590 NC records related to parts  The NC parts were observed in production – respectively identified, Isolates , traceable by so called FQ Numbers Example of NC materials were sampled in prodcuation quarantine area and assessed during the audit: FQ 810000399249 Abdeckung Heizstrahlerarm, Gewinde abgebrochen – registered 05.06.2023  Decision – 06.06.2023 – scrap – no additional investigation  FQ 810000416716 13.09.2023The heating element - - in process - the parts were isolated  FQ 810000359190 02.11.2022 temperature outside of tolerance – the failure in basis device TN500 ASRL 0056 - Norwandmotage - - Rework – - errored part ASRJ 0460 -  - The evidence the part was reworked and retested was found in DHR for the S/N TN500 ASRL 0056, Completed 03/11/2022 |
| Reviewed  documents  and records (identification and revision) | Control of DMR and DHR  DEMF SC6500 Documentation von Produktionsprozessen DEMF SC6500‐de‐02, Rev. 2 DWAG PQ2140 International Labeling Requirements for Medical Devices, Rev. 04.00 DCS SC6110 Behandlung von Abweichung in der Produktion Ver 00  Production  DWAG IN4300 New Product Introduction, Rev. 09.00  DEMF SC6100 Qualifizierung in der Fertigung DEMF‐SC6100‐de‐00.00 , Rev. 00.00 DEMF SC6200 Produktherstellung DEMF SC6200‐de‐02 , Rev. 2  DEMF SC6210 Fertigungsauftrag ‐ Fremdbearbeitung DEMF SC6210‐de‐01.00 , Rev. 01.00 DEMF SC6220 Reparatur‐Austausch‐Teile (RAT) DEMF‐SC6220‐de‐00 , Rev. 0  Packaging / Traceability / Identification / Release  DEMF GM2150 Rückverfolgbarkeit von Produkten und Komponenten, Rev. 02.00 DWAG OF5310 Maschinenlesbare Codierung, Rev. 04  DWAG PQ2110 Regulatory Approval to Market Product, Rev. 02.00  Infrastructure / Environment / Cleanliness  DEMF SC6400 Handhabung von Material und Hilfsstoffen DEMF SC6400‐de‐00 , Rev. 0  DEMF SC6700 Handhabung elektrostatisch gefährdeter Bauteile (ESD) DEMF‐SC6700‐de‐00.01 , Rev. 00.01 DEMF SC6720 Schutz vor elektromagnetischen Einflüssen in der Produktion DEMF SC6720‐de‐00 , Rev. 0  Non-confirming product  DEMF SC6111 Lenkung von fehlerhaftem Material DEMF‐SC6111‐de‐00.01 , Rev. 00.01  DEMF SC6110 Behandlung von Abweichungen in der Produktion DEMF‐SC6110‐de‐00.00 , Rev. 00.00 DEMF SC6130 Produktionsstopp und Lieferstopp DEMF‐SC6130‐de‐00.00 , Rev. 00.00  DEMF SC6110 Behandlung von Abweichungen in der Produktion, Rev. 00.00 (??) DEMF SC6120 Qualitätskennzahlen in der Produktion, Rev. 00.00 ??  Incoming inspection and acceptance  DEMF SC5120 Incoming Inspection Planning DEMF‐SC5120‐en‐02.00 , Rev. 02.00  DEMF SC5210 Umgang mit mangelhaftem Einkaufsmaterial DEMF SC5210‐de‐01.01, Rev. 01.01 DEMF SC6010 Inward stock movement DEMF SC6010‐de‐01 , Rev. 1  DEMF SC5130 First Article Inspection (FAI) DEMF SC5130‐de‐02.00 , Rev. 02.00  MMDR 106091 Babyleo TN500 Document of STED Ver 6 2022-11-09 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 81 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
|  | babyleo-tn500-ifu-9054863-en Instruction for Use Babyleo TN500  Booklet babyleo-tn500-pi-9102128-en-master  Marketing brochure neonatal-and-pediatric-accessories-ca-9066934-en Production Layout Production Babyleo TN500 – as on the day of the audit  CS Hoses Risik asessemnt V2.3 2023-07-04  Production Risk Control measure: CS\_RM-566 The product shall be delivered Clean but not sterile  CS-TSR-432 The Product shall not have a level of hydrocarbon greater than 550mg/spm and be free from particles acc.  To ISO15001  Verification report CS\_TRS\_156\_TR3  Test report 14-00128-PR-004 rev. 0 Test Result: Particle measureent, Oils Content, Ignition temperature passed.  DEMF SC6330 Instandhaltung und Reinigung Rev 00  DCS SC6100 Qualifizierung in der Fertigung Rev 00.00  Identification of water cartridge and Instruction for the water cartridge DI2800 installed 23-01-2016 ESD test protocol Werk 3 Building B23 13.04.2023  DWAG OF4160 Betreiben von Reinraumprozessen DWAG‐OF4160‐de‐00 , Rev. 0  Temperature records Functional test area Babyleo production Order 65577324 2023-09-22  Functional test / incl temperature test for TN500 S/N 2M6001-19-ASSK-0088  AV0-3220 Final / Performance test  Functional final temperature test record Device Order 65577324 performed – in production on day of the audit Work Plan material Base device TN 500 Planer 5006010 Rev 5  Vorgang 3190 Arbeitsplatz 4214 /012 TN500  Vorganag 3250 Work Instruction Functional test TN500  W01-006Radiant heater assembly work station 4actual on the day of the audit Prodcuation Order 6557743 S/N 2 M600-1-19-ASSK-0106 – open on the day of the audit  Training record Operator Marius Wydra Arebeitsvorgang 3250 Work Instruction Functional test TN500 – actual Training record Operator Dirk Schnoor Arbeitsvorgang 1590 Final release assembly basis device–actual  US 416581 Calibration certificate Torque controlled wrench by Test valid 28.10.2020  DEALL PQ3130\_A02 - Rev 04.02 Control of Documents and Recordss  RMB 400760 /2022-10-12 Investigation Toque wrench – failed calibration  Calibration CERTFICATE id400760 Wrench Hazet by test lab, 12.10.2022  99054863\_09 IfU Babyleo TN500 SW 1.0n EN 2021-06-22  2M60003\_17 Produktions- und Test Spezifikation BABYLEO TN500 2023-01-16  2M60002\_11\_Assembly\_TN500 2M60002 – 11 Assembly Drawing top level 2022-12-09  2M60002\_11 Part- Specification for Assembly TN500 2022-12-09  2M60000\_29\_AP\_HA\_HP Druckliste Arbeitsplan – 2M60000 the list for Work Instruction 22.09.2023 2M60000\_29 Part- Specification for Babyleo TN500 2023-02-22  2M60000\_28 Information für Rückverfolgb Rev 28  DEMF SC6500 Dokumentation von Produktionsprozessen Rev00  DWAG PQ2140-en-04.00 International Labeling Requirements - for Medical Devices DHR for Babylog TN500 ASRL 0056  DCS SC5120-en-013-02.00 Incoming Inspection Planning  DCS SC6110 Behandlung von Abweichung in der Produktion Rev 00  DCS SC6111 Lenkung von fehlerhaftem MaterialRev 00.01  DCS SC6120 Qualitätskennzahlen der Produktion Rev00  DCS SC6220-Reparatur-Austausch-Teile (RAT)-013-00  DCS SC6130 Produktionsstopp und Lieferstopp Rev 00  FQ 810000399249 NC Record Abdeckung Heizstrahlerarm, Gewinde abgebrochen – registered 05.06.2023 FQ 810000416716 NC-record the heating element 13.09.2023  FQ 810000359190 temperature outside of tolerance – the failure in basis device TN500 ASRL 005602.11.2022 |
| Names and titles of  persons  interviewed | Product focus: Line 1 – Babyleo  Production area Baby Leo TN500 Factory 3 Building B production area B23  Timo Harms Director Quality & Regulatory Affairs BU HCA  Jan Paulssen Supplier Quality Manager - BU HCA  Jochen Meyn Quality Manager BU Therapy  Dirk Geisteier Bereichsleiter  Hasan Tatli Industrial Engineer  Tobias Scotti Product Quality Manager  Stephan Both Quality System Manager Auditing  Constantin Lüthjw Team Leiter Bereich Babyleo  Nico Zeitz Quality Engineer  Marius Wydra Operator  Dirk Schnoor Operator  Thomas Schoop Product Owner BabyLeo  Luba Lange Regulatory Compliance  Sebastian Maerz (Scribe) Product Quality Manager - BU Therapy |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 82 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / BabyLeo)** |
|  | Sussan Tapy – Anestesy  Konstantin Ludky  Tobias Scotty  Sebastjan Maerz – Quality Therapy |
| Products,  components, or projects  reviewed | See above |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | ☒Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 83 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.14 Production and Service Controls - #90464 (Revalstraße / HM Filter)

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
| Audit trail  records of | Melanie Gaßen |
| Area(s) visited (location, e.g., site visited) | Location **#90464 (Revalstraße)**  For more details related to audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | MDSAP Tasks: #1-2, #5-7, #11-14,  #16-17, #20-22, #25-27, #29  ISO 13485:2016, 7.5  ISO 9001  MDR PRODUCTION AND PROCESS CONTROLS Annex  IX.2.2d) & e), XI.6.2  Specific Personnel Competency and Training  ISO 13485: 6.2  ISO 9001: 7.2, 7.3, 7.5.1  MDR: Annex IX 2.1, 2.2 (a), Article 15, [MPDG §83]  MDD: Annex II (3.1, 3.2), Annex V (3.1, 3.2), Annex VI (3.1) |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records  reviewed  below  considering  inputs,  outputs, and  measures | \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*HME / filter production line (MGa)  PSC-1  ISO 13485:2016: 7.1, 7.2.1, 7.5.1;  Process Description:  The Manufacturer has implemented a product realization processes that including any necessary controls, controlled conditions, and risk management activities required for the product to meet the specified or intended uses, the statutory and regulatory requirements related to the product, and (when applicable) unique device identifier requirements.  Planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.  For the selected process, the production and service process that is planned and conducted under controlled conditions has been audited.  Planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.  Business Manager establish a forecast, production is relaying on demand. A safety stock is implemented to be able for distribution at any time.  The logistic is responsible for the availability of raw material to be ready for production.  The production order is controlled by logistic and is feed into SAP.  In SAP Hejunkaboard shows the realization process.  US:  The UDI will be issued under the GS1 scheme. The information will be converted into a data matrix code, which is on the product label. A procedure is in place.  The following samples are taken based on the following criteria: Availability, as the Humidstar 25 Plus is produced at the time of the audit.  PSC-2  ISO 13485:2016: 7.1, 7.2.1, 7.5.1  Process Description:  At the time of the audit the HME Humidstar 25+ had been produced on the AFO-line.  For the selected process, the production and service process are planned and conducted under controlled conditions that include the following:  - the availability of information describing product characteristics  - the availability of documented procedures, requirements, work instructions, and reference materials, reference measurements, and criteria for workmanship  - the use of suitable equipment  - the availability and use of monitoring and measuring devices  - the implementation of monitoring and measurement of process parameters and product characteristics during production  - the implementation of release, delivery and post-delivery activities  - the implementation of defined operations for labeling and packaging  - the establishment of documented requirements for changes to methods and processes  Inputs to the production plan are inventory and sales order information from sales forecast information.  The production of HME and filter is conducted on an automatic production line, the line requires the input of components (housing bottom and top, medium (foam) and filters (when applicable), the output is the ready packed distribution unit (devices packaged in blister with Tyvek lid, wrapped in double bags and boxed in a labeled carton box, including IFUs).  The production-line is located in clean room, ISO class 8.  A Material lock and a separate lock for operators are implemented, the material flow is defined: Double bag into material lock; outer bag disposed; inner bag into the cleanroom  Incoming rawmaterial is located in the production area, outside the cleanroom.  At location shelf life check is requested  PSC -5 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 84 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
|  | ISO 13485:2016: 4.2.1, 6.3, 7.5.1;  Process Description:  Dräger realizes that product quality can be influenced by the production work environment. Dräger directs, regulates, coordinates, and monitors activities and variables that affect the conditions such that the quality of the work environment is known. Manufacturing equipment is designed, constructed, installed, and located to facilitate proper operation, maintenance, adjustment, and cleaning.  The organization has determined and documented the infrastructure requirements to achieve product conformity, including buildings, workspace, process equipment, and supporting services.  Buildings, workspaces, and supporting services allow product to meet requirements.  There are documented and implemented requirements for maintenance of process equipment where important for product quality, and that records of maintenance are maintained.  In the Cleanroom the monitoring of temperature and humidity is ensured by continuously measuring by installed sensors. For the access of the cleanroom, material and personal locks are separated. Clear instruction for entrance are available.  PSC -6  ISO 13485:2016: 4.2.1, 6.4; TG  Process Description:  Please see also task PCS 5  Hygiene instruction are outlined, protection equipment such as coat, hair/ facial hair cover and shoe covers are mandatory for entering the cleanroom.  Equipment permitted in the cleanroom are  mobiles, cosmetics and jewelries, persons with pacemakers are permitted to enter the cleanroom.  Monitoring of cleanroom is conducted twice a week, Tuesday and Thursday . In operation the particle count is conducted.  26 sampling locations are defined; sonde is located of the height of activities.  Exceptional measuring reasons are given, e.g. in case of a black out  Alarm and Action level and limit exceeding are defined: according to ISO 14644-1 The maintenance of the cleanroom is outsourced to Dräger Gebäude und Service GmbH.  If action limit is exceeded, required actions are defined, such as e.g. information to dedicated responsible persons, Change of Air input sacks:  PSC-7:  ISO 13485:2016: 4.2.1, 4.1.6, 7.5.6;  Process Description:  The organization determine which production processes require validation and which processes can be verified during the design and development process. Process validation may apply to processes that generate components, subassemblies, or finished devices.  As an examples of processes that require validation label information printing of the AFO line had been audited. The Bellmark printer had been newly implemented.  PSC-11  Process Description  Control and monitoring procedures include in-process and finished device acceptance activities as well as environmental and contamination control measures.  Processes used in production are controlled, monitored, operated within specific limits. Work instructions for assembling are available and final tests are established. Final test reviewed.  The cleaning of the cleanroom is conducted by an external service provider.  Please see also PSC-2/ PSC-6  PSC-12:  A training records of external cleaning operators had been reviewed. The hygiene instructions are trained on regular basis.  PSC-13  ISO 13485:2016: 7.5.1, 7.6;  Process Description:  Production and test equipment selected for review is suitable for its intended purpose and capable of giving valid results.  Monitoring and measurement devices are defined, calibrated in specific intervals and maintained. The calibration is done internal and external.  Dräger has determined the monitoring and measurement to be undertaken and the monitoring and measuring devices needed to provide evidence of conformity of product  PSc-14  ISO 13485:2016: 7.5.1, 7.6;  Process Description  The measurement equipment is appropriate labeled. An impact analysis of monitoring and measuring device found out of specifications is required according to SOP. Product labels are printed and directly attached to the product.  PSC-16  Process Description: |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 85 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
|  | The manufacturer has established and maintained a file for each type of device that includes or refers to the location of device specifications, production process specifications, quality assurance procedures, traceability requirements, and packaging, labeling specifications.  The manufacturer determined the extent of traceability based on the risk posed by the device in the event the device does not meet specified requirements. DMR is established, DMR is filed in different database solutions, including SAP, e.g. work routing plan per workplace is provided in SAP, work step description can be further explained in further documents, e.g. drawings that are stored in SAP.  BRA:  Components (e.g. housing, foam) and enclosure have a separate label with their serial number. All these components are documented in the DHR per each device in the ERP System .  CAN:  All devices are designed to meet the safety and effectiveness requirements of the CMDR. The technical documentation is checked while the regular technical file review according to MDD/ MDR. Additionally the passed final test (see above) makes sure that essential safety aspects are verified. The language is English or symbols are used on the label.  US:  The device gets a label with the identification number which is also used for the packaging label.  All products are clearly identified with labeling with the following minimum information: Part Number, Revision, Lot or serial number, expiration date where applicable and acceptance status. The labeling is maintained throughout the movement of the product within the Dräger facility. A procedure defines that the labeling must be legible, properly adhered and applied to the individual packaging unit to ensure identification and traceability is maintained.  PSC-17  ISO 13485:2016: 4.2.1, 7.5.1, 7.5.8, 7.5.9.1, 8.2.6  Process Description  Dräger maintain a record of the amount manufactured and approved for distribution for each batch of medical devices, the record is verified and approved, the device is manufactured according to the specific instructions, and the requirements for product release were met and documented.  Brazil:  the batch record contains the date of manufacture; components used; quantity manufactured; results of inspections and tests; parameters of special processes; quantity released for distribution; labeling; identification batch of production; and final release of the product  US:  The label and labeling used for each production lot are documented in the batch record.  For the Humidstar 2+LL an example of batch record had been reviewed of the supplier ULAX.  PSC-20  ISO 13485:2016: 7.5.10;  Process Description  The organization has implemented controls to identify, verify, protect, and safeguard customer property provided for use or incorporation into the product. The organization treats patient information and confidential health information as customer property.  PSC-25  Distribution of accessories, including HME and Filter is conducted by Hegele, an external distribution provider, located in Frankfurt.  New supplier is Fiege.  Distribution records are available in SAP and can be edited on demand.  Distribution to Brazil, Japan and Australia had not been performed yet for the Humidstar  PSC-29  Process Description  Based on the assessment of the production and service control process, the management provides the necessary commitment to the production and service control process. |
| Reviewed  documents  and records (identification and revision) | Andre Paul, remotely, logistic,  Standard process at Dräger:  DCMF SC6200 Produktherstellung, Rev.02; 2021-11-21  Flow diagram of production from production order to finished products and transport.  Other instructions are linked, e.g.  DEMF SC6200\_A01-de-02  Weitere Vorgaben zum Produktionsherstellungsprozess, 2021-11-30  SC6110 Handling of Nonconformities in Production  Product status has to be identifiable during production  AFO line is a continuous production line, feed with raw material, output finished product.  In process control: start with random samples, will be inspected by line operator. 100% inspection for leakage, visual, etc.  Plan Primär-Planung via Product Manager  Planning orders are considered. SAP automatically checks if all raw materials are available. The production order will be released by logistics and shop floor specialist.  US:  (Stefan Lange) Label UDI: |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 86 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
|  | DWAG LM 2132 Object Approval for Labelling Relevant Technical Specification, 2012-05-17 Material specific  Transfer of data from development status to production  Screenshot: SAP Hejunkaboard for AFO line: production order listed according priority, Partno., order no. production quantity  Order no. is unambiguously and given by SAP automatically.  Excel sheet Material. 1570081-A1 specification for Humidstar:  Datamatrixcode is predefined.  Lable UDI:  Drawing of 1570081-A1: primary lable: place holder M for datamatrix : GS1 datamatrix code DMS OF5310; GTIN, 1570081-A1 manufacture date; expiry date; LOT Number, serial number, material number reversion.  Drawing of 1570081-A1: primary, No. 11203201-00  Clear writing is also available.  Document of STED Filter Plus MDR 108-043, Product and packaging label: Label of Humidstar 55+ MP05730, included data matrix code  1570081-D: outer packaging for Humidstar 55+ MP05730,  Tour of HME / filter production line (AFO):  The production of HME and filter is conducted on an automatic production line (A210026), in line are following processes:  -assembling of filter /HME, bottom and top housing, foam and filters  -ultrasonic welding of top and bottom housing  -surface activating of top housing-preparation for printing  -printing on top of top housing  Control panel: +GLP3\_OP1, integrated in production line  -Packaging is integrated within production line:  Thermoforming foil:  -Label print on Tyvek with required label information;  The equipment “Multivac” is integrated in the line, the Tyvek lid is sealed on the blister  100pcs in one bag;  Drawing MP05735-03 HME Humidstar 25 Plus, released 2022-10-13  Part Specification MP05735-05 HME Humidstar 25 Plus, 2023-03-15  Herstellungsanweisung “Medical Filters”  Produktionlinie Medical Filter (Equipment Nr. A210026)  Area of production is colour coded:  Room no. 1015; 1012 clean room:  Assembly and blistering (primary packaging) and secondary packaging (bag), transport packaging is outside the cleanroom  Herstellanweisung:  Qualitätssicherung “Medical Filter”, 2023-02-01  Visual random sampling  Nonconforming materials  Shelf life Prüfung  In process control, which is in-line, and applies 100%: Leakage, resistance, filtration performance, printing At each production change additional tests are conducted. The equipment are dedicated to the calibration process  PTS:  MP 05798\_05 Produktions-und Test Spezifikation für medizinische Atem Filter und HME, 2022-10-14 -Interface of the product: two cones ISO 5356-1) and luer connector acc. 80369-1  Adjusting and test guidelines  Definition of test environment  Clean room ISO class 8:  Environmental conditions:  Temp: 5-40°C  Humidity 5-95%  Ambient pressure : 570-1200hPa  Functional test-100%:  F-HMR\_TSR\_555 (EDO : essential design output)  Leakage: 11.8ml not more than =>55hPa  Resistance check: <0 2ml bei >= 30l/min  Cleanliness of products: visual check  Acceptance criteria  Definition of sampling: per production order and at the start and end of shift, 8 samples are taken for in process control: Visual inspection: Sealing of blister, label printing of Tyvek readable, lint on filter (Cleanliness No visible contamination)  Nonconforming products:  SC6111 Lenkung von fehlerhaften Material , 2018-11-01 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 87 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
|  | Failure analysis/ identify nonconforming products:  Identification of non-conforming device  Blocking label: blocked Material, separated in blocked area  Stock of material will be blocked  Special releases: possible with a “Bauabweichung”  Handling in case of stock blocking  Rework is not applicable  Special releases: possible with a Bauabweichung  Freigabe einer Bauabweichung FBA 860000003178:  Humidstar 55+, MP 05730, Rev.6, from order 65396950  2022-08-25 to 2023-02-01/ released 2022-11-14  Soll: a validated printer shall be used/ IS: new printer was used; process validation is missing Team has defined: DTE1: function not affected.  Risk management included: patient and user risk is acceptable.  Blister lable printer Validation was done, but no document No influence to intended use, following processes not affected.  DMS OF4160-de-105-00 Betreiben von Reinraumprozessen., 2008-04-01  DWAG PQ810 Betriebsmittelüberwachung, Rev. 02, 2023-05-13  \_A04 Kennzeichnung von Betriebsmitteln:  Date of calibration/ date of next calibration  DMS OF4160-de-105-00 Betreiben von Reinraumprozessen, 2008-04-01  Herstellanweisung 11030448-01 Checking the air purity “Medical Filter”, 2023-01-05  Klassifizierung der Luftreinheit anhand von Partikelkonzentration, 2023  Reports reviewed:  Test report:  Particle measuring:  2023-09-15 AFO Reinraum, target class 8, 0 particles are measured  Certificate result: passed  2023-09-08: one fail/ Certificate result: failed, Messpunkt 11, 0,5: 3574664 vs 3.520.000 limit exceeded (exceeded limit) In case of exceeded limit: Production stopp/ information to IE (industrial Engineer) and QE  2023-09-05: one fail/ Certificate result: failed, Messpunkt 12, 0,5:  4.728.834  => please see finding list  2022-12-21: Certificate result: passed, with measures in particle.  OIn case of deviation:  CFT Cross function team shall be informed; im D&D plan: employee production/ quality engineer/ MRP Controller/ product quality manager.  Refer to DCS SC 6110-de-013-000 Behandlung von Abweichung in der Produktion, 2016-07-04 QE shall be informed, limitation and correction.  Influence of following processes to be assessed  Corrective action shall be defined  Bellmark printer ( new printer on line AFO)  Medical Filter Inhouse Verification and Validation Bellmark printer Protocol: V& V Afo Plan \_P\_V\_V\_P A210026 for complete line: reference to initial IQ OQPQ  IQ-plan: 101137  Medical Filter Inhouse Process Installation Qualification for line AFO, dated 2023-01-31: Test items defined:  Implementation of bell mark printer: Test Item nr. PIQ\_09\_001  Protocol: IQ OQ PQ  Medical Filter Inhouse Verification and Validation Bellmark printer Protocol: IQ OQ PQ Dated 2023-01-31:  Bellmark IQ OQ PQ takes place after supplier installation has been performed Test items: IQ\_01\_001 to 003are defined and checked and passed  Test items: OQ\_01\_001 to 003 are defined and checked and passed  Test items: PQ\_01\_001 to 003 are defined and checked and passed  Current production order:  FA: 65577935; Mp 05735  Chargen no. 1011552545  Produktmappe  Herstellungsprotokoll, shelflife Prüfung, visual inspection of raw material  Defected parts  Test parameters set up and checked: set up direct online,  Content of document file:   Change history, special releases, manufacturing instruction, protocol, drawings MP05735-03,  3 lines of raw material (bottom case, top case and foam) are feeding the assembly line. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 88 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
|  | Top case: plasma-activation, and print – print check via online-camera, Inprocess control station: 1. leakage, 2. resistance, 3. filtration performance  Change of shift at 14:00h:  Shift operator meeting:  Information are transferred regarding  Non conformities, deficiencies occurred during the shift  Inprocess control at shift change:  Shift transfer minutes are documented in Excel schedule: AFO Schichtprotokol, includes date, early and late shift, performance data, filtertyp,  Break down lock book:  Kinematik failure delta  Herr Kötze: Calibration expert  The maintenance is responsible to the department “Betriebsmittelbau”.  Dichtigkeitsmessgerät von der Linie: Prüfmodul 9 DichtigkeitsZED:  Kalibrierung: last 2023-06-22  Next 2024-06-22  WK Werks Kalibrierschein: Registriernummer 420658, in House Kalibration: within specification, 2021-10-02 Dräger eigenes Kalibrierlabor: nach 17025; Accreditierungs nr. D-K-15191-01-00-2021-04  Cleaning of cleanroom; material lock, persona lock, external service  Cleanroom responsible person: Andre Putzer  Cleaning training Bockholt  External cleaning operators: trained to Hygieneconcept AFO, Prozessschulung; dated 2021-11-29, 12 trainees of company Bockholt and Optima /line manufacturer- for service); and intern operator  Offer, 2022-05-19, Bockholt  Cleaning activities in cleanroom and cleanroom equipment:  Material & personal lock, floor, banks, switches, taster,  Outside cleanroom: floor  Cleaning agents is listed  Cleaning of cleanroom coats:  Company elis: chargen documentation for cleaning of cleanroom coats:  Particle count acc.to ASTM F51: >= 3Mm/ ft  DMS OF4160-de-105-00 Betreiben von Reinraumprozessen, 2008-04-01  Herstellanweisung 11030448-01 Checking the air purity “Medical Filter”, 2023-01-05  ccontrol of air particle : 2x weekly: reg no. 420575 Aero trak portable particle count, model 9310-02/ 93102106002 Last calibration: 2023-03-14  Certificate of calibration  TSI Instruments Ltd  Result: in tolerance   New Mims is calibration database  Batch record  Records reviewed:  Batch record: Product MP05840; Humidstar 2+LL  Outsourced production by ULAX: SP-4.1, for MP05840 Neo Luer Lock  First production batch of the device  Production dates: 21.08-24.08.2023, Batch no. 2023-08-23  ULAX:  Incoming inspection: for MP05843  Supplier: MPV , batch no. plastic housing: 230816, part no. ULAX 00.00.045; PP Bormed  Quality control: cert. enclose, 200 sample size: released  COC: material bachno. 3170022\_532  Related to sepc. MP05843 Rev.04  15mm measuring for all 200 samples  Foam: supplier ABC Euro softs Sweden:  COC: Order no. 50207/ Product 0-01-015, batch no. 01308355  Order no. for impregnation: Lot 22/207, lsg. MP25441  In process inspection: Batchno. 01308335: weight cal hex. M chlorid  Order of Dräger: dated 2023-08-23 Po number TSINB4303102511  Order confirmation for MP05840 3300 pieces Page 2:  Material MP05840, shelflife controlled material accord. to DSC SC2090 required  COC of finished device: for orderno. 4303102511, traceability of raw material used, inspected and in conformance Label:  Inspection of labels: product label and secondary packaging label  Humidstar 2+LL primary and secondary label:  Lot no. 2023-08-23  DDrägerwerk AG & CoKG  Moissliner Allee 53-55  23558 Lübeck  US:  Draeger Medical Canada Inc  5025 Tuggle Road |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 89 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
| Subsystem | **Production and Service Controls - #90464 (Revalstraße / HM Filter)** |
|  | Memphis 38118, US  Order packing no. unambiogously  CANADA:  Order packing list:  Consignee:  Draeger Medical Canada Inc  2425 Skymark Ave Unit  Mississauga L4W 4Y6, CA  Information listed:  -Part no.  -quantity  -Delivery note,  -Batch/ lot  Based on the assessment of the production and service control process, the management provides the necessary commitment to the production and service control process. |
| Names and titles of  persons  interviewed | Matthias Ahrends, Wertstrom Manager- line Manager including Humidstar  Lucie Sander, Quality System Manager; Skipt  Alexandre Barette, Quality System Manager for Humidstar  Tim Aumann, supplier quality manager, for Filter and Sensor  Alexandra Kreymeyer  Axel Bürger, Industrial Engineer , technical for line  Alex Kühn, Industrial engineer, Verification & Validation, maintenance of equipment, establish of machine Gerrit Meta, Quality engineer, in production  Steffen Lange, remote: Label |
| Products,  components, or projects  reviewed | See above |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | ☒Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 90 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.15 Purchasing

|  |  |
| --- | --- |
| Subsystem | **Purchasing** |
| Audit trail  records of | Pavlov |
| Area(s) visited (location, e.g., site visited) | Location # 10578  For more details related to Audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | "Purchasing: Planning Activities Regarding Purchased Products and Outsourced Processes (MDSAP Chapter 7, Task 1, Site: 10578);  (DIN)(EN) ISO 13485 - 4.1.2, 4.1.3, 4.1.5, 7.1, 7.4.1, 7.4.2, 7.4.3 + (DIN)(EN) ISO 9001 - 4.4, 8.1, 8.4 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d)(ii) + MDSAP - Brazil - RDC ANVISA16/2013: 2.5.1, 2.4 + MDSAP - Japan - MO169: 5-2, 5-3, 5-5, 26, 37, 38, 39; [Old: 5, 26, 37, 38, 39] + MDSAP - USA - 21 CFR 820.20, 820.50 + MDR - Article 10.9 ¶3 (d), 10.15; Annex IX 2.2 ¶2 (b3, e); Annex XI 6.2 ¶2 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2), [EK-MED 3.09B16]"  Purchasing: Selection of Supplier File to Audit (MDSAP Chapter 7, Task 2, Site: 10578  "Purchasing: Procedure for the Control of Purchased Products and Outsourced Processes (MDSAP Chapter 7, Task 3, Site: 10578);  (DIN)(EN) ISO 13485 - 7.4.1 + (DIN)(EN) ISO 9001 - 8.4.1, 8.4.2 + MDSAP - Australia - TG(MD)R Sch3 P1  Cl1.4(5)(d)(ii) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.5.1 + MDSAP - Japan - MO169: 37 + MDSAP - USA - 21 CFR 820.50 + MDR - Article 10.9 ¶3 (d); Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Extent of Controls Applied to the Supplier and the Purchased Product; Criteria for Selection, Evaluation, and Re-Evaluation of the Supplier (MDSAP Chapter 7, Task 4, Site: 10578);  (DIN)(EN) ISO 13485 - 7.4.1 + (DIN)(EN) ISO 9001 - 8.4.1, 8.4.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.5.2, 2.5.3 + MDSAP - Japan - MO169: 37 + MDSAP - USA - 21 CFR 820.50 + MDR - Article 10.9 ¶3 (d); Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Selection of Supplier Based on Ability of the Supplier to Satisfy the Specified Purchase Requirements (MDSAP Chapter 7, Task 5, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.1, 7.4.1 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.4.1, 8.4.2 + MDSAP - Australia - As required by MDSAP AU P0002 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.3,3, 2.5.3, 2.4 + MDSAP - Canada - As required by MDSAP AU P0002 + MDSAP - Japan - MO169: 6, 26, 37; [Old: 6, 26, 37, 65] + MDSAP - USA - 21 CFR 820.50(a) + MDR - Article 10.9 ¶3 (d); Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Records of Supplier Evaluation (MDSAP Chapter 7, Task 6, Site: 10578);  (DIN)(EN) ISO 13485 - 7.4.1 + (DIN)(EN) ISO 9001 - 8.4.1, 8.4.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.5.3 + MDSAP - Japan - MO169: 37 + MDSAP - USA - 21 CFR 820.50(a) + MDR - Article 10.9 ¶3 (d); Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Effective Controls over Supplier and Products (MDSAP Chapter 7, Task 7, Site: 10578);  (DIN)(EN) ISO 13485 - 7.4.1 + (DIN)(EN) ISO 9001 - 8.4.1, 8.4.2 + MDSAP - Australia - TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.5.2, 2.4 + MDSAP - Japan - MO169: 37 + MDSAP - USA - 21 CFR820.50(a) + MDR - Article 10.9 ¶3 (d); Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Verification of the Adequacy of Purchasing Information, Specified Purchase Requirements, and Written Agreement to Notify Changes, Before Their Communication to the Supplier (MDSAP Chapter 7, Task 8, Site: 10578); (DIN)(EN) ISO 13485 - 4.2.1, 7.4.2 + (DIN)(EN) ISO 9001 - 7.5.1, 8.4.3 + MDSAP - Australia - TG(MD)R Sch1 P1 2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 2.5.4, 2.5.6 + MDSAP - Japan - MO169: 6, 38 + MDSAP - USA - 21 CFR 820.50(b) + MDR - Article 10.9 ¶3 (d), 10.15; Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Documented Purchasing Information and Specified Purchase Requirements (MDSAP Chapter 7, Task 9, Site: 10578);  (DIN)(EN) ISO 13485 - 7.4.2, 7.5.9 + (DIN)(EN) ISO 9001 - 8.4.3, 8.5.2 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.3.3, 2.5.4, 2.5.5, 6.4 + MDSAP - Japan - MO169: 38, 48, 49 + MDSAP - USA - 21 CFR 820.50(b), 820.65, 820.160 + MDR - Article 10.9 ¶3 (d), 10.15; Annex IX 2.2 ¶2 (b3); Annex XI 6.2 ¶2"  "Purchasing: Verification of Purchased Products (MDSAP Chapter 7, Task 10, Site: 10578);  (DIN)(EN) ISO 13485 - 4.2.1, 7.1, 7.4.3 + (DIN)(EN) ISO 9001 - 7.5.1, 8.1, 8.4.2, 8.4.3, 8.6 + MDSAP - Australia - TG(MD)R Sch1 P1 2, Sch3 1.4(5)(e) + MDSAP - Brazil - RDC ANVISA 16/2013: 2.4, 2.5.2, 3.35.3.1, 5.3.2, 5.3.3 + MDSAP - Japan - MO169: 6, 26, 39 + MDSAP - USA - 21 CFR 820.50, 820.80(b) + MDR - Annex IX 2.2 ¶2 (e); Annex XI 6.2 ¶2 + MDD - Annex II (3.2), Annex V (3.2)"  "Purchasing: Purchasing Control Activities as Source of Quality Data for the Measurement, Analysis, and Improvement Process (MDSAP Chapter 7, Task 11, Site: 10578);  (DIN)(EN) ISO 13485 - 8,4 + (DIN)(EN) ISO 9001 - 9.1.3 + MDSAP - Brazil - RDC ANVISA 16/2013: 7.1.1.1 + MDSAP - Japan - MO169: 61 + MDSAP - USA - 21 CFR 820.100 + MDR - Article 10.9 ¶3 (m); Annex IX 2.2 ¶2 (b2); Annex XI 6.2 ¶2 + MDD - Annex II (3.2), Annex V (3.2), Annex VI (3.2)"  "Purchasing: Top Management Commitment to the Purchasing Process (MDSAP Chapter 7, Task 12, Site: 10578); (DIN)(EN) ISO 13485 - 4.1.3, 4.1.5, 5.2 + (DIN)(EN) ISO 9001 - 4.4, 5.1.2, 8.4 + MDSAP - Brazil - RDC ANVISA 16/2013: 2.2.1 + MDSAP - Japan - MO169: 5-3, 5-5, 11, [Old: 5, 11] + MDR - Article 10.9 ¶3 (c) + MDD - Annex II (2, 3.1)" |
| Brief  description of processes or  activities  evaluated to  demonstrate  what was  audited related to the listed  key QMS  documents  and records | PUR #1 - Planning activities regarding purchased products and outsourced processes  Planning activities regarding purchased products including product acceptance and outsourced processes are established. The established data base system contains relevant information to required documentation / information / acceptance criteria for purchased products/components and related suppliers. Supplier selection and purchasing is described in SOPs. Risk management is part of supplier selection and purchasing.  The list of outsourced process is defined and demonstrated during ether audit The list is created as attachment to the Quality Manual CS100.  - The examples of the outsourced process include:  Archiving of the documents  - Design and development  - HR / Training \*Fa Skillnet - training process) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 91 of 107 |

Report No: 0713308726 Version 1

Audit Report

reviewed - Service and maintenance - outsourced to the sales and service partner organization below - IT Service – outsourced considering - Logistic service - Hegele HealthCare logistics / Simon Hegele (also repackage and relabel, including separates). inputs, - Project handling – outsourced to the own country partners organizations.

outputs, and - Regulatory roles and service measures - Sterilization – Depending on the product)e.g. BGS Betagamma- Gamma service GmbH - Suppl of finished Medical devices – Category Approval category Z01 according to SP2110 - Clinical evaluation consultant - Quality and regulatory services – Dr. Proff. Imhoff - Cyber security expert

The structures of the purchasing process is defined in the organization structures, each Business Unit (BU) defines the roles and the leadership for the process of supplier control are defined at the level of Business unit.

The role Lead Byer is defined globally as global for larger supplier, which shall be control at the corporate levels between the BU’s.

The commodity managers are responsible for the particular larger material supply such as major plastic and metal suppliers.

The roles for supplier Quality Management, including claims and supplier inspections. Draeger Corporate Global Guido Willman.

The roles and responsibilities are defined and presented during the audit: Supplier Quality assurance Therapy Head of Quality Kevin Dornau

Global commodity Manager (larger suppliers e.g. plastic)

PUR #2 - Selection of supplier file to audit Following supplier were selected as linkage from management review as suppliers indicated with problems: - The supplier Global med Canada was listed as the critical suppliers with problems in Management review - High PPM value 597, Flex Hose - (accessories – inspiration devices) – manufacturer Gaelmed - Supplier Zolner MU26494 – Power supply assembly – High Quality issue spike in Feb 2022 - The clinical consultant Prof Dr. Professor Imhof was selected as critical service provided – consultant service clinical evaluation was chosen as Consultant with impact to the safety and permeance – as link from CER process

There is no Supplier or Consultant from Brazil.

PUR #3 - Procedure for the control of purchased products and outsourced processes.

The supplied categorization is performed as Supplier Phase in and Quality Approval (SP2110), the Categories are defined as Attachment 04.

The examples of categories include: ZEX – the material supplier - for Drager Safety division – note relevant Z01 – finished medical device (supplied externally) Z- materials / components or Treadwear (handlebar) ZES - approved materials – Engineers solution – not relevant for medical devices ZL - limited material supplier to different reasons, (e.g. quality problems) ZS – service parts supplier, which are not as materials for production P – approved suppliers for prototypes N - disapproved supplier

The categories of the service providers are categorized as following: DB- Operations equipment , INCLUDEING PRODUCTAION EQUIPMENT AND SERVICES, laboratory equipment, DB1 - Operational equipment and materials for production process with high impact for the safety and performance such as Calibration gases, amnesty gases for calibration DC Consultants services relevant for product safety and performance [SAP consultants services] DE – developments of Hardware and software DE-1 – same as DE, however with higher risk class DH – human resource services DK calibration services DK1 – calibration, with requirements for Accreditation

Approval category indicates if the supply categorization would require additional Prioritization according to The Supplier Prioritization SP6250 This is required specifically for the Suppliers categories: Z01 / Z (depend of product) and DC01 (consultants), DE1 (design with impacts), DK1 (calibration with accreditation) and DL1 (critical logistics) The Prioritization is performed as a result for prioritization or Criticality of suppliers – Priorities supplier means Critical but not as defined according to IEC6060 Typical Priorities are: P1 – traceability and product class According to GM2150 (requires traceability) P2 – components with Breathing gas contact P3 – Critical Part according to 60601

Receiving inspection procedure are implemented (DCS SC 5130), the results are documented on individual forms, and in SAP system.

The check of prioritization was performed during the audit based on example:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 92 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

The component part MP01061 Experationventil Einweg valve categorized as critical components for Traceability (exchange of Energy) Ct 50

PUR #4 - Extent of controls applied to the supplier and the purchased product; criteria for selection, evaluation, and re-evaluation of the supplier Criteria for selection, evaluation and re-evaluation of suppliers are given within procedures and annexes DEMF SP2110, DEMF 2110\_A04-en-03.00, DEMF SP625005.05.2023. The Supplier Control criteria documented in DEMF SP2110, are used to define the type and extent of control to be exercised over the product, services, suppliers, consultants and experts.

Suppliers are categorization in different approval category e.g. ZEX approved-supplier of EX material, Z01- approved supplier for finished medical devices, DC -consultants and experts.

KPI are basically splatted to the logistic performance (date reliability, VMI performance) and quality performance (FAI Performance, failure rate performance, ship holds). Based on that KPIs suppliers are classified to: High performance supplier > 95% to 100 % Adequate supplier > 75% to 95% Low performance supplier > 60&% - 75 % Poor performance supplier up to 60%.

Risk categorization of suppliers and service providers and the controls required for a sourced product or service depends on many factors and are reviewed for all suppliers and service providers which are quality relevant This take a place in separate meetings, as a part of product quality board or as a part of reviewing overall purchasing performance. The inputs are global/ local supplier quality targets, total failure rates, supplier evaluation planning and results, supplier audits.

Following control were observed for specific examples selected in Task PU-2 Example 1 Prof. Dr. Imhoff – supplier Consultant fir Clinical Evaluation: The supplier is released from 2022 Reapprovals was performed according to reclassification for the supplier 2019 Prof Imhof The supplier qualification cat DRO according to SPS21 Supplier Questionnaire Service provider for Clinical evaluation 2018-08-13 97506 Disapproval – re-approval of the supplier b

Example 2: Supplier Zollner (power supply) 96849 First approval Questionnaire Zolner electronic ag, Zandt , Germany - 218-11-2011 CS96849 Production Records - indicated as Traceable Class 40 and 50, the part is relevant for Electrical safety (P3) The initial approval indicated ISO13485 certification QMS Certificate 13485:2016 DEKRA - 2024-08-09 Quality agreement - Zollner (power supply) – 17.12.2009 The Quality evaluation is performed twice per year CS96849 Delivery and Quality Performance evacuation - HY 01/ 2023

Quality issue Zollner 20012551 Supplier Corrective action report Zollner Stecker issue MU26494 28.02.1012 20012551 8D report Zollner Stecker issue Investigation performed – 100% conformed - corrective action planned

PUR #5 - Selection of supplier based on ability of the supplier to satisfy the specified purchase requirements The requirement for the suppliers are defined per supplier’s category listed in A04 attachment for SP21110, The evaluation Plan is established for the year.

For example, for clinicals consultant – Category DRO – requirement is Attachment 08 Service Provide for clinical evaluation. The attachment is sufficiently covering specific requirements for the clinical consultant

The Framework Agreement Supplier Dr Prof Imhoff - 14 par 2016 The supplies is notes as supplier with prior station - a continuous supplier control: The supplier from Priories list undergoes annual evaluation according the Supplier evaluation Tool GoBench (process SP6110).

Delivery and Quality Annual evaluation : Prof Imhof : 19.09.223 CS97506 Supplier Dr Imhof -- evaluation result 100% Criteria – single expert person: CV / Scientific record - demonstrated CV – Prof Imhof – Clinical consultant Stand 31.05.2018 - demonstrated Response rate for the supplier 100%

Agreed supplier Evaluation Plan 2023 – 12 Jun 2022 The plans show, who and when is responsible for periodical evaluation, Lead Commodity category, PPM and if evaluation is applicable.

Example II MP00303 Hose system Anesthesia set Flex latex free Supplier Complete set (Finished Medical device) Gaelmed Corporation (China) – category Z01 94676 Supplier data card SAP Gale Med Corporation Taiwan 116761 Suppler Gale Med China – production Factory The Row Hose supplied from Globalmed Canada

Supplier approval: for category Z01 (supplier of finished Medical ) following documents are required: requires SP2110 Attachment A10 and Attachment Supplier A09, the reapproval is documented on the Supplier Approval sheet A01

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 93 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

DEMF SP2110 A09 – additional supplier questionnaire for Contract manufacturers /developers: Rev 01 The shall be agreed by Quality, Product owner and Supplier Quality In the approval sheet is signed DEMF\_SP2110\_A01 Supplier approval sheet Ver 04 (Form) Supplier approval - DEMF SP2110 AA Rev 00 Supplier requirements for Finished medical devices 2019-04-01

The Supplier Gaelmed was approved - 08 August 2016, according to the legacy process SP2010, Attachment 1 Gaelmed Xiamen (116761) The supplier Questioner and Approval card - 08 August 2016 Australia Supplier is certified by TUV Rhineland to ISO13485 The supplier Category station is performed Supplier categorization table CS94676 Gaelmed Xiamen Categories Z01, Breathings Gas Contact and Traceable and CS94676 Gaelmed Xiamen Supplier prioritization record

Supplier evaluation requirements demonstrated from List of prioritizations of suppliers: - ISO 13485 Active control - DQPE - QAA Supplier evaluation records: ISO 13485 certificate from TUV Rhineland – Gaelmed Xiamen - valid 2024-06-21 ISO 13485 certificate from TUV Rhineland – Gaelmed Taiwan – valid 2023-12-28 CS94676 Gaelmed Xiamen Supplier Delivery and Quality performance HY 02/2022 - CS94676 Gaelmed Xiamen Supplier Delivery and Quality performance HY 01/2023

PR 123501 Vendor assessment report Gaelmed Taiwan - 09 Nov 2022 PR 121516 Vendor assessment report Gaelmed Xiamen - 22 Sept 2022 Quality assurance agreement Gaelmed Corporation Taiwan 27.05 2011 The agreements have included the requirement for Change contra and approval from Draeger

Supplier Audits – is defined as apart of initial approval.

The supplier audits requirement is defined in The supplier audit report was shown for the supplier Gaelmed Taiwan The audit report for 2023 was demonstrated – detailed deport present, 7 recommendation, 1 minor Finding, The Auditor Jan Paulsen

The audit report supplier - Gaelmed Xiamen was demonstrated 22 Sept 2022 Lead Auditor Wang, Min; No Findings, 2 recommendations.

Special Country requirements Australia (TGA): The registered Sponsor is Dräger Australis PTY , Noting Hill. Vic 3168 Australia The Distributor agreement – contains the responsibility of the Australian sponsor Distributor Agreement Drager Australia PTY 10.08.2018.

Japan (MHLW): The MAH for Japan is Draeger Japan LTD The Distributor Agreement Dräger Japan 27 may 2019 The Facility registration was demonstrated: 13B1X00173 from 2-13-17

Brazil, The representative in Brazil is Draeger Industria e Comercio Ltd, Centre Impresarial tambore 06460-100 Sao Paolo , Brazil The Agreement with the Brazilian regulatory representative was demonstrated: Distributor agreement Drager Brazilia – 52/08/2018 Canada: Draegerwerk AG&Co Company ID 103279 , The regulatory corresponded registered Mr. Mebius from Draeger Germany, Canada renewal conformation by the letter from health Canada: 2022-11-09

PUR #6 - Records of supplier evaluation REF to Task PUR 4 for the supplier evaluation records for - Gaelmed Corporation (China) / Gaelmed Xiamen - Prof Dr. Imhoff – Quality Consultant for clinical evaluation Additionally, the auditor has assessed investigation of supplier quality issues for Gaelmed The follow pa in relation to supplier quality issue was performed as part of this audit.

The Supplier Gaelmed Xiamen – manufacturer has identified contamination (white particles) inside the breathing hose: Demonstrated as 8D report The issue was highlighted by the manufacturer of the Tube set Gaelmed - communicated via Email in July 2022 as telephone conference and email from Gaelmed to Drager The Corrective action: 1) cleaning of the instrument every 4 hours 2) Run DOE (design of experiment) – validated new process window 3) Installation of Temperature Gages – for the extrusion temp of the process media am nozzle The Corrective corrective action completed on 07 January 2023 MDR 2017/745 – Article 11(2)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 94 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
|  | Authorized representative accepted its designation in writing, and it is effective at least for all devices of the same generic device group –  The Contract for legal -Draeger Medical systems Inc, USA   The agreement demonstrated:  Agreement Draeger Telford USA and Drägerwerk AG Lübeck Germany 24 Jan 2019  PUR #7 - Purchasing  The re-evaluation of the capability of suppliers to meet specified requirements is performed with the significance of the product on the finished device. Re-evaluation is performed with the same system as initial evaluation.  REF to Task 4 for detailed description and examples  PUR #8 - Verification of the adequacy of purchasing information, specified purchase requirements, and written agreement to notify changes, before their communication to the supplier  It could be verified that Draegerwerk assures the adequacy of purchasing requirements for products and services that suppliers are to provide, and defines risk management activities and any necessary risk control measures.  This is ensured by Approved Drawings, Incoming Goods Inspections Test Plan, Einkaufsrahmenvertrag, Quality Assurance Agreement.  QSVs are needed at least in cases if Supplied Parts are to be traceable.  Approval of DRÄGERWERK is required especially in Change Cases that affect Safety and Reliability, Conformity with Regulatory and Technical Standards, Form, Fit, Function and Labelling.  Purchase orders are approved by the designated Material Resource Planner electronically supported and digitally signed, including date and signature.  The requirements re defined as product specification and optionally as adoption of e QMS from Draeger by the suppliers.  Example: verification of relevant information was performed for finished device (accessory) Anesthesia Set latex free The purchasing requirements are documented in PLM ARAS system  MP00303 10 ARAS production drawing Ver 09 2020-10-22  MP00303 10 ARAS Part specification Anesthesia Set latex free 2020-11-09  Brazil:  The purchase orders are approved by a designated person with electronic signature in SAP system  PUR #9 - Documented purchasing information and specified purchase requirements  Verified that the medical device organization documents purchasing information, including where appropriate the requirements for approval of product, procedures, processes, equipment, qualification of personnel, sterilization services, and other quality management system requirements.  It also was confirmed that documents and records for purchasing are consistent with traceability requirements where applicable.  Example: assessment was performed in relation to plastic hood for part for Babyleo TN500 incubator and a radiant warmer – t was verified that the degassing process is performed for hood in production: The Part drawing was requested and demonstrated during the audit.  Production Drawing Hood Complete Part 2 M60010 156.01.2020 Degassing process is defined as 180min at 80C  PUR #10 - Verification of purchased products  It could be confirmed that the verification (inspection or other activities) of purchased products is adequate to ensure specified requirements are met.  Further it could be confirmed that DRÄGER has implemented an appropriate combination of controls applied to the supplier, the specification of purchase requirements, and acceptance verification activities that are commensurate with the risk of the supplied product upon the finished device.  Verified that records of verification activities are maintained.  Example was verified in relation to the prat sampled during the audit of production floor for Babyleo TN500 incubator and a radiant warmer. Records of successful inspection demonstrated as following:   Example observed for the Part 368451 The test protocol incoming inspection Part 8421200   N 3 parts were checked from overall 192 incoming batch.  Brazil is covered.  PUR #11 - Purchasing control activities as source of quality data for the measurement, analysis, and improvement process  The periodical process for the quality review according to the defined process, the example was demonstrated for BU TH, the process is defined DEMF 1010, the BU has identified specific requirements, each commodity is looked at twice a year according to the reequipments defined in Purchasing and supplier Quality control review Definition BU Therapy Sept 2022  PUR #12 - Top management commitment to the purchasing process  Based on the observed exampled and process, Top Management has demonstrated commitment to the Purchasing process |
| Reviewed  documents  and records (identification and revision) | Quality Manual CS100.  List of outsourced process Rev 07 2023-08-25  BU Therapy Commodity review M2 (PCBA units Quality) Septembers 20223 DCS SC5120-en-013-02.00 Incoming Inspection Planning |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 95 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |
| --- | --- |
|  | DWAG CS1000-de-08.00, 2023-05-01 DWAG CS1000- The Quality manual - including attachment for outsourced processes  DEMF SP2110 : Supplier Phase in and Quality Approval DEMF SP2110‐en‐03.00 , Rev. 03.00  DEMF SP2110 : Supplier Phase in and Quality Approval DEMF  SP2110 Attachment A04 – approval categories Ver 3  DEMF SP2210 : Supplier Audits DEMF SP2210‐en‐02.00 , Rev. 02.00  DEMF SP6110 : Supplier Evaluation DEMF SP6110‐en‐04.00 , Rev. 04.00  DEMF SP6210 : Supplier Control Risk Analysis DEMF SP6210‐en‐01.00 , Rev. 01.00  DEMF SP6250 : Identification and Control of Prioritized Suppliers DEMF SP6250‐en‐03.00 , Rev. 03.00  DWAG OF3310 : Control of Standards ‐ with Respect to Suppliers DWAG‐OF3310‐en‐00 , Rev. 0  DWAG SP2120 : Disapproval, Limitation and Reapproval of Suppliers DWAG‐SP2120‐en‐00.00 , Rev. 00.00 GM2150 Traceability of products and components V03  Purchasing and supplier Quality control review Definition BU Therapy Sept 2022 defines  DEMF 1010 rev 2 Quality control loops (used for Quality Control review)   DEME GM1250 Checklist Traceability Product and components V03  MP01061 Categorization record Experationventil Einweg valve categorized as critical components Supplier Questionnaire Service provider for Clinical evaluation 2018-08-13  97506 Disapproval – re-approval of the supplier bs  20012551 Supplier Corrective action report Zollner Stecker issue MU26494, 28.02.1012  20012551 8D report Zollner Stecker issue  TThe Framework Agreement Supplier Dr Prof Imhoff - 14 par 2016  CV – Prof Imhoff – Clinical consultant Stand 31.05.2018  Supplier evaluation records:  ISO 13485 certificate from TUV Rhineland – Gaelmed Xiamen - valid 2024-06-21  ISO 13485 certificate from TUV Rhineland – Gaelmed Taiwan – valid 2023-12-28  CS94676 Gaelmed Xiamen Supplier Delivery and Quality performance HY 02/2022 -  CS94676 Gaelmed Xiamen Supplier Delivery and Quality performance HY 01/2023  PR 123501 Vendor assessment report Gaelmed Taiwan - 09 Nov 2022  PR 121516 Vendor assessment report Gaelmed Xiamen - 22 Sept 2022  Quality assurance agreement Gaelmed Corporation Taiwan 27.05 2011  Supplier Audit report Gaelmed Xiamen was demonstrated 22 Sept 2022  200161146 MP00303 8D report Investigation Supplier quality – breathing hose contamination 20/12/2022 Production Drawing Hood Complete Part 2 M60010 156.01.2020  Purchasing and supplier Quality control review Definition BU Therapy Sept 2022 defines  DEMF 1010 rev 2 Quality control loops (used for Quality Control review)  PUR Commodity dashboard V10 – quality |
| Names and titles of  persons  interviewed | Guido Willmann, Leiter Strategischer Einkauf BU Therapy  Timo Harms, QAA Business Unite HCA incl Supplier Quality  Jochen Förster-Adler, Supplier Quality manager  Tobias Vieth, (Supplier Quality Manager, Therapie)  Jan Paulsen (Supply Quality Manage, HCA c(Hopital consumabales ) Jochen Foerster-Adler, Supplier Quality, Indirect beshaffung |
| Products,  components, or projects  reviewed | See above |
| Statement  concerning  conformity  based on  objective  evidence  reviewed for  this subsystem | ☒ This process is effectively implemented and conforms to requirements.  ☐Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 96 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.16 Cyber Security

|  |  |
| --- | --- |
| Subsystem | **Cyber Security** |
| Audit trail records of | Gabriele Mousset with Somesh Rasal (deputy Expert for Jan Küffner) |
| Area(s) visited (location, e.g., site visited) | Location # 1  For more details related to Audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | MDR 14.2 (d) IT security |
| Brief description of  processes or activities evaluated to  demonstrate what was audited related to the listed key QMS  documents and records reviewed below  considering inputs,  outputs, and measures | Responsibility and authority for cyber security is documented and communicated appropriately as seen in audit. Personnel is competent based. On training, skills (Software Engineering and forensics specialist) and experience (Medical device development) as verified during audit. During audit it was noticed that the same person leading development as well as security for the product  During audit it was verified, that security risk management was done at an early stage as seen in the audit.  They use ERNW as an outsourced penetration laboratory. Few components like USB, etc., were not part of testing scope as seen in the audit.  STRIDE (manual approach) was used as threat modelling technique as seen in the audit. The sampled technical documentation (Atlan A350) provided evidence of appropriate penetration testing. Product undergoes through Penetration testing for every major release.  The sampled TDs (Atlan A350) provided a list of SOUP components.  The SOUP components are regularly discussed (at least once in a month) if they need corrective actions.  During audit it was noticed that documents are managed using Configuration Management rather than document control. Hence, document numbers mentioned below section are reference numbers to documents. |
| Reviewed documents and records  (identification and  revision) | 1. Atlan SW 2.00.02 - Threat Analysis.pdf - TA\_A3x0\_MDR Rev 1 – Signed on 25-1-2023.  2. Atlan A350 - Pentest Report.pdf – E20209046 – Created on June 22, 2021  3. Atlan 2.00.02 Software bill of material.pdf - SBOM\_A350\_2.00.02 Rev 13 – Created on 13-9-2023.  Atlan SW 2.0n Cybersecurity maintenance and patch management.pdf - PMP\_A3x0 4.  Rev 11 |
| Names and titles of persons interviewed | Mike Neumann |
| Products, components, or projects reviewed | Software Engineer and Product Security Engineer |
| Statement concerning conformity based on objective evidence  reviewed for this  subsystem | ☒ This process is effectively implemented and conforms to requirements.  ☐Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 97 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.17 STB assessment of cleaning instruction (Atlan)

|  |  |
| --- | --- |
| Subsystem | **STB assessment of cleaning instruction (Atlan)** |
| Audit trail records of | G. Pavlov |
| Area(s) visited (location, e.g., site visited) | Location # 1 HQ: Moislinger Allee  For more details related to Audit location and time refer to chapter 2.2 of this report. |
| Audit criteria according to audit plan | MDR Regulation EU 2017/745 (MDR); ANNEX I, III 23.4. Information in the instructions for use ISO 17664-1:2021 / 17664-2 Edition 2021  IEC 60601-1:2020, Edition 3.2 Clause 7.9.2.12 Cleaning, Disinfection and sterilization |
| Brief description of  processes or activities evaluated to  demonstrate what was audited related to the listed key QMS  documents and records reviewed below  considering inputs,  outputs, and measures | Claims  Following statement is document in the Marketing Brochure:  Infection Prevention and Control  Breaking the chain of infection and complying with your hospital's hygiene protocols is critical in today's clinical  environment. For this reason, during the development phase of Atlan anesthesia machines, we designed them  with infection prevention regulations in mind to support hygiene measures in the OR.  ‒ Tool-free and quick disassembly of breathing system with few parts to be compliant with infection  prevention regulations  ‒ Smooth and rounded surfaces ease cleaning/wipe disinfection  ‒ Cable ducts and channels reduce number of potential contamination sources  ‒ Compatible with original Dräger single-use consumables support hygiene standards  ‒ Generated message\* reminds personnel about the replacement of the RFID technology-based consumables (Infinity ID breathing circuit, Infinity ID WaterLock 2 water trap, Infinity ID flow sensors,  Infinity ID CLIC absorber) when their maximum period of use are exceeded  ‒ Compliant with ISO 17664  Provision of Information for Use on Reprocessing  It was verified that reprocessing instructions include in validated reprocessing method were included in the Labeling / Instruction for Use  For Rev 1.0 Instruction for Use Ver SEW-1.0 –formation for reprocessing was included in the IFU directly  For Rev 2.0 Instruction for USE Anesthesia workstation Software 2.0n – info on reprocess was removed from main IFU and included in the dedicated Information on reprocessing is now included in standalone reprocessing Instruction for Use (9510631\_1\_en)  Identification of criticality of reprocessing  According to Reprocessing Instruction, following classification defined:    Identification of parts subject for reprocessing  The following classification is a recommendation from Dräger.  Non-critical  – Device surfaces  Semi-critical  – Breathing system  – Housing (lower part and upper part)  – Inspiratory port  – Expiratory port  – APL valve  – Inspiratory valve (yellow)  – Expiratory valve (blue)  – Fresh-gas decoupling valve (black)  – Absorber container and absorber insert  – Sensor cap of the O2 sensor1)  – Piston diaphragm  – Breathing bag arm (option)  Critical  The device does not contain any components that are classified as critical. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 98 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

Indication of the reprocessing process for related parts

a) Surface disinfection with cleaning – Device surfaces

The validation of the device service cleaning was not assessed in thei audit as law risk and not directly relevant to safety and performance of the device. The recommended chemical for surface cleaning were widely available and listed by national Guidance documents.

b) Machine cleanable parts

The machine decontamination in washer-disinfector observed during the audit is widely acceptable standard washer-disinfector cycle with A0>3000 (high level disinfection)

Validation / verification of the reprocessing procedure Two validation documents were demonstrated during the audit. Valuation was performed in Miele Washer-disinfector, using the decontamination cycle and process chemicals as recommended in the Reprocessing Instruction.

Two documents were demonstrated during the audit:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ID: 31505 | 1) | Cleaning Efficacy for the representative parts from the breathing circuit – | | | Page 99 of 107 |
| Test soil used – BCA Protein Assay KIT from Thermo Scientific Pass Criteria used  Residual protein < 6,4 pg pro sq. cm of tested surface | | | |
| Doc No: MED\_T\_09.50 | | Revision: 12 – released | Effective: 28 May 2021 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Residual carbohydrates <12 mkg per sq. cm  The application of the test soil – documented, seems to be chosen based on risk for most difficult for cleaning – observed on photo documentation in the validation report  The result of the report – all values within the defined levels.  Record presented: Fachhygienische Stellungnahme zur chemischen Validierung  der maschinellen Reinigung verschiedener Komponenten Anästhesiegerät „A350 28. Dezember 2018   |  |  | | --- | --- | | 2) | Microbiological test – the investigation for the count reduction >10-6 as required for High-level disinfection A0=3000 |   The selection and characterization of the test microbial cultures discussed – and  documented, selection was perfomed in line with recomndation of US-Norm ASTM E 18376, US-Guideline  AAMI TIR 124 and FDA-Guidelines, taken int account area of application (breathing pathways / lungs).  Pass results are documented>  Record presented: Fachhygienische Stellungnahme zur mikrobiologischen Validierung der  maschinellen Desinfektion verschiedener Komponenten Anästhesiegerät „A350“28. Dezember 2018  Competency of the validation SMEs  The validation documentation consists of Professional Statement reports prepared by third party: Report authored by Dr. med. Arne Martensen, Facharzt für Hygiene und Umweltmedizin Facharzt für Mikrobiologie, Virologie und Infektionsepidemiologie;  im Auftrag der: BZH GmbH Deutsches Beratungszentrum für Hygiene Schnewlinstr. 4  The test / experimental part was performed by Herrn Dr. Andreas Sammann, Institut für Hygiene und Umwelt Hamburg, durchgeführt (durch die Deutsche Akkreditierungsstelle DAkkS GmbH gemäß DIN EN ISO/IEC 17025 akkreditiertes Prüflabor, Akkreditierungsnummer D-PL-14095-03-02).  The competency of the parties perfumed the volition is relevant for the performed validation  Result of assessment during this audit  The demonstrated Professional Statement (Fachhygienische Stellungnahme) from BZH GmbH (Deutsches Beratungszentrum für Hygiene) doe not fully meet the requirements of ISO15883 / ISO 17664-1:2021 / 17664-2:2021.  Nevertheless, the methodology, criteria for validation and the tests performed can be regarded as state of the art commensurate to the area and criticality of application taking into account:   |  |  | | --- | --- | | 1)  2)  3)  4) | Standard widely used methodology for machine reprocessing of reusable medical devices – thermo-disinfection with standard cycle and A0=3000  Widely used chemicals for cleaning and neutralization, also recommended by manufacturer of washer-disinfector.  The Validation used methods generally accepted in ISO15883-1  The fact the reprocessed parts are not invasive and in normal not coming with blood and tissues of the patients. |   The cleaning instruction was found in lined with verified reprocessing methods |
| Reviewed documents and records  (identification and  revision) | Marketing Brochure Atlan atlan-a300-a300xl-pi-9107089-en-master 9056001\_05 \_en IFU Atlan A300, A300 XL, A350, A350 XL Anesthesia workstation Software Ver 1.0  9510601\_1\_en IFU Atlan A300, A300 XL, A350, A350 XL Anesthesia workstation Software Ver 2.0  9510631\_1\_en Reprocessing instructions Atlan A300, A300 XL, A350, A350 XL  HRSR\_SCALA AthlanA3X0 Hygienic Summary report 2022-06-21  REF163\_sc\_2018-12-28\_A350 Semikritisch\_DES\_18-00242-AU001\_exVal  REF162\_sc\_2018-12-28\_A350 Semikritisch\_REI\_18-00242-AU001\_exVal |
| Names and titles of persons interviewed | Jens Köhne, Malte Zeuner, Jan Dannemann, Anna-Lena Brügmann, Stefan Thal, Dirk Zumtobel  Jens Koehne Programm Manager  Jan Dannemann, System Engineering, R&D Perioperative Care, BU Therapy  Stefan Thal, System Product Manager Infection Prevention & Control"  Dirk Zumtobel, "Head of Test Laboratories, Quality & Regulatory Affairs |
| Products, components, or projects reviewed | Atlan A300, A300 XL, A350, A350 XL Anesthesia workstation |
| Statement concerning conformity based on objective evidence  reviewed for this  subsystem | ☒ This process is effectively implemented and conforms to requirements.  ☐Actions are needed for this process to conform to requirements. See audit finding list. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 100 of 107 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

2.5.18 Technical Documentation Assessment

|  |  |
| --- | --- |
| Subsystem | **Technical Documentation Assessment EC-Directives** |

|  |  |
| --- | --- |
| ☐ ☒  ☒ | The auditee is not a legal manufacturer of class IIa and IIb devices according to MDD 93/42/EEC and therefore does not maintain technical documentation, which needs to be assessed.  The auditee is not a legal manufacturer of annex II list B and / or self-testing devices according to IVD 98/79/EC and therefore does not maintain Technical Documentation, which needs to be assessed.  The sampling plan and log contains detailed information about the manufacturer’s technical  documentation of MDD 93/42/EEC class IIa and IIb devices, IVD 98/79/EEC annex II list B and self-testing devices and the examples audited. |

Refer to the table below for referenced applicable documents for attached TDARs.

|  |  |
| --- | --- |
| Subsystem | **Technical Documentation Assessment EU Regulations** |

|  |  |
| --- | --- |
| ☐ ☐  ☒  ☒ | The audited organization is a not legal manufacturer according to a European Regulation and therefore does not maintain technical documentation, which needs to be assessed by a Notified Body.  The audited organization is legal manufacturer according to a European Regulation, but product classification does not require Technical Documentation Assessment by a Notified Body.  The audited organization is a legal manufacturer according to a European Regulation and product classification requires sampling for Technical Documentation Assessment by a Notified Body.  The Notified Body maintains a Sampling Plan and Log (MDR Annex IX, 2.3/3.5 / IVDR Annex IX, 2.3/3.5) for internal use, which contains detailed information about the organizations technical documentation assessment (TDA) planning according to applicable European Regulation, the selected devices and the examples audited. This document also contains the Log for assessment history including a justification for sampling.  For technical documentation assessment based on MDR / IVDR  The auditee has submitted all required "Periodic Safety Update Reports" (PSURs according MDR article 86 / IVDR article 81) and if indicated other reports like an update of "Summary of Safety and Clinical Performance" (SSCP) according MDR article 32 and update of "Summary of Safety and Performance" (SSP) acc. to IVDR article 29 to the Notified Body. |

Refer to the table below for referenced applicable documents for attached TDARs.

|  |  |
| --- | --- |
| ☒ | This audit report package includes following technical documentation assessment result(s) (TDARs) including involved expert assessment results / attachments, if applicable. |

|  |  |  |  |
| --- | --- | --- | --- |
| **TDAR #** | **Device name and REF** | **TÜV SÜD order number** | **TDAR Date** |
| 1 | CS-hoses | 0713315041 | PSUR ongoing |
| 2 | TN500 | 0713315029 | TDA ongoing |
| 3 | Core Software 1.x | 0713315091 | TDA ongoing |
| 4 | VentStar | 0713315096 | TDA ongoing |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 101 of 107 |

Report No: 0713308726 Version 1

Audit Report

2.6 Areas not audited although within the original Audit scope

☒All areas / processes from the planned audit scope as defined in the audit plan were audited.

☐The audit was not conducted as scheduled in the audit plan. Followings were skipped or Audit was not sufficient:

2.7 Obstacles encountered, reliability of the Audit

☒There were no obstacles encountered or unresolved issues, if identified, that could comprise the reliability of the audit findings and conclusions.

Documents, records, and qualified answers were available within a reasonable amount of time. The Audit was conducted within the timeframe scheduled in the audit plan.

The Information and Communication Technology (ICT) methods described in the audit plan were employed effectively throughout the audit.

2.8 Verification of effective implementation of corrective action(s) from the previous Audit

The Audit Team evaluated all measures related to the nonconformities from the previous audit(s). The audit team verified that all measures were effectively implemented as planned. The implementation and effectiveness of the measures were followed up by the company using their internal processes.

|  |  |
| --- | --- |
| ☒ ☐ | N/A, no nonconformities during previous requiring a follow-up  Below is a summary of the evidence reviewed to verify the effectiveness of the implemented actions for the nonconformities from the prior audit(s). |

• (Please specify or refer to the section of this report that’s addresses the follow-up of previous conformances)

•

•

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ☐ | The Audit Team was not able to close all nonconformities from the previous audit(s). See new finding number(s): | | | | |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 102 of 107 |

Report No: 0713308726 Version 1

Audit Report

2.9 Conclusion for Action Items derived from various sources (e.g. source TÜV SÜD CBW)

Action items derived from various sources were considered and closed as follows:

CRT Action Item Dräger FSCA ICM PR126573, TPS ID VM63012:

“The investigation confirmed that when ICM is used in combination with a syringe pump connection, under certain under certain conditions, ICM may show entries in the daily curve that were not deliberately created by the user.

These entries cannot be edited or deleted by the user. If these additional entries unnoticed, this can lead to inaccurate documentation of prescriptions or previous treatment in the program. Program and thus potentially lead to incorrect treatment decisions.”

Action Item: “Since the Cause of the behaviour has been identified, please review the rationale for not updating the affected systems, considering the principle of integrated safety”.

During audit, manufacturer provided updated information on that case and behavior. This behavior has been changed in the next regular release of the Software (V14) and in Bugfix Version (V 13.02, released 07/2023). Therefore, the requested rationale is not needed anymore.

The Bugfix Version will be rolled out with a new Field action (see “Decision and Order”)

Background Information (as communicated to BFARM 2023-08-08): - ICM is used by customers in 5 different Software Versions (V9-V13).

- Bug fixing was available with V13.02 (available since 07/2023) and V14.

- Installation of V12 + V13 are technically updateable to 13.02; however, this involves a high effort withing hospitals, since the IT infrastructure is involved; therefore, Dräger forecasts this update to take around 12-months’ time.

The problem described within FSCA can only happen in installations that use the option “Syringe Pumps Connection”; this connection is only be used by very few customers. Dräger will approach customers with these versions in order to either update to V13.02 or to deactivate the option causing the issue.

Records for this case: Competent Board Decision 2023-01-13 Specific Risk Assessment RM CAPA PR123704-signed.pdf TSB\_4\_ICM\_Decision and Order\_signed.pdf 2023-08-01 „13.02 ist verfügbar“ Release Notes ICM Patientenmanagement Software 13.02 6495.525\_de, versendet 2023-07-28 Kundeninformationsschreiben im Entwurf vorhanden (…), wird noch im September versendet.

eMail 2023-08-08 to Competent Authority Landesamt für soziale Dienste Schleswig-Holstein PR123101 Decision Closure Report 2023-09-19 Jira-Defect Entry Ticket ICM-13149 Jira-Defect Entry Ticket ICM-13254 – for V13.02 – 1306887 Test case 13254: Approved, Passed RQM Test case 114863 SW-release-No mt-1622 Prt-No. MK0517103 for V13.02 ICM Customer letter Fluid Management Deutsch update \_final.pdf (2023-09)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 103 of 107 |

|  |  |  |
| --- | --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 | |  |
| **3** | **Events, changes, follow-up, action items** |
| **3.1** | **FSCA/FSN, Recalls, Product Removals, Replacements, other Vigilance Information** |

See subsystem “Device Adverse Events and Advisory Notices Reporting, Post Marketing Surveillance and Vigilance system”.

|  |  |
| --- | --- |
| **3.2** | **Substantial / Significant Changes Since the Last Audit** |

|  |  |  |
| --- | --- | --- |
| **Reported Changes** | **Change Notification Number (if applicable)** | **Verification**  **(if applicable)** |
| none | none | ☐ Prior to Audit ☐ During audit |

The auditee(s) must notify the TÜV SÜD project handler of all significant and substantial changes to the approved quality management system and device-range covered by the certificate(s) before implementing changes.

3.3 Audit Program Status An update of the audit program was not necessary.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 104 of 107 |

Report No: 0713308726 Version 1

Audit Report

4 Conclusion, Final Summary and Recommendation to the Notified Body / Certification Body

4.1 Multi-Site / Facility Audit

☐Not applicable

☒Audit Team as listed on page 1 conducted the audit at all sites / facilities within the scope of certification. No further conclusion necessary.

☐See audit report for site / facility [enter site if applicable] (Head Quarter) for Synthesis Report Information.

4.2 Audit Team recommendation

The audit team confirms that the audit has covered the audit criteria and objectives as indicated on page 1 of this report and the verification of the

• Effectiveness of the quality management system in meeting its specified quality objectives

• Capability of the quality management system in ensuring compliance with relevant statutory, regulatory, and contractual requirements (as applicable)

• Effectiveness of the quality management system in ensuring that agreed requirements for products and/or services are met

• Effectiveness of the company’s internal audit program in identifying and correcting noncompliance’s with the standard and internal documentation

• Proper promotional use of certifications (certificates and certification marks). This includes checking website content and any referenced links and attachments. Use of certification mark and references in documents, product labeling and websites must not be misleading.

Based on the objective evidence, the audit team confirms that the audit objectives have been met (if applicable, with the limitations described in sections 2.6 and 2.7). The Audit Team concludes that the company’s quality management system

|  |  |
| --- | --- |
| ☐ ☒  ☒ | Conforms with the audit criteria as specified above.  Does not fully conform with the audit criteria as specified above. The audit team identified nonconformities. Refer to findings list for more details including follow-up actions.  ☒ Submission of necessary documents. For details refer to audit findings list,  section “Client Responses: Deadlines and Required Actions”  ☐ Special audit needed for verification of corrective and preventive action implementation Re-Certification Audit: The audit results from the last three years were considered for both the Audit planning and the current conclusion for this recertification |

The Audit Team recommends

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| ☐ | Issuance/update/continuation of certificates | | | | Page 105 of 107 |
| ☒ | Issuance/update/continuation of certificates upon successful closure of follow-up actions | | | |
| ☐ | Suspension of certificate | | | |
| ☐ | Withdrawal of certificate | | | |
| ☐ | Reduction of certificate scope | | | |
| ☐ | Increase of Audit frequency to semiannual surveillance | | | |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 |

|  |  |
| --- | --- |
| **Audit Report**  Report No: 0713308726  Version 1 |  |

The proposed scope statement for issuance of new or revised certificate(s) is displayed below.

|  |
| --- |
| For (DIN) EN ISO 13485:2021, EN ISO 13485:2016+A11:2021, ISO 13485:2016  OLD - 10578 “Design, Development, Manufacture and Distribution of Diagnostic and Therapeutic Medical Devices and Installations as well as Consulting and Services in the Field of Medical Technology. Diagnostic and Therapeutic Medical Devices andInstallations: Anaesthetic Equipment, Infusion Equipment, Pediatric Equipment for Warming- and Photo-Therapy, LungVentilator Equipment, Monitoring Equipment, Clinical Decision Support Software, Patient Data Management Software, Equipment for Suction, Breathing-, Inhalation-, O2- and Aerosol-Therapy, Medical Gas Management and Supply Systems as well as Medical Lights”  OLD - 90464 “Manufacture and Distribution of Diagnostic and Therapeutic Medical Devices and Installations as well as Consulting and Services in the Field of Medical Technology.  Diagnostic and Therapeutic Medical Devices andInstallations: Anaesthetic Equipment, Infusion Equipment, Pediatric Equipment for Warming- and Photo-Therapy, LungVentilator Equipment, Monitoring Equipment, Clinical Decision Support Software, Patient Data Management Software, Equipment for Suction, Breathing-, Inhalation-, O2- and Aerosol-Therapy, Medical Gas Management and Supply Systems as well as Medical Lights”  NEW - 10578  “Design, Development, Manufacture and Distribution of Diagnostic and Therapeutic Medical Devices as well as Installations and Services in the Field of Medical Technology.  Diagnostic and Therapeutic Medical Devices and Installations: Anaesthetic  Equipment, Infusion Equipment, Pediatric Equipment for Warming- and Photo-Therapy, Lung Ventilator Equipment, Monitoring Equipment, Clinical Decision Support Software, Patient Data Management Software, Equipment for Suction, Breathing-, Inhalation-, O2- and Aerosol-Therapy, Medical Gas Management and Supply Systems as well as Medical Lights and sterile Equipment for Medical Lights”  NEW - 90464  “Manufacture and Distribution of Diagnostic and Therapeutic Medical Devices as well as Installations and Services in the Field of Medical Technology.  Diagnostic and Therapeutic Medical Devices and Installations: Anaesthetic  Equipment, Infusion Equipment, Pediatric Equipment for Warming- and Photo-Therapy, Lung Ventilator Equipment, Monitoring Equipment, Clinical Decision Support Software, Patient Data Management Software, Equipment for Suction, Breathing-, Inhalation-, O2- and Aerosol-Therapy, Medical Gas Management and Supply Systems as well as Medical Lights and sterile Equipment for Medical Lights”  ISO 9001:2015  No changes |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 106 of 107 |

|  |  |  |
| --- | --- | --- |
| **5** | **Audit Report**  Report No: 0713308726  Version 1 |  |
| **Disclaimer Statement** |

Auditing is based on a sampling process of the available information and therefore is not a guarantee of 100% conformity with requirements. Any audit recommendations are subject to an independent review prior to a decision concerning the awarding, continuation, update, or renewal of certification. A management system certification audit (initial, surveillance or recertification audit) is not a legal compliance audit (see ISO/IEC 17021-1:2015, 9.2.1.2).

|  |  |
| --- | --- |
| 2023-10-13  Report Date | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  Szepannek, Martin |

This report may only be quoted in full. Any use for advertising purposes must be approved in writing. This report is confidential and the property of TÜV SÜD Product Service GmbH.

6 Attachments

The Audit reporting includes this document and below referenced applicable records:

|  |  |
| --- | --- |
| ☐ ☒  ☒  **7** | Stage 1 Audit Report [(MED\_T\_09.31)](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=20497) [in](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=2413)cluding relevant attachments Current audit finding li[st (MED\_F\_09.](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=20497)[61)](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=2413), if appl[icable](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=163350)  MHS Opening and Closi[ng Document P](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=2413)ackage [(MED\_F\_09.24)](https://roxtra.tuev-sued.com/Roxtra/doc/showfile.aspx?FileID=163350)  **Version History** |

|  |  |  |  |
| --- | --- | --- | --- |
| **No.** | **Date (yyyy-mm-dd)** | **Name of Author** | **Description of Change** |
| 1 | 2023-10-13 | Szepannek, Martin | Completion of record |
| 2 |  |  |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ID: 31505 | Doc No: MED\_T\_09.50 | Revision: 12 – released | Effective: 28 May 2021 | Page 107 of 107 |